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ABSTRACT 
Diabetic neuropathy (DN) is the most common type of neuropathy, with 25-50% of patients 
experiencing pain at any stage of its progression. However, the understanding of the 
pathophysiology of DN is still incomplete. No disease-modifying treatments have yet been 
developed and pain is only treated symptomatically with drugs targeting the central nervous 
system (CNS). These have limited efficacy and can produce serious side effects. Research 
into novel analgesics is turning away from the CNS and now focusing on the peripheral 
nervous system (PNS) and more specifically the pain-sensing neurons (nociceptors) to 
produce better-targeted and safer treatments. However, to this end, a suitable medium-to-high 
throughput screening tool is needed, able to discriminate nociceptors from non-nociceptors 
in a heterogeneous cell population, such as the dorsal root ganglia (DRG). Previously, our lab 
showed a link between the veratridine (VTD)-induced oscillatory (OS) and slow decay (SD) 
calcium response profiles with nociceptors and non-nociceptors, respectively. Here, we 
validated the VTD-response profiles as broad functional markers of these DRG subpopulations 
using mice with genetically ablated nociceptors (1.8-DTA). Then, by using voltage-gated 
sodium channel (VGSC) blockers with different specificities, we demonstrated that the VTD-
Ca2+ imaging assay can be used as a drug screening platform for drugs, individually or in novel 
combinations.  The VTD-Ca2+ imaging assay was then applied in combination with nociceptive 
agonists to investigate the excitability changes in distinct neuronal subpopulations during DN. 
In db/db mice, during the early metabolic phase, small- to medium-diameter nociceptors 
showed 1.4 -fold increased sensitivity to CAP and 1.2-fold increased VGSC excitability. In the 
late, NEU phase, small-diameter nociceptors showed increased sensitivity to CAP (1.6-fold)  
and increased VGSC excitability (1.4-fold), whereas medium nociceptors show decreased 
sensitivity to AITC (1.8-fold) . This is the first study to characterise phase- and subpopulation-
specific excitability changes in the well-established db/db mouse model. Collectively, these 
results point to specific subpopulations of DRG neurons affected during the early and late 
stages of DN. These findings could aid in the better targeting of novel therapies for the 
treatment of DN and pain. Furthermore, we have demonstrated that the VTD-Ca2+ imaging 
assay can be applied as a tool for the characterisation of excitability changes in distinct DRG 
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CHAPTER 1: INTRODUCTION 
1.1. The nervous system and dorsal root ganglia (DRG) neurons  
The nervous system is the most complex body system with a highly organised structure. It is 
composed of two major parts: the central nervous system (CNS), constituting the brain and 
spinal cord; and the peripheral nervous system (PNS), comprising all the nerves connecting 
the CNS to all organs, tissues and skin. The PNS contains sensory (afferent) neurons 
responsible for conveying sensory stimuli to the CNS, where the information is processed and 
a response to the stimuli is generated. The response signal is then relayed through efferent 
neurons and expressed in the form of movement1.  
The sensory branch of the PNS comprises an intricate network of sensory neurons and 
pathways responsible for transducing and transmitting information that organisms can “feel”. 
The cell bodies of sensory neurons are contained within small, ball-like structures called 
ganglia. These can be located at the base of the skull, innervating the head and face, called 
trigeminal ganglia (TG). The cell bodies of the neurons innervating the rest of the body reside 
in ganglia along the spinal column called dorsal root ganglia (DRG) – the focus of this thesis 
(Figure 1.1). The pseudounipolar nature of DRG neurons somata means a single afferent fibre 
(axon), extends briefly from the cell body and then bifurcates into: a short central branch, 
Figure 1.1. Cross section of a spinal cord illustrating the relative position of the dorsal root ganglion 
containing the cell bodies of sensory neurons. Source:  CNX OpenStax. (2012, August 22). Biology [Cross 
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projecting into the CNS through the spinal cord; and a longer peripheral branch, innervating 
peripheral tissues and terminating in the skin, viscera, tendons, bones and muscles1,2.  
1.1.1. DRG neurons: heterogeneity and classification 
Sensory neurons relay complex information from an abundant variety of innocuous (harmless) 
and noxious (painful) stimuli to the CNS. This richness of sensory potential is supported by the 
complex heterogeneity of DRG neurons. The cell bodies of sensory neurons are intermingled 
together within the DRG, however they are organized into a number of types and subtypes, 
each specialised for the detection of distinct stimuli. These include neurons sensing body 
movement and position (proprioceptors), touch and pressure (mechanoreceptors), itch 
(pruriceptors), temperature (thermoreceptors) and pain (nociceptors). Although a certain level 
of distinct categorisation exists, sensory neurons can also be “polymodal”, or able to integrate 
multiple modalities, e.g., thermal and mechanical stimuli. Additionally, up to 25% of DRG 
nociceptors are normally dormant and only activated upon injury and are thus called “silent 
nociceptors”3,4. 
The basis for the classification of DRG neurons was formed as early as the 1920s by Gasser 
and Erlanger – the first to show a relationship between DRG neurons soma diameter, axon 
myelination degree, signal conduction velocity and fibre projection targets within the spinal 
cord lamina. They established that the smaller the soma diameter, the less the myelin 
sheathing and the slower the conduction velocity but the higher the excitation threshold is, 
and vice versa (Figure 1.2)5,6. From their morphological and electrophysiological observations 
arose the conventional DRG sensory neurons classification as it is known today: mammalian 
sensory neurons can be categorised into three general types: Aβ-fibres, Aδ-fibres and C-
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Aα-fibres are the largest in diameter, with conduction velocities in the range of 80 – 120 m/s. 
Defined by Gasser and Erlanger as motor nerves, the sensory neurons of the proprioceptive 
modality are usually denoted by the Aα-fibre type. They project into the deeper laminae of the 
spinal cord 5. 
Aβ-fibres have large soma diameter, heavily myelinated and with fast conduction velocities 
(30 – 70 m/s). The majority have low thresholds of activation and are dedicated to the detection 
of innocuous mechanical stimuli, such as touch and vibration, stretch and hair deflection 7. Of 
note, a significant proportion (e.g. ~20% of A-fibres in rat) of Aβ-fibres are Aβ-nociceptors, 
conducting in the Aβ conduction velocity range 8. In the spinal cord lamina, Aβ-fibres project 
into laminae III-V 9.  
Aδ-fibres have thin myelination and hence slower signal conduction velocity (5 – 30 m/s) than 
Aβ-fibres. Their size distribution in DRG is skewed, with populations of small- and medium-
sized cells. In the body, Aδ-fibres innervate mostly superficial organs (e.g. the skin). Aδ-fibres 
are associated with the detection of innocuous as well as noxious stimuli. Therefore, they 
include Aδ low-threshold mechanoreceptors (LTMRs) and Aδ nociceptors, responding to 
noxious mechanical and heat stimuli 10. Aδ nociceptors can be further divided into Type I and 
Table 1.1. Table summarising the relationship between neuronal properties and features. CV, conduction 
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Type II Aδ-mechano-heat (AMH) units according to the degree of sensitivity to either stimulus. 
Type I AMH are sensitive to chemical stimuli and have lower threshold to mechanical and 
higher threshold to heat (>53°C) stimuli. Hence, they are suggested to mediate first pain to 
noxious mechanical stimuli. In contrast, Type II AMH have lower heat (<46°C) and higher 
mechanical threshold and are thus suggested to serve the first pain sensation to noxious 
heat11. Activation of Aδ-nociceptors by noxious thermal or mechanical stimuli results in short-
lasting, prickling type of pain. In the spinal cord, Aδ-fibres terminate in laminae I, V (Aδ 
nociceptors) and III (Aδ-LTMRs) 10. 
C-fibres constitute over 50% of all DRG neurons and are of the smallest soma diameter. Their 
axons are unmyelinated and the signal conduction velocity ranges between 0.5 – 2 m/s. They 
are activated by one or a combination of two or more modalities, including temperature shifts, 
pruritogens, chemical irritants and mechanical pressure. Their high activation thresholds to 
these stimuli render the majority, but not all, of them nociceptors. Nociceptive C-fibres 
innervate deep somatic structures, such as the muscles and joints 12. While Aδ-fibre 
nociceptors convey acute and localized nociception, called ‘first’ or fast pain, nociceptive C-
fibres propagate ‘second pain’ which is more diffuse, dull and longer lasting 13. A portion of C-
fibre neurons, termed C-LTMRs, are responsible for propagating innocuous touch stimuli 9.  
Centrally, C-fibres project into the superficial laminae I-III.  
Albeit still used today, fibre classification of DRG neurons does not reflect the full 
heterogeneous spectrum of neuronal function and hence is not an adequate functionality 
predictor on its own.  Neurochemical markers and molecular classifications of DRG neurons 
have become key in building a more complete picture. A comprehensive summary of 
somatosensory cell type markers is presented in Table 1.2. 
More recently, transcriptomic techniques such as microarray, single-cell PCR and RNA 
sequencing (scRNA-seq) have produced their own elaborate DRG classifications. Usoskin et 
al. used scRNA-seq  to analyse 622 DRG neurons, detecting 3900 ± 1880 genes per neuron 
and distributing the neurons into 11 molecularly distinct subtypes with in vivo validation of the 
predicted subpopulations 14. Not long after them, Li et al. performed an even more in-depth 
sequencing of 197 DRG sensory neurons detecting 10950 ± 1218 genes per neuron and 
generating 17 molecularly distinct neuronal subtypes (however, not in vivo validated) 15. Their 
work was later reanalysed and their predicted number of classes reduced to 9 subtypes which 
largely overlapped with the predicted subtypes by Usoskin 16. Most recently, Zeisel et al. 
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that of 
Usoskin’s, delivers the most elaborate molecular classification of DRG sensory neurons to 
date, with a total of 18 neuronal subtypes identified 17.  
1.1.2. DRG neurons excitability 
A non-firing, or ‘resting’ neuron maintains an electrochemical gradient across its membrane 
called a resting membrane potential (RMP). It is determined by the uneven distribution of 
sodium (Na+), potassium (K+), chloride (Cl-), calcium (Ca2+) and organic anions across the 
membrane. The RMP is established by the difference in ion concentrations inside and outside 
the neuron and the relative permeabilities of the membrane to different ions. At rest, there are 
more extracellular Na+ ions than intracellular K+ ions. This concentration difference is 
maintained by Na+/K+ pump cycles, exchanging 3 Na+ out for 2 K+ into the cell.  
At rest, the membrane is more permeable to K+ than Na+, ions, letting them diffuse down their 
concentration gradient to the outside of the cell. Eventually, the free movement of K+ ions, 
Marker Sensory cell type 
Parvalbumin Proprioceptors and Aβ-fibres 
CGRP Peptidergic C fibres, subpopulation of Aδ-fibres 
Substance P Peptidergic C fibres 
NF200 Myelinated Aδ-fibres, Aβ-fibres and proprioceptors 
IB4 Non-peptidergic C-fibres 
Trpv1 Small diameter C-fibres (heat & pain) 
Trpm8 Small diameter C-fibres (cold & pain) 
MrgprD Small diameter C-fibres (noxious mechanical,pain) 
MrgprA3 Small diameter C-fibres (itch) 
MrgprB4 Small diameter C-fibres (innocuous mechanical) 
VGlut3 Non-peptidergic C-fibres (innocuous mechanical, cooling) 
TH Non-peptidergic C-fibres (innocuous mechanical, cooling) 
TrkB Aδ-fibres (innocuous mechanical, cooling) 
Npy2r Aβ-fibres (innocuous mechanical) 
Chondrolectin Aβ-fibres (innocuous mechanical) 
DOR 
Subpopulations of non-peptidergic C fibres and myelinated 
NF200+ fibres 
 
Table 1.2. Summary of the most commonly used markers for neuronal 
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unbalanced by the movement of Na+ to the inside, will cause the neuron to have negative 
charge inside and positive charge outside. Due to the established extracellular/intracellular 
charge difference, the excess negatively charged ions on the inside are attracted to the outside 
and vice-versa, accumulating along the inside and outside surfaces of the membrane and 
establishing a negative membrane potential. The membrane is ‘polarised’, causing the RMP of 
an average neuron to be around -70mV (Figure 1.2). Stimulus detection causes membrane 
depolarisation, which even small can activate some VGSCs and increase the Na+ permeability 
of the membrane, producing even greater depolarisation. The ‘threshold’ potential (~ -55mV) 
of a neuron is the critical point at which the membrane is depolarised to elicit an action 
potential (AP). During its depolarised state, the membrane shifts its permeability from K+ to Na+ 
ions, influencing the reversal of the charge difference across it. A critical component of the AP 
is the influx of Ca2+ ions through voltage-gated Ca2+ channels (VGCCs), important for the 
activation of K+ channels (key during repolarisation) and transmitter release 2,18 . Following AP 
generation, the neuron needs to engage cellular mechanisms for Ca2+ ion clearance to avoid 
Ca2+ overflow in the cell and initiate repolarisation. Most of the intracellular Ca2+ is cleared 
through extrusion via the transmembrane Na+/Ca2+ exchanger or Ca2+ ATPase. Alternatively, 
Ca2+ ions can also be sequestered through uptake by the neuronal endoplasmic reticulum via 
its own transmembrane Ca2+ ATPases or into mitochondria 19. All Ca2+ clearance mechanisms 
require energy in the form of ATP to shuttle Ca2+ ions out of the neuronal cytoplasm and play 
an important protective role and influence the shape of the Ca2+ signal and thus AP 19,20.  
The pathway of the signal propagation follows three main steps: transduction, transmission 
and perception. Each of them is carried out through the highly coordinated activation and 
deactivation of all the different ion channels across the membrane, allowing the external 
stimulus to travel through the PNS and be perceived and processed in the CNS. This process 
will be reviewed in more details in the context of pain signalling in the next section of this 
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1.2. Pain: the good and the bad  
1.2.1. The pain signalling pathway 
The ability to detect, transmit and perceive pain is a key protective mechanism essential for 
one’s survival. The process of pain signalling is called nociception. It starts with a noxious 
stimulus (chemical, mechanical or thermal) being detected at the terminals of nociceptors. The 
detection of the stimulus activates ion channels and receptors such as transient receptor 
potential activated (TRP) channels. This leads to the influx of Na+ which starts depolarizing the 
membrane, bringing it closer to the activation threshold of voltage-gated sodium channels 
(VGSCs) which act to amplify the signal. Once the threshold potential is reached, local VGSCs 
open simultaneously resulting in complete membrane depolarization and peak potential. The 
external stimulus is transduced into an action potential (AP)21. VGSCs then begin inactivating 
and voltage-gated potassium channels (VGKCs) and K+ leakage channels open allowing K+ 
efflux. This initiates membrane repolarization and subsequently hyperpolarization. Finally, the 
Na+/K+ pump takes over to restore and maintain the RMP (Figure 1.2). In the meantime, the 
AP generated is propagated up the axon driven by the same sequence of ion channels opening 
and closing akin to a chain reaction, going through the DRG cell body and eventually reaching 
the dorsal horn of the spinal cord. Once at the nociceptor’s presynaptic terminal, the AP 
Figure 1.2. A simplified visualisation of the action potential generation in neurons and 
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causes VGSCs there to open and Na+ to flood in, which in turn activates local voltage-gated 
calcium channels (VGCCs). This results in calcium influx, bringing on a release of 
neurotransmitters such as substance P, CGRP or glutamate. The AP is thus passed over to 
the postsynaptic terminal of a second-order neuron (interneuron), completing the synaptic 
transmission. Finally, from there the signal can be propagated to the brain, where the site of 
pain perception and processing lies 21.   
1.2.2. Pain as a disease   
Dysregulation in any of the signalling steps outlined above can lead to abnormal pain signalling 
producing neuropathic pain. Unlike nociceptive pain, which is transient in nature and benefits 
the individual, neuropathic pain is sustained, usually chronic and evolving throughout the 
neuropathy duration. In its pathological state, pain becomes a serious disease affecting 7-10% 
of people worldwide22,23. Neuropathic pain can arise from a direct injury to the sensory nerves 
or as a complication of a disease such as diabetes mellitus and other metabolic diseases24; 
cancer and chemotherapy25; HIV-infection26, leprosy27 and immune and inflammatory 
responses28 amongst others29. Damage to different pathway components can produce 
different signalling impairments such as decreased or increased AP firing thresholds, causing 
hyper- and hypoexcitability, respectively; dysregulated firing duration and/or degree and 
hence pain intensity (hyper- or hypoalgesia) or inappropriate nociceptive firing in the presence 
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1.2.3. DRG-expressed channels and receptors involved in pain  
From noxious stimuli detection to pain perception, pain signalling is a highly organised and 
controlled process. It relies on the appropriate expression and function of different voltage-
gated sodium, potassium and calcium channels, leak channels and ligand-gated channels 
(TRPs and acid-sensing ion channels). Among the vast diversity of ion channels implicated in 
pain signalling, several specific families and subtypes have been demonstrated as key 
regulators of sensory neurons excitability (Figure 1.3). Channel subtype-specific changes in 
distribution, density and kinetics are the main drivers of abnormal activity in the afferent 
neurons 21,31,32 . Genetic and pharmacological studies have validated several of them as 
promising drug targets in human conditions of pain signalling malfunction 21,32–34. These include 
DRG-expressed voltage-gated ion channels (VGSCs, VGCCs, VGKCs), channels of the TRP 
family and ligand-gated ion channels and leak channels. Those of them relevant to the 
experiments in this thesis will be discussed in more detail next.  
Figure 1.3. The ion channels involved in the pain signaling pathway.  
Site 1, Transduction: Noxious stimuli are sensed by DRG neuron terminals which activates local VGSCs and 
nonselective cation channels (e.g. TRP channels); Site 2, Propagation: the action potential is propagated along the 
axon driven by the activation of VGSCs, VGKCs. Site 3, Synaptic transmission: action potential reaches DRG cell 
bodies and activates local ion channels which mediate the transmission to the synaptic terminals in the dorsal horn. 
There, VGSCs and VGCCs open to enable neurotransmitter release necessary for the transmission of the signal to 
the CNS where it is processed. TRP, transient receptor potential; VGSC, voltage-gated sodium channel; VGKC, 
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1.2.3.1. Voltage-gated sodium channels 
VGSCs regulate AP firing in all electrically excitable cells, such as skeletal and cardiac muscle 
cells and neurons. Their main role in neurons is to initiate, amplify and propagate the AP. The 
major functional Na+-conducting component of VGSCs is formed by their α-subunit 35, while 
their kinetics and biophysical properties are regulated by their β-subunits 36. In mammals, there 
are nine VGSC α-subunits and thus nine different VGSC isoforms (Nav1.1-Nav1.9) sharing 
overall structural and gating motifs but differing in their expression patterns, pharmacological 
and functional signatures (table 1.3). A 10th VGSC isoform has also been identified (Nax), 
however it does not share the voltage-gating properties of the rest37.  
VGSCs have different sensitivity to pore-blocking toxins, the most extensively used of which 
is tetrodotoxin (TTX). Accordingly, it is used to differentiate TTX-sensitive (TTX-S) from TTX-
resistant (TTX-R) VGSCs. Sodium channels of the PNS can be both TTX-S and TTX-R 38–40. 
Distinct TTX sensitivity has been used to distinguish VGSC biophysical properties and 
Table 1.3. Voltage-gated sodium channel isoforms discovered 
to date with respective gene, tissue distribution and sensitivity 
to tetrodotoxin (TTX). TTX-S, tetrodotoxin-sensitive; TTX-R, 
tetrodotoxin-resistant;TG, trigeminal ganglia; SCG, superior 
cervical ganglia;  ND – not determined. Source: Cummins et al. 
(2020) 
Channel Gene Tissue distribution 
TTX 
sensitivity 
Nav1.1 SCN1A DRG, TG, CNS TTX-S 
Nav1.2 SCN2A CNS TTX-S 
Nav1.3 SCN3A Foetal DRG, CNS TTX-S 
Nav1.4 SCN4A Skeletal muscle TTX-S 
Nav1.5 SCN5A Heart muscle TTX-R 
Nav1.6 SCN8A DRG, TG, CNS TTX-S 
Nav1.7 SCN9A DRG, TG, SCG TTX-S 
Nav1.8 SCN10A DRG, TG TTX-R 
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contributions, particularly in nociceptive neurons. By and large, TTX-S VGSCs are 
characteristic with fast activation and inactivation, whereas TTX-R channels are slowly 
activating and inactivating41 .  
Five VGSC isoforms are expressed in the DRG (Nav1.1, Nav1.6-1.9) and of these, three (Nav1.7-
Nav1.9) are expressed relatively specifically in nociceptors. Although virtually all isoforms have 
been implicated in pain, the contribution to nociception of Nav1.3, Nav1.6, Nav1.7, Nav1.8, and 
Nav1.9 has been the most extensively evidenced42,43. The next part of this chapter will explore 
their role in nociception and pain disorders in more detail by discussing the expression and 
biophysical properties of each as well as evidence from clinical and animal studies.   
• Nav1.3 
Albeit not as strongly implicated in pain as the rest of the channels discussed in this section, 
Nav1.3 is of particular interest as a pain target due to its circumstantial expression pattern. 
Namely, this channel is usually not detectable in the adult, fully developed nervous system but 
its expression is upregulated in DRG neurons as well as second- and third-order neurons of 
the dorsal horn and thalamus under certain pathological conditions such as peripheral nerve 
inflammation and transection 44,45. Nav1.3 has fast activation and inactivation and rapid 
repriming kinetics as well as persistent current that contribute to spontaneous ectopic 
discharges and sustained repetitive firing in injured neurons 31. Due to the absence of isoform-
selective and safe blockers, evidence of its involvement in neuropathic pain stems from 
genetic experiments. Antisense-driven Nav1.3 knockdown studies show both attenuation of 
pain 46  and no effect 47. More recently, knockdown based on adeno-associated virus delivery 
of Nav1.3 short hairpin RNA has been demonstrated to produce amelioration of pain behaviour 
in rodent models of neuropathic pain 48 as well as diabetic neuropathy 49.  
• Nav1.6 
The TTX-S channel Nav1.6 is the most abundantly expressed isoform in the CNS. In the PNS, 
it is present in all parts of the peripheral nerves, but it is especially abundant in the nodes of 
Ranvier, the microscopic myelination gaps along an axon, in myelinated DRG fibres. It is 
expressed constitutively in all DRG sensory neurons, with higher concentration in large, 
NF200+ neurons 50. In fact, Nav1.6 has been shown to contribute to up to 60% of Na+ currents 
in large DRG compared to 34% in small DRG neurons 51. It has a more hyperpolarised 
activation voltage compared with other VGSC isoforms and mediates persistent and resurgent 
Na+ currents contributing to repetitive AP firing 52,53. The role of Nav1.6 in pain signalling has 
been established mainly through genetic studies. While gain of function mutations are linked 
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Nav1.6-knockdown decreases TTX-S resurgent DRG currents and mechanical allodynia 55,56. 
Emerging evidence has pointed to the differing temporal upregulated expression of Nav1.6 in 
different stages of neuropathic pain. Different models of neuropathic pain, including nerve 
injury and diabetic neuropathy, show decreased or unchanged levels of expression of Nav1.6 
in DRG in the first 4 weeks of pain 57,58, whereas at later stages there appears to be a consensus 
over the upregulated expression of Nav1.6 in DRG neurons 59,60.  
• Nav1.7 
Nav1.7 is highly expressed in the PNS, predominantly in DRG, TG and sympathetic neurons. 
In DRG neurons, it is detected mainly in Aβ-fibres and C-fibres (nociceptors), along the entirety 
of the neuron 61,62. Other excitable cells expressing Nav1.7 include myenteric neurons, visceral 
sensory neurons and neurons of the olfactory sensory system 63,64 as well as in the 
hypothalamus of rodents 65. In non-excitable cells, it has been demonstrated to have a 
functional role in the pancreatic islet β-cells of some species 66.  
Nav1.7 is TTX-S and, like the rest of the channels from this category, is characteristic with rapid 
activation and inactivation kinetics. However, it has a distinct slow recovery rate from 
inactivation, making it unlikely to contribute to repetitive firing 53,67. Nav1.7 also inactivates 
slowly at negative membrane potentials, which means it can remain open for longer at 
potentials close to RMP. Thus, it contributes to Na+ currents at RMP, generating “ramp 
currents”, important for recruiting other VGSCs (such as Nav1.8) to elicit an AP 53. These 
specific biophysical properties, together with its high expression in fibre terminals, render 
Nav1.7 an AP generator or ‘threshold’ channel, setting the gain in nociceptors. 
The first clues for Nav1.7 implications in pain signalling were provided by genetic and functional 
profiling studies of mutations in the gene encoding it – SCN9A.  Missense mutations in SCN9A 
produce inherited erythromelalgia (IEM), a disorder presenting with severe burning pain in the 
distal extremities in response to mildly warm stimuli (thermal hyperalgesia) 68,69. The 
exaggerated thermal pain phenotype is presumed to be the result of a gain of function (GoF) 
mutations in the SCN9A gene causing hyperpolarized activation of Nav1.7 bringing its 
activation threshold further down. Being easier to activate, even small depolarizing stimuli are 
sufficient to trigger Nav1.7 opening in nociceptors causing allodynia and hyperexcitability 70,71. 
Another dominant GoF mutation in the SCN9A gene, which impairs Nav1.7 rapid inactivation, 
causes a syndrome known as paroxysmal extreme pain disorder 72. The depolarising shift in 
the channel’s fast inactivation produces an increase in resurgent Na+ currents leading to 
enhanced DRG excitability 73,74. Patients suffering from this disorder experience extreme rectal, 
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to occur in up to 30% of patients with diagnosed small-fibre neuropathy, impairing Nav1.7 
kinetics in both directions, i.e. hyperpolarising its activation potential and depolarising its 
inactivation potential in nociceptive Aδ- and C-fibres 75. GoF Nav1.7 variants have also recently 
been associated with diabetic neuropathy 76 - discussed in more detail later. The increased 
Nav1.7 activity in these subjects produces spontaneous firing in DRG neurons causing severe 
pain.  
In contrast, loss of function (LoF) recessive mutations in the SCN9A gene have been linked to 
channelopathy-associated insensitivity to pain (CIP). Affected individuals present with normal 
sensitivity to innocuous stimuli but display painless wounds, fractures and childbirth 77,78 as 
well as, curiously, an inability to smell (anosmia) 63. In this case, the mutations produce a 
truncated variant of the Nav1.7 channel which is not functional. The function of the small fibres 
is impaired while that of large fibres is preserved. Further to that, a recent study investigating 
the role of Nav1.7 in CIP patients in more depth showed that the absence of a functional Nav1.7 
leads to structural changes in the affected afferents as well. They reported a significant 
decrease in intraepidermal nerve fibre (IENF) density of the distal leg and thigh of patients, 
implying a potential role of Nav1.7 in long-term structural integrity in human nociceptors, 
particularly in the distal terminals 78. Additional links between Nav1.7 and human pain disorders 
have also emerged from studies showing that single nucleotide polymorphisms in the Nav1.7 
gene lead to a subtle increase in nociceptor excitability and increased pain sensitivity in pain 
disorders 79,80. Albeit extremely rare, collectively, these mutations strongly support the 
importance of Nav1.7 in the pain signalling pathway and as a target for pain relief.  
Clinical case data has been further supported by animal studies. Nav1.7-knock-out (KO) mice 
have aided significantly in the understanding of the mechanisms of Nav1.7 role in pain. 
Originally, a Nav1.7-/- global KO in mice was lethal due to producing pups unable to feed. It was 
later demonstrated that this was due to the high expression of Nav1.7 in olfactory sensory 
neurons in rodents 64. Knocking the channel out completely prevented blind new-born pups 
from relying on their sense of smell to feed. This insight allowed for the successful generation 
of a robust global Nav1.7-KO model in 2014 by manually supporting KO mouse pups feeding 
81. The optimised Nav1.7-KO model produced mice with near complete acute, inflammatory 
and neuropathic pain deficit.   
Tissue-specific Nav1.7-KO mutants utilising the Cre-recombinase-loxP system have also been 
available for the last decade. The first evidence of Nav1.7 function in pain from such studies 
was supplied by a KO mouse whereby Cre- was driven specifically into Nav1.8-expressing 
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conditional deletion of Nav1.7 led to a dramatic loss of mechano- and inflammatory pain 
sensitivity 82. Other tissue-specific Nav1.7-KO models employing alternative DRG-targeting 
approaches (e.g. DRG-specific advillin, or neural crest-specific protein Wnt1) produced similar 
phenotypes 83,84.  
Of note, not long ago it was demonstrated that there exist Nav1.7 independent pain states. One 
case study reported a unique CIP patient experiencing chronic neuropathic pain following 
pelvic fractures and lumbar nerve impingement where Nav1.7 signalling was intact 85. Similarly, 
a different study showed that Nav1.7 was not required for the phenotype of chemotherapy-
induced or cancer-induced bone pain in a mouse model 86 suggesting that similar pain 
phenotypes can be driven by different molecular mechanisms.  
Overall, Nav1.7 has been strongly established as a key regulator in DRG excitability, specifically 
in nociceptors. Its dysregulation has been extensively demonstrated to contribute to abnormal 
pain signalling in animal experiments and patients 78. Thus, it has remained as, perhaps, the 
most studied target for analgesic drugs with various Nav1.7 channel blockers being developed 
(discussed in more detail in section 1.3.3.2.) 
• Nav1.8 
Encoded by the SCN10A gene, Nav1.8 is expressed in sensory neurons in the DRG, TG as well 
as nodose ganglion neurons 87,88. In the DRG, it is expressed in up to 90% of both non-
peptidergic (IB4+) and peptidergic (IB4-) small nociceptive fibres 89, however it has been 
shown to be expressed in large myelinated neurons, including LTMR C- and Aβ fibres 
responsible for touch sensation 90 . Elsewhere, it is detected in high quantities in intracardiac 
neurons where it plays a significant role in cardiac electrophysiology 91. Nav1.8 is of the TTX-
R family of VGSCs, but it is characteristic with its own unique biophysical properties. 
Compared to Nav1.9 and TTX-S channels, Nav1.8 is distinguished with a more depolarized 
activation threshold and slow inactivation. What this means is that: 1) Nav1.8 can be activated 
only following the activation of a TTX-S channel and 2) Nav1.8 channels can remain active long 
after other VGSCs have been inactivated, contributing to most of the generated Na+ current 
upon depolarisation 92,93. Nav1.8 also recovers quickly from inactivation and thus, contributes 
to high frequency AP firing when membrane depolarisation is sustained 92.  
Several GoF mutations have emerged from patient cases. An international coalition from 2012 
conducted genetic analyses of 104 small-fibre neuropathy patients. No SCN9A (Nav1.7) 
mutations were identified, but 7 SCN10A mutations were described in 9 of the patients. All of 
them shared similar shifts in the Nav1.8 channel’s kinetics, including hyperpolarization of its 
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generation threshold and increased the rate of AP firing, thus producing high-frequency 
spontaneous firing even in the absence of stimuli, culminating in DRG hyperexcitability. 
Natural SCN10A LoF mutations have not yet been identified in humans, therefore knowledge 
of Nav1.8’s role in pain has been derived from genetic studies on animal models. The global 
Nav1.8KO mouse showed only moderate analgesia to painful stimuli 97. In a later study, a 
Nav1.8KO mouse model of neuropathic pain displayed no change in its painful phenotype 98. 
These observations contradict those obtained from mice with genetically ablated neurons 
expressing Nav1.8 channels, where animals showed profound loss of pain 99; or knocked-down 
Nav1.8 channel, where TTX-R current was reported to be significantly reduced and spinal 
nerve ligation-induced neuropathic pain behaviour reversed 100. This discrepancy was 
attributed to a key compensatory mechanism being triggered in the global Nav1.8KO, whereby 
Nav1.8 absence induced upregulation of Nav1.7 expression and hence TTX-S current, thus 
preserving the neuropathic pain phenotype 87. However, in a later study, a Nav1.7/Nav1.8 
double KO mouse model displayed reduced inflammatory pain and impaired mechanical and 
thermal acute pain thresholds but developed normal levels of neuropathic pain, implicating 
Nav1.8 is not necessary for nerve injury-induced pain 101. 
Interestingly, Dib-Hajj et al. (1996) observed that Nav1.8 expression and TTX-R current is 
downregulated in injured DRG neurons (following transection of the peripheral nerve), 
however they were upregulated in neighbouring uninjured neurons102. A similar conclusion 
was also reached by Gold et al. (2003) who observed a significant redistribution of Nav1.8 
channels to uninjured neurons adjacent to injured fibres of the sciatic nerve. This was 
accompanied by an increase in the TTX-R current, particularly in uninjured C-fibres and 
partially in thinly myelinated Aδ-fibres following injury, leading to spontaneous activity in these 
neurons 103. Remarkably, Coward et al. (2000) established a time-dependent shift in Nav1.8 
involvement in such neuropathic pain. Overtime, post-injury Nav1.8 upregulation and 
hyperexcitability affected not only uninjured but also the injured nociceptors as well. Therefore, 
considering neuropathic pain in particular, Nav1.8 might be involved via a temporal role shift 
from intact to injured neurons as the injury progresses 104. In contrast to neuropathic pain, the 
contribution of Nav1.8 to inflammatory pain is better established. Different inflammatory 
mediators, such as NGF, TNFα and other cytokines, have been evidenced to modulate Nav1.8 
biophysical properties and causing hyperexcitability in DRG neurons 98,105–108. 
• Nav1.9 
The other DRG-expressed TTX-R channel is Nav1.9, encoded by the SCN11A gene. Unlike 
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and produces a persistent current 109. Nav1.9 is expressed in the soma of small-diameter DRG 
and TG neurons. Expression in the PNS is particularly concentrated in non-peptidergic 
nociceptors 110,111. The specific biophysical properties of Nav1.9 and its distribution along 
sensory neurons suggest it may determine the activation threshold of small DRG neurons 109. 
The role of Nav1.9 in neuropathic pain is not fully understood and the literature remains 
controversial. In humans, 7 different mutations have been identified in the SCN11A gene in 
peripheral neuropathy patients which modified the channel properties via various 
mechanisms. These include reducing the current threshold and increasing the firing frequency 
thus increasing DRG excitability and causing patients to experience episodic chronic pain 112–
114 and, in the case of some – cold pain 115. Nerve-injury models of Nav1.9-null mice including 
partial sciatic nerve injury 116, chronic constriction injury 117 and spinal nerve transection 86, 
demonstrated no change in the pain-thresholds of the animals. In contrast, similar to Nav1.8, 
Nav1.9 expression and current in sensory neurons has been reported to be significantly lower 
in different animal models of neuropathic pain, including in DRG  118,119 and TG 120 neurons.  
Inflammatory pain, on the other hand, has been strongly linked to the presence of Nav1.9. 
Several studies assessing the effects of a great diversity of inflammatory agents on Nav1.9KO 
mice were all consistent in their reports, observing reduction in the pain behaviour of these 
animals 116,121–123. It is speculated, that inflammatory mediators act via a G-proteins-dependent 
mechanism to increase Nav1.9 persistent current and lead to spontaneous activity in affected 
sensory neurons 124. 
From all of the above, DRG-expressed VGSCs contribute greatly to various pain states and 
represent attractive targets for novel analgesics in development. Characterising the changes 
in their function in models of neuropathic pain is, therefore, essential for the development of 
better-targeted and safer therapies. However, they are only one avenue of research into 
neuropathic pain.  
1.2.3.2. Transient receptor potential cation channels: TRPV1 and TRPA1 
External stimuli are transduced into APs via the activation of another group of specific cation-
conducting channels expressed in the neuronal membrane. These are the superfamily of 
transient receptor potential (TRP) ion channels which contribute to sensory perception in 
animals. Most lately, the great diversity within TRP channels was categorised into nine animal 
subfamilies: TRPA (ankyrin), TRPV (vanilloid), TRPVL (vanilloid-like), TRPC (canonical), TRPN 
(no mechanoreceptor potential C), TRPM (melastatin), TRPS (soromelastatin), TRPML 
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channels with distinct structural homology giving rise to specific signal integration and 
regulation functions. Members of the TRP subfamilies are activated by a great range of stimuli, 
including photosensation, mechanosensation, thermosensation and nociception, some 
integrating two or more modalities. Thus, they are key polymodal cellular sensors (for in depth 
reviews see 125,126). 
ThermoTRP channels represent those members of the families that are particularly sensitive 
to temperature. Of all TRP channels, nine are characteristic with differing ranges of activation 
temperatures (Figure 1.4). TRPV1-4, and TRPM2, 4 and 5 are heat-activated, while TRPA1 and 
TRPM8 are cold-activated 127. Of these, two have received a great amount of interest and have 
been implicated in nociception the most 128,129. Since functional changes in the same two TRP 
channels are also the focus of part of the upcoming experiment chapters, the rest of this 
section will cover the properties and role in pain of these two channels, namely TRPV1 and 
TRPA1.  
• TRPV1 
The TRPV1 (transient receptor potential cation channel subfamily V member 1) channel is the 
first channel of the TRP family to be cloned and have its structure resolved. To date, it is also 
the most studied member of the TRP superfamily due to its intriguing polymodality and role in 
pain 130. Encoded in humans by the TRPV1 gene, it is a nonselective cation channel with a 
ligand- and heat-gated mechanism. In the nervous system, it is mainly expressed in the TG 
and DRG sensory neurons and cranial nerve cervical ganglia neurons innervating organs in 
the head 130,131. In primary afferents, TRPV1 is distributed throughout, from the skin-terminating 
free endings (highest density), along the axons and in the cell bodies, with especially high 
Figure 1.4. Diagram depicting the thermal sensitivity spectrum of thermoTRP channels. 
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expression rates in small-diameter peptidergic nociceptors demonstrated using reporter mice 
(up to ~82% in the adult mouse DRG) 132.  
The structure of TRPV1 has been studied extensively 130 due to its sophisticated gating, 
regulation and ion selectivity mechanisms. TRPV1 is a cation-permeable channel with a strong 
preference for Ca2+ ions (10-fold more Ca2+ conductance than other ions). Upon TRPV1 
activation, a strong Ca2+ and moderate Na+ influx is triggered, depolarising the membrane 
which, if strong enough, can lead to the activation of voltage-gated ion channels (such as  
Nav1.7) and thus generate an AP 133. 
A homotetrameric membrane protein, TRPV1 possesses a distinct structural complexity to 
which it owes its vulnerability to a range of different stimuli categories. These include vanilloids 
(capsaicin, resiniferatoxin), lipids, noxious heat (≥43°C) and acidic solutions (protons) (pH< 
6.0) 134. Interestingly, each group of stimuli has its distinct site of action on TRPV1. For example, 
vanilloids are lipophilic and have been shown to diffuse through the lipid membrane and bind 
to an intracellular site on TRPV1 135,136. Protons, on the other hand, act exclusively on an 
extracellular acidic site of the channel 137,138, while high temperatures critically change the 
proximal region of the C-terminus 138. The segregation of active sites allows for each stimulus 
to trigger channel gating alone but also for two or more stimuli to act together and cooperate 
to potentiate the channel. For instance, when pH is low, for example during tissue acidosis 
following an injury, local TRPV1 channels have lowered temperature activation thresholds so 
that they can be activated at as low as room temperature 139–141. This facilitates TRPV1 
activation, thus sensitising nociceptors during moderate acidosis in ischemic or inflamed nerve 
tissues, contributing to allodynia and/or hyperalgesia 140. 
TRPV1 has been strongly linked to nociception. Upon an injury, various inflammatory 
molecules (such as bradykinin and prostaglandin E2) are released which together with 
cytokines and neurotrophins have been shown to sensitise TRPV1 to its stimuli through 
phospholipase C, protein kinase A (PKA) or C (PKC) pathways 142–145; or even directly activate 
it (such as some lipid mediators) 146 147. Evidence for the role of TRPV1 in inflammatory pain 
comes from experiments with TRPV1-null mice. The mutant mice showed no capsaicin-
induced pain behaviour and had attenuated inflammation-induced thermal hyperalgesia and 
did not respond to noxious heat 148,149. These observations were confirmed by pharmacological 
experiments with mice injected with a TRPV1 antagonists (such as capsazepine), also 
reporting attenuated thermal hyperalgesia under inflammatory conditions 148,150.  
In neuropathic pain, the evidence of TRPV1 contribution is still contradictory. In TRPV1-null 
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models of neuropathic pain exhibit decreased pain following pharmacological inhibition of 
TRPV1 152,153. In addition, development of sustained thermal hyperalgesia has been correlated 
with the increased expression of TRPV1 154. Finally, TRPV1 has been implicated in neuropathic 
pain arising as a complication from certain conditions. Elevated expression levels of the thermo 
channel in DRG and dorsal horn have been reported in diabetic neuropathy and cancer-
induced chronic pain models, correlating with hyperalgesia behaviour 58,155,156. Therefore, 
targeting TRPV1 for pain alleviation may prove promising. In fact several TRPV1-targeting 
ligands have been in development and focus appears to be equally on agonists as well as 
antagonists 157.  
• TRPA1 
Another well-studied TRP channel is the TRP ankyrin 1 (TRPA1) channel. TRPA1 is expressed 
in the sensory neurons of the DRG and TG 158, predominantly in, non-peptidergic (IB4+) 
nociceptors 159. It is often co-expressed with TRPV1 in a subset of nociceptive neurons 160 and 
has been suggested to interact with it and form a heteromeric channel 161. Being a Ca2+-
permeable channel, upon TRPA1 activation intracellular Ca2+ levels increase drastically 
leading to neuronal excitation 158.  
Much like TRPV1 and other thermoTRPs, it is activated by a range of stimuli, individually as 
well as simultaneously. These include mechanical perturbations 162, exogenous irritants such 
as cinnamaldehyde (compound in cinnamon), cannabinoids, acrolein (present in tear gas), 
menthol and allyl isothiocyanate (AITC, found in wasabi, radish and mustard) 163–165; as well as 
endogenous molecules released upon tissue damage and inflammation 165. In addition to being 
a chemosensor, TRPA1 has been implied to be activated by cold temperatures (~17°C), 
demonstrated clearly in vitro 160,166,167. However others using heterologous expression systems 
163,168 as well as TRPA1-null mice 169 report contradicting findings on its ability to be activated 
by noxious cold, leaving the role of TRPA1 as a cold sensor highly controversial.  Of note, 
TRPM8 is also activated by menthol and cool temperatures (~25°C), shaping a separate 
population of cells specialised for low temperature sensing 170.  
With high expression levels in nociceptors, TRPA1 has been implicated in acute, inflammatory 
and neuropathic pain. The role of TRPA1 in inflammatory hypersensitivity was first reported in 
a study demonstrating its contribution to the excitatory effects on nociceptors induced by the 
inflammatory mediator bradykinin164. These results were confirmed by a pivotal study showing 
decreased formalin-induced nociceptive response in rodents following TRPA1 
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documented to be involved in mechanical and cold hypersensitivity associated with 
inflammation as well 172–174. 
The involvement of TRPA1 in neuropathic pain was initially suggested by observations made 
in spinal nerve ligated mice, where TRPA1 was downregulated in injured L5 DRG but 
upregulated in uninjured L4 DRG (much like the case with Nav1.8 in the same nerve injury 
model, see section 1.2.3.1, Nav1.8) 175. Similar redistribution of TRPA1 expression was noted 
in other nerve injury models 176–178. Several TRPA1 antagonists 179,180 and TRPA1-/- animal 
models 181–183 have shown attenuated allodynia and hypersensitivity after peripheral nerve 
injury. TRPA1 has been implicated in diabetic neuropathy: its inhibition reduces mechanical 
allodynia and hypersensitivity in rat diabetic neuropathy models 184, while methyglyoxal, an 
abundant glucose metabolite during diabetes, has been shown to activate TRPA1, contributing 
to hyperalgesia 185. 
1.2.3.3. Purinoceptors: P2X purinoceptor 3 (P2X3) 
The P2X purinoreceptor family includes ligand-gated ion channels activated by binding of 
extracellular adenosine 5’-triphosphate (ATP). Apart from providing energy for cellular 
processes, ATP also acts as an important intercellular messenger released locally by damaged 
tissues. It binds P2X receptors expressed by sensory neuronal terminals and cell bodies in the 
periphery and interneurons in the dorsal horn 186,187. There are seven different P2X subunits 
(P2X1-7) expressed in DRG, TG and nodose ganglia. Amongst them, P2X3 is the only subtype 
selectively expressed in small C-fibre nociceptors, particularly the non-peptidergic 
subpopulation 188,189. P2X3 is a trimeric cation channel contributing to up to 96% of ATP-induced 
responses in DRG sensory neurons 186. Upon ATP binding, P2X3 channels activate and are 
desensitized within milliseconds, however ATP dissociation and desensitization recovery can 
take minutes thus limiting repetitive AP firing 190,191. 
Pharmacological studies using P2X3 selective antagonists 192–195 and animal studies using 
P2X3-deficient 196,197 or P2X3-selective-antisense-treated animals 198–200 have demonstrated 
that P2X3, along with its heteromeric assembly with P2X2 (forming P2X2/3), are responsible for 
transmitting persistent, inflammatory and neuropathic pain. For example, the intraplantar 
flinching in P2X3-/- mice was reduced in response to α,β-MeATP and formalin (used to induce 
inflammatory pain in animals) 197, indicating a strong role of DRG P2X3 receptors in 
inflammatory pain. Antisense-driven knockdown of P2X3 confirmed these findings  and 
demonstrated reversal of mechanical allodynia in different neuropathic injury models 199,200. 
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antagonists are in development for treating migraine, itch-associated pain and cancer pain 201–
204. 
To summarise, these sections highlighted the importance of several VGSCs, TRPV1, TRPA1 
and P2X3 in nociception and pathological pain promoting further research into their function 
during chronic pain conditions. These channels form an attractive cohort of targets for efficient 
molecules that can downregulate their function to alleviate pain and have an important function 
as markers of sensory subtypes in DRG characterizing experiments. The study presented here 
focuses on targeting the activation of VGSCs, TRPV1, TRPA1 and P2X3 in order to investigate 
their contribution, as well as that of the neuronal subpopulations they mark, to neuronal 
excitability changes during diabetic neuropathy – the topic of the next section of this chapter. 
1.3. Diabetic neuropathy and pain  
Diabetes mellitus is an umbrella term covering a group of metabolic disorders leading to 
impaired glucose uptake and metabolism by the body. In a healthy organism, its metabolization 
involves several steps, simplified and summarised in Figure 1.5. Glucose molecules are 
obtained from food and metabolised in cells to release energy. Their uptake by the cells from 
the blood relies on the adequate function of the anabolic hormone insulin, secreted by the 
pancreatic β-cells. Its role is to bind to its receptor on the cell membrane of hepatocytes, 
skeletal muscle cells and promote glucose absorption from the blood primarily for energy 
generation (ATP). If not utilized for energy, excess glucose is stored in the form of glycogen 
(chains of glucose molecules) in the muscle and liver tissue or triglycerides (fat) in adipose 
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1.3.1. Diabetes  
The main characteristic of all diabetic disorders is impaired insulin signalling rendering the 
body unable to regulate blood glucose levels. The result is chronic hyperglycaemia, or 
elevated blood glucose. If uncontrolled, prolonged hyperglycaemia can lead to disabling and 
even fatal acute and chronic complications including cardiovascular disease, kidney damage 
(nephropathy), eye disease (retinopathy) and nerve damage (diabetic neuropathy) 207,208. 
Although diabetic complications are all predominantly caused by excess blood glucose, the 
cause of hyperglycaemia can be different, giving rise to the two main distinct forms of diabetes: 
type 1 (T1D) and type 2 diabetes (T2D). In order to understand the underlying mechanisms of 
diabetic neuropathy and address its research and treatment adequately, one must first 
consider T1D and T2D as the distinct, if not opposite in some respects, diseases that they are, 
which is the aim of this chapter section. A brief outline of the characteristics of each is given 
in table 1.4  
Figure 1.5. Normal physiology of 
glucose metabolism. (1) Food rich in 
sugars and carbohydrates is broken 
apart by the digestive system into its 
constituents, mainly glucose 
molecules. Glucose enters the 
bloodstream; (2) Glucose molecules 
bind to glucose transporters on the 
pancreatic β-cells triggering a 
cascade of events leading to the 
release of insulin; (3) Insulin increases 
the uptake of glucose from the blood 
by target tissues (muscle, liver) for 
energy production and/or storage 
thus decreasing blood glucose 
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1.3.1.1. Type 1 Diabetes – an autoimmune response 
T1D is now well-recognised as a chronic autoimmune disorder, characteristic with immune-
mediated destruction of the insulin-producing pancreatic β-cells. Their absence leads to a 
marked deficiency in insulin secretion (Figure 1.6b). With no circulating insulin to regulate 
blood glucose levels, hyperglycaemia develops. With insulin unavailable, target cells cannot 
uptake any of the abundance of glucose and become starved and unable to produce energy 
leading to rapid weight loss despite an increase in appetite amongst other symptoms (Table 
1.3). The underlying causes for this devastating process are believed to include a combination 
of genetic susceptibility (with multiple genes altered, typically ones encoding components of 
the immune system) and environmental factors, commonly viral infections, toxins or diet, that 
trigger an autoimmune response 209. The prevalence of T1D is approximately 10% of diabetic 
cases with highest incidence in children and adolescents 209,210. Diagnosis of both diabetes 
Table 1.4. Summary of the main characteristics for diabetes type 1 and 2. Adapted from Ozougwu O. (2013). 
 Type 1 Diabetes Type 2 Diabetes 
Prevalence ~ 10 % ~ 90 % 
Onset Sudden Gradual 
Age of diagnosis Mostly children Mostly adults 






Low or absent High initially, then decreasing 
Insulin resistance No  High 
Autoantibodies Present No 
Symptoms 
• Abnormal thirst & 
frequent urination 
• Sudden weight loss  
• Fatigue  
• Chronic hunger 
• Blurred vision  
• impaired wound healing  
• Excessive thirst & urination 
• Weight gain 
• Fatigue 










• Cardiovascular disease 
Treatment Insulin supplementation 
Lifestyle and diet changes, 
thiazolidinedione,  
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types requires fasting blood glucose levels over 7 mmol/L and blood glycated haemoglobin 
levels of 6.5% or higher. To distinguish it from T2D, T1D diagnosis also requires detection of 
diabetes-associated autoantibodies, which can be present up to years before symptomatic 
onset 211. Daily insulin supplementation begins immediately following diagnosis and is normally 
efficient at controlling the disease. Patients usually develop chronic T1D complications over 
approximately 10 years from diagnosis, depending on blood glucose levels management and 
the degree of blood vessels damage 209. The prevalence of symptomatic diabetic neuropathy 
in T1D patients is substantial and consistent.  Two large scale studies from 2020 established 
an average 11-13% prevalence estimate of  symptomatic diabetic neuropathy in T1D 
population, with the proportion approximating 20% in older subgroups 212,213. 
1.3.1.2. Type 2 Diabetes – a lifestyle problem 
In contrast, T2D does not involve an autoimmune response, but is rather more tightly 
influenced by environmental factors, with an especially strong link to the global obesity 
pandemic 214,215. In T2D, initially, insulin is still being produced and secreted, however it cannot 
exercise its effect on target cells (muscle and liver). This state of cell insensitivity to the 
hormone is termed “insulin resistance” (IR) and is the key component distinguishing T2D from 
T1D pathophysiology. Thus, target cells remain “closed” for the high glucose flow from the 
blood. Ironically, the body’s response to IR is to secrete even more insulin, which over time 
leads to β-cell failure and inadequate insulin production 216. 
While genetics, advancing age and ethnicity have been shown to be potential risk factors in 
T2D 217, the driving force behind IR is mainly high sugar and processed carbohydrate 
consumption, sedentary lifestyle and obesity and usually IR develops many years before T2D 
is diagnosed 215,218–220. When the sugar intake is chronically excessive and exceeding energy 
demands, the cells in a healthy body metabolise and store the excess as glycogen (in muscle 
and liver cells) and triglycerides (in liver and adipocytes). With time, muscle and liver cells 
reach full glycogen storage capacity and thus become irresponsive to insulin attempts to store 
more incoming glucose. Still, the body prioritises lowering blood glucose levels, so the excess 
sugar can now only be metabolised into free fatty acids and deposited into new fat cells, 
continuing to increase body weight 221. Thus, in T2D blood levels of glucose as well as insulin 
(hyperinsulinemia) and triglycerides (dyslipidaemia) are abnormally high 222222–224.  With these 
two additional pathophysiological elements, T2D already differs significantly in its natural 
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T2D typically has a much less dramatic presentation, occasionally developing 
Figure 1.6. Insulin production compared between healthy, type 1 diabetes and type 2 diabetes setting. Insulin 
(blue triangles) is released by pancreatic β cells to allow glucose (red circles) uptake by target cells through 
glucose transporters (GLUT 4, pink). In a T1D scenario, insulin production is impaired leading to deficiency in 
insulin signaling to target tissue and no glucose uptake. In a T2D setting, insulin is still being produced, however 
target tissues are saturated with glucose, preventing insulin binding to its receptor and inhibiting further glucose 
uptake. In both T1D and T2D glucose is not cleared from the blood, leading to hyperglycemia. While in T1D cells 
are starved, leading to overall weight loss. Adapted from: Monica Schroeder, Science photo library, in T2D excess 
glucose is diverted to de novo adipose cells generation, contributing to weight gain and in severe cases obesity. 
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asymptomatically for a prolonged time 215. 
Ninety percent of diabetic patients suffer from T2D. It is most common in older adults (age 
40+) but has been increasingly more often diagnosed in young adults and children due to the 
worldwide rise in sedentary lifestyle and energy-dense diets. These circumstances are also 
propelling the overall T2D high and rising prevalence worldwide 225.  
1.3.2. Diabetic neuropathy 
Diabetic neuropathy (DN) is the most common complication arising from diabetes. DN is an 
impairment of the nerves of the body, caused mainly by prolonged hyperglycaemia damaging 
the microvasculature supplying the nerves (vasa nervorum). This can alter the functions of 
proximal and distal sensory, motor and autonomic nerves and thus damage virtually any organ 
system of the body causing a wide variety of symptoms 226. Worryingly, it is also the most 
problematic diabetic complication with statistics placing it as the most widespread form of 
neuropathy in developed countries. Approximately 50% of diabetic patients develop some type 
of nerve impairment, with neuropathy onset correlating positively with diabetes duration 227,228. 
DN accounts for more patients hospitalised than all other diabetic complications combined 
and is the leading cause of lower limb amputations 229. It thus represents a great economic 
burden for any healthcare system as well as the patients themselves 228.  
The most common type of DN is a symmetric neuropathy of the peripheral, predominantly 
sensory neurons or “distal symmetric polyneuropathy”. Since this form is the focus of this 
thesis, from here on and throughout, “DN” shall refer to distal symmetric polyneuropathy. It 
initially affects the distal nerves, innervating the feet and hands and gradually spreads 
proximally following the “stocking-glove” distribution model 230. Symptoms include 
paraesthesia (prickling sensation), dysesthesia (abnormal sensations), pruritus (itching), 
sensory loss, numbness and loss of balance. However, one particular symptom is deemed so 
debilitating and characteristic for patients that has defined a separate neuropathic condition 
stemming from DN. Pain during DN is experienced by 8 to 50% of DN patients and is clinically 
termed as painful diabetic neuropathy (PDN) 231. Patients suffering with PDN describe pain as 
burning, shooting, stabbing, dull and aching, usually exacerbated at night. Frequently, PDN 
patients present with allodynia and hyperalgesia 232. Although symptoms and progression of 
DN vary from patient to patient, it has been proposed that, overall, positive symptoms 
(prickling, tingling, pain) are characteristic of the early stages of DN, while negative symptoms 
(numbness, loss of sensation) are typical of the late stages, with possible extension of pain 
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T1D long-term complications largely overlap with those seen in T2D in their detriment and 
intensity. For decades, DN in T1D and T2D has been considered to be one and the same 
disease brought about by a shared underlying master mechanism – hyperglycaemia. However, 
accumulating evidence points to differences in the pathophysiology underlying T1DN and 
T2DN 231,233,235–239. The next section discusses the common and contrasting features of the two 
diabetes forms and how they may impact the neuropathy progression in each.   
1.3.2.3. T1D and T2D inconsistencies  
Diabetes is ranked 5th globally in disease incidence, affecting 1 in 11 people 225. Albeit the 
lifetime incidence of neuropathies is estimated to be between 10% and 50% for both T1D and 
T2D 228, the superior global prevalence of T2D over T1D (90% vs 10%, respectively) 240 makes 
T2D-associated nerve damage the most common and imperative cause of neuropathies. 
Logically, therefore, if the focus is on treating DN in T2D patients, this prompts the use of T2DN 
pre-clinical models over T1DN ones to dissect the underlying mechanisms driving the 
disease’s progression. Yet, our understanding of painful DN pathology has mostly been 
obtained from streptozotocin (STZ)-induced diabetes in rats, a model of T1D 241,242. Pre-clinical 
model selection has been speculated as an important reason for the failure of translating drug 
efficacy from pre-clinical animal models to patients 242. For example, the involvement of 
oxidative stress 243, the polyol pathway 244 and aldose reductase 245 was confirmed largely by 
studies using the STZ rat (also reviewed in 246). Subsequently, the STZ rat was also 
implemented as a pre-clinical DN model for the development of aldose reductase inhibitors as 
a potential DN-modifying treatment. Indeed, in STZ rats, the novel family of drugs corrected 
DN-induced nerve structure and nerve conduction velocity (NCV) impairments 247. Yet, despite 
the promising pre-clinical data, all clinical trials failed to replicate the drug’s pre-clinical 
efficacy. A meta-analysis of 32 aldose reductase inhibitor clinical trials showed that participants 
were predominantly T2D patients and diagnostic criteria for diabetes were not even stated in 
most of the studies included, highlighting the lack of discrimination between the diabetes types 
248. A very similar drug development course was followed by PKC inhibitors. Most of the pre-
clinical success noticed with this drug class was obtained from STZ rodents, however, PKC 
inhibitors were ineffective in the treatment of DN in human patients 249. 
Evidence for fundamental differences in the underlying mechanisms of T1DN and T2DN is also 
provided by clinical research with patients. In 2012, Callaghan et al. published a 
comprehensive systematic review of 17 clinical studies investigating the effects of glycaemic 
control on DN development in T1D and T2D. It was concluded that intensive glycaemic control 
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beneficial in T2DN patients 250. Their analysis shows that hyperglycaemia alone is not the 
driving force of DN in T2D. What is more, it strongly accentuates on the concept of T1DN and 
T2DN being separate disease entities 236. Furthermore, painful symptoms have been shown to 
have higher prevalence in T2D patients than T1D 231,239,251. In one of the largest cohort 
observational clinical studies (n = 15,692) of diabetic UK patients, Abbott et al. demonstrated 
that the adjusted risk of painful neuropathy in T2D is double that of T1D patients 231.  
What is more, these observations confirm those reached in studies conducted by Sima and 
Kamiya investigating DN in T1D and T2D rat models of each. They demonstrated that T1DN is 
much more severe than T2DN, with bigger decrease in NCVs and thermal sensitivity latencies 
as well as more acute IENF damage and loss, all reversible with an insulinomimetic compound 
233,252,253. Others showed that in contrast to T1D animals, limited amelioration to the DN 
phenotype was seen in db/db mice too, even when administered 3 times higher doses of 
insulin than T1D animals 254. The contrasting effects of insulin intervention were attributed to 
the different insulin levels, actions and signalling impairments in the two diabetic types. These 
conclusions were a strong indicator of different mechanisms driving DN in T1D and T2D. 
Factors other than hyperglycaemia are now being widely discussed as contributors in the 
development of T2DN with the main focus falling on metabolic syndrome components 
including dyslipidaemia 255, inflammation 256 and IR 257.  
In the next sections, I will address the pathways, conventional and emerging, known to be 
dysregulated during DN, some of which are common for both diabetic types, while others are 
more characteristic of T2DN. 
1.3.3. Mechanisms implicated in (painful) diabetic neuropathy 
Although DN development varies amongst individuals, it is generally accepted that it follows a 
specific temporal and spatial progression. The earliest changes during DN are believed to 
affect the C-fibres leading to an axonal degeneration/regeneration cycle 258. This causes 
‘positive’ symptoms such as pain, tingling, allodynia and hyperalgesia 259. Overtime, 
degeneration prevails resulting in the loss of C-fibres, as well as Aδ-fibres and consequently 
diminished pain sensation. As DN progresses, myelinated A-fibres undergo a 
demyelination/remyelination cycle until complete destruction of the myelin sheath 258,260,261. The 
loss of protection and nutrient supply by the supporting Schwann cells (SCs) (constituting the 
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For a long time, DN was argued to either originate from metabolic abnormalities within the 
nerve and Schwan cells or develop secondary to diabetic microvascular complications. It is 
now believed that DN pathogenesis is shaped by an intricate interplay between both vascular 
and metabolic factors at all stages of the disease. Hyperglycaemia, dyslipidaemia and insulin’s 
abundance (hyperinsulinemia, T2D) or absence (insulinopenia, T1D) all affect both the 
microvasculature and the nerves themselves. The next part of this chapter will look into these 
mechanisms in more detail. 
1.3.2.1. Damage to the microvasculature supplying the neurons 
Blood vessels and nerves rely on one another to upkeep their normal function: nerves depend 
on adequate blood flow for oxygen and nutrient supply and blood vessels depend on normal 
nerve function for flow dynamics regulation 262. Excess blood glucose damages smaller blood 
vessels (microvasculature) early on in diabetes progressing towards major blood vessels and 
the heart (macrovasculature) in later stages. The increased number of glucose molecules per 
millilitre of blood flowing through damages the endothelial cells lining the inside walls of 
capillaries supplying the neurons. This leads to increased cell proliferation (hyperplasia), 
thickening of the walls and thus narrowing of the lumen 263,264. Peripheral perfusion to the 
nerves is severely reduced leading to neuronal ischemia. Glucose-induced microvascular 
injuries underlie the development of DN, retinopathy and nephropathy 265. The critically low 
oxygen levels (hypoxia) 266 to the neurons results in progressive neurodegeneration 265,267,268.  
With the extremities (fingers, toes) and also retina, being supplied by the smallest and thus 
most vulnerable capillaries, these areas are typically the first to be affected and to present with 
neuropathic symptoms. The role of vascular factors in DN etiology has been confirmed in 
experiments with diabetic rats where vasodilators corrected NCV deficits caused by 
microvascular complications 269,270.  The role of microvascular damage is further supported by 
clinical trials employing drugs targeting vascular changes in DN patients, reporting slowing of 
the progression of neuropathy and/or improving nerve function 271–273. 
1.3.2.2. Metabolic pathways 
Microvascular complications lie in the heart of the pathogenesis of DN. Triggered by 
hyperglycaemia, a collection of detrimental metabolic pathways is initiated that contribute to 
the damage of the vasa nervorum. Research suggests that hyperglycaemia drives 
microvascular damage through multiple cellular mechanisms, including the formation of 
advanced glycation end products (AGEs) , oxidative stress, polyol pathway, protein kinase C 
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supply but also directly by the same hyperglycaemia-triggered pathways that damage 
endothelial cells. These will be discussed in the next sections in the context of direct neuronal 
damage, however the mechanisms by which these processes cause damage in neuronal and 
endothelial cells overlap. Figure 1.7 shows a schematic summary of the main detrimental 




DRG neurons and SCs metabolise free fatty acids (FFAs) as well as glucose for energy. FFAs 
are processed by β-oxidation into nicotinamide (NADH) and flavin (FADH2) adenine 
dinucleotide + hydrogen, which are then used by the mitochondria to produce ATP through 
oxidative phosphorylation 274. Low levels of ROSs are generated as a by-product of this 
Figure 1.7. Metabolic mechanisms of diabetic neuropathy. Factors driving diabetic neuropathy in type 1 
diabetes (T1D, marked with blue dots), type 2 diabetes (T2D, marked with yellow dots), highlighting the 
difference in the pathogenesis between the two diabetic neuropathy types. Factors participating in the 
pathogenesis of both diabetes types (marked with green dots) are or are triggered by hyperglycemia. In 
the end, all mechanisms culminate in the same neurodegenerative events (orange boxes). Adapted from 
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process, usually rapidly cleared by endogenous antioxidants. However, under T2D conditions, 
there is an excess of FFA entering this cycle thus leading to ROS overproduction 275, 
mitochondrial overload and eventually failure, causing metabolic and oxidative damage to SCs 
and DRG neurons 276. Levels of cholesterol are also reported to be increased in the plasma of 
T2D patients 277 (hypercholesterolemia). Similarly, excess cholesterol metabolism leads to the 
accumulation of oxysterols. Oxidised low-density lipoproteins (LDLs), in particular, are able to 
bind specific receptors such as oxidized-LDL-receptor 1 (LOX1), toll-like receptor 4 (TLR4) 
and RAGEs, initiating a cascade of events driving apoptosis such as caspase 3 activation and 
DNA degradation. This all contributes to inflammation and ROS accumulation and ultimately 
SC impairment and neurodegeneration (Figure 1.7). 
 
• Insulin signalling  
The metabolic mechanisms underlying DN that are most investigated are predominantly 
concerning signalling pathways triggered in response to hyperglycaemia that lead to cellular 
damage (polyol pathway, glycation of proteins, oxidative stress and others). However, it is 
important to remember that hyperglycaemia is the result of the primary diabetic insult – 
impaired insulin signalling. Insulin’s complete absence (T1D, late T2D) or abundance (early 
T2D) has been increasingly reported to contribute to the symptoms of T1DN and T2DN as a 
main hyperglycaemia driver but also through direct effects on neurons 278. 
Neurons do not rely on insulin for glucose absorption but take it up via a concentration 
gradient-mediated manner through membrane-expressed glucose transporters (GLUT) 279. 
However, insulin receptors are still expressed by sensory neurons in DRG cell bodies and 
axons 280–282. They are predominantly expressed by small nociceptors with approximately 68% 
of TRPV1-positive neurons expressing the insulin receptor 283. Neuronal expression of the 
receptor for insulin implicates direct signalling dynamics between the hormone and the PNS. 
Indeed, for a couple of decades insulin has been well-established as a potent neurotrophic 
factor, essential for supporting normal neuronal health, growth and function as well as increase 
in neuronal survival 284–286. In vitro, insulin supplementation has been demonstrated to increase 
the rate of neurite generation, length and area in both embryonic sensory neurons and adult 
DRG 287. Similar results were obtained from in vivo studies on nerve injury models 288–290. 
Experiments with rat DRG neurons also show that insulin sensitises TRPV1 by lowering the 
activation threshold and increasing its translocation to the membrane. Such TRPV1 alterations 
are established to contribute to early T2DN positive symptoms, suggesting a direct effect of 
insulin on neuronal excitability 291–293. Therefore, disruption in insulin-neuron signalling can be 
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In order to evaluate the damaging effects of dysregulated insulin signalling on the nerves 
independently from the effects of glucose in a diabetes setting, one must experimentally sever 
the intimate physiological connection between insulin and blood glucose levels. Achieving this 
has proven challenging, however several studies succeeded and supply the literature with 
perhaps the strongest evidence of insulin’s role in T1DN. STZ-injected rats develop robust 
T1D and DN 294,295. However, the response to STZ can be variable and sometimes STZ injection 
produces a unique phenotype of normal glucose levels (euglycemic) and significantly 
decreased serum insulin. Romanovsky et al. benefited from this abnormal STZ reaction and 
used this cohort of euglycemic rats for their study into the effects of insulin unavailability on 
neuronal health. Despite not being hyperglycaemic, these rats developed sensory 
abnormalities just like animals with high blood glucose levels. They presented with mechanical 
hyperalgesia which was correlated with insulin deficiency and reversed with low dose insulin 
injections 296,297. Similar observations were made in another low insulin/normal glucose animal 
model, the Goto-Kakizaki rat, where severe DN symptoms were apparent after 18 months of 
T1D development 298.  The findings of these two studies support a dependence of neurons on 
insulin for normal cellular health. More importantly, this may explain the marked improvement 
of nerve signalling seen in T1DN animal models and beneficial effects seen in T1DN following 
insulin supplementation, but not T2DN patients, where insulin levels are usually higher than 
normal 299. These studies provide evidence for a strong connection between insulin’s direct 
signalling to neurons and neuropathic complications, but only in the context of T1DN.  
T1D and T2D can be viewed as opposing diseases in view of the insulin availability in each in 
the initial stages of the disease.  In T2D, insulin overproduction and skeletal muscle IR  is 
detected up to 10 years before diagnosis and lasts for the earlier stages of the disease 300. 
Neurons have also been demonstrated to develop IR in vitro 301,302 and in animal models of 
T2DN 286 but not yet in humans. PNS IR in animal models of T2DN was shown to correlate with 
reduced neurite outgrowth 303. Therefore, neuronal IR is another component speculated to 
contribute to neuronal insulin deficiency and the following neuronal damage in T2DN. 
Overall, emerging research implicates insulin signalling as a glucose-independent trigger to 
the progression of DN in both diabetes types, be it due to insulinopenia or insulin resistance.  
• Polyol pathway 
Neuronal glucose uptake is insulin-independent and neurons rely solely on the direct glucose 
supply by the microvasculature 279. Thus, vascular barriers are also their only protection 
against glucose toxicity in a state of hyperglycaemia. Therefore, during hyperglycaemia, when 
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concentrations are also abnormally high. Then, instead of undergoing normal metabolism 
through glycolysis, glucose is diverted to metabolic pathways that can result in neurotoxicity304.  
The polyol pathway is one of the first proposed mechanisms underlying hyperglycaemia-
induced neuropathy. Under hyperglycaemic conditions, hexokinase (the first step in the 
glycolysis pathway) is saturated with glucose and another glucose-converting enzyme, aldose 
reductase (AR) takes over. AR converts excess glucose to sorbitol which accumulates 
intracellularly due to its low membrane permeability (Figure 1.7). Sorbitol is an osmolyte and 
increased intracellular sorbitol concentrations generate intracellular osmotic stress. In 
response, the neuron begins compensatory efflux of taurine and myoinositol 305. Myoinositol is 
an essential component of Na+/K+ ATPase and its depletion from neurons leads to impaired 
neuronal physiology 306–309. AR activity also depletes cellular stores of reduced nicotinamide 
adenine dinucleotide phosphate (NADPH), a proton donor for reactions generating nitric oxide 
and regenerating glutathione (antioxidant). This consequence of the polyol pathway activation 
defines the “metabolic flux” hypothesis (see 309). It contributes to the generation and reduced 
clearance of cytoplasmic reactive oxygen species (ROS) which mediate intracellular injuries, 
discussed next.  
• Oxidative stress and reactive oxygen species (ROS) 
Oxidative stress is promoted by two glucose-driven events: ROS generation and the 
impairment of ROS scavenging mechanisms. During hyperglycaemia, mitochondria in neurons 
are overwhelmed and glucose oxidative metabolism increases. This generates superoxide (O2-
) which is converted to hydrogen peroxide (H2O2) by superoxide dismutase and, under normal 
conditions, H2O2 itself is metabolised by glutathione peroxidase (GP) to harmless water. 
However, as mentioned above, during hyperglycaemia the polyol pathway uses up NADPH, 
which is needed in the glutathione cycle, and thus prevents GP from converting H2O2 to water. 
H2O2 is then diverted to conversion into superhydroxyl free radicals (•OH) exerting oxidative 
stress in the neuron 310,311. Moreover, H2O2 and O2- can react with nitrite to produce 
peroxynitrite which causes nitrosative stress to the cell 312. Oxidative and nitrosative stress 
result in triggering DNA-strand breaks which activate poly(ADP-ribose) polymerase (PARP). 
This protein is involved in DNA repair and its action depends on NAD+. Overactivation of PARP 
depletes cellular NAD+, also augmented by the polyol pathway. This slows down glycolysis, 
electron transport and ATP-generation rates resulting in neuronal dysfunction and death 311.  
• Disruptions of Schwann cell metabolism 
Schwann cells (SCs) are a type of glial cells supporting neurons and an essential component 




CHAPTER 1: INTRODUCTION 
as the “Remak bundles” – an association of a bundle of C-fibre afferents via non-myelinating 
SCs 313. However, the role of SCs in neuronal health goes beyond myelination as accumulating 
research suggest they provide active metabolic support to axons. Thus, dysregulation of SC 
metabolism and function, such as under diabetic conditions, will ultimately affect neuronal 
function and health 313. SCs express GLUT through which glucose uptake is possible via an 
insulin-dependent manner for metabolism and energy production 314. For example, in a healthy 
environment, glucose is metabolised in the SCs to lactate which is transported to the 
underlying axon for energy production. However, under hyperglycaemic conditions, the 
excess glucose activates the polyol pathway leading to the AR-dependent accumulation of 
sorbitol which has been suggested to lead to SC de-differentiation to immature cells, 
contributing to nerve demyelination and dysfunction 315. Furthermore, SCs are highly efficient 
in lipid metabolism 316. They are able to uptake FFAs, activating a sequence of events leading 
to ATP production. However, during T2D, where extracellular levels of FFA can be very high, 
there is a substrate overload, resulting in metabolic reprogramming of the SC and 
overproduction acylcarnitine molecules. These are then shuttled into the underlying axon, 
where they exercise their toxic effects, contributing to axonal degeneration 274,313. These 
diabetes-induced alterations to SC metabolism, along with evidence for high glucose-induced 
oxidative damage 317,318 are now shaping a novel idea that the disrupted communication 
between SCs and their axons contributes to DN pathogenesis. 
• PKC activity 
Excess glucose increases the rate of glycolysis. In a series of biochemical reactions, this 
eventually leads to the overproduction of complex molecules such as 5-diphosphate-N-
acetylglucosamine (GlcNac) and diacylglycerol (DAG) 319. GlcNac reacts with transcription 
factors to promote lipid dyshomeostasis, inflammation and peripheral nerve injuries 320. 
Similarly, DAG accumulation in the nerves has also been shown to lead to neuronal damage 
via activating PKC. Its activation can cause a myriad of metabolic complications through 
increasing neuronal IR and disturbing Na+/K+ ATPase function and thus signal propagation. It 
has also been demonstrated to impair expression of genes associated with vascular function 
thus contributing to the microvascular complications surrounding neurodegeneration 321.  
• Protein glycation and advanced glycation end products (AGEs) 
Excess glucose levels lead to its reaction with amino acids of proteins to generate potentially 
detrimental products knows as advanced glycation end-product (AGEs) (Figure 1.7). AGEs 
have been shown to accumulate in the peripheral nerves of T2D patients with DN 322. AGEs 
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AGEs react with AGE receptors (RAGEs) on neurons initiating downstream signalling cascades 
partially mediated by nuclear factor (NF) -κβ activation, leading to neuronal dysfunction and 
loss of nerve cells. This can eventually result in reduced nociception. Events such as 
vasoconstriction, inflammation and loss of neurotrophic support have also been reported to 
occur in rodent PNS as a consequence of AGE-RAGE activation 323,324. 
• Inflammation 
The array of cellular imbalances underlying DN discussed so far are also powerful triggers of 
systemic inflammation in peripheral tissues, including the nerves. Indeed, the role of the 
immune system components has been established in DN patients. For example, T2D patients 
who have DN show higher levels of inflammatory cytokines in their plasma compared to non-
diabetic patients and T2D patients without DN 325. 
In the last decade, pre-clinical experiments and clinical studies have provided strong evidence 
for the role of inflammatory processes in DN of both diabetes types 255,256. The proposed 
mechanism states that glucose-, insulin- and lipid metabolic abnormalities kick-start cycles of 
oxidative/nitrosative, endoplasmic and mitochondrial stress that in turn cause cellular damage 
in the neuron. Neuronal injuries activate multiple downstream kinases (including PKC) and 
redox-sensitive transcriptional factors, such as NF-кB which is responsible for the regulation 
of genes associated with the immune response of the body 326. Activated regulation factors 
trigger a surge of cytokine and chemokine production which enhance existing inflammatory 
responses but also feed back to and amplify the whole process by triggering more cellular 
stress 327. This cascade of events targets not only neurons but endothelial cells of the blood 
vessel walls supplying the nerves, thus further feeding into the vicious damage loop 255,326.  This 
idea is supported by pre-clinical 328–330 and clinical 325,327,331–335 studies. A couple of studies 
demonstrated not only that DN patients have increased serum levels of inflammatory cytokines 
and markers of endothelial dysfunction, but that these were even further increased in patients 
with PDN 325,336, adding to similar evidence from studies with T2DN animal models 337. One 
mechanism by which this is believed to occur is the modification of channels and receptors 
implicated in pain by inflammatory molecules. For instance, the expression density and 
activation thresholds of TRPV1 and TRPA1 have been demonstrated to be modulated during 
inflammation by a range of kinases thus sensitizing nociceptors to painful stimuli following 
injuries 142,338–341. Such and other dysregulations in ion channel activity during DN will be 
discussed in the next, final part of this section. Collectively, these observations strongly 
implicate that inflammatory processes during diabetes contribute greatly to DN and pain 
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1.3.2.3. Ion channel alterations  
As discussed in more detail earlier, ion channels expressed by sensory neurons set and 
govern the overall neuronal excitability. The carefully regulated activity and expression of each 
channel creates a fine balance upon which the normal functioning of the PNS relies. Their 
plasticity, however, allow for modifications of their expression, trafficking and kinetics that may 
result in changes in neuronal excitability. Increased excitability of nociceptors due to such ion 
channel alterations is one of the most widely implicated mechanisms underlying pain during 
DN 313.  
Diabetes triggers multiple signalling pathways that often work together to promote different 
post-translational modifications of ion channels. One of the best studied reactive metabolites 
participating in such detrimental cascades is methylglyoxal - a protein-glycating agent and 
important precursor of AGEs. Its levels increase during diabetes – in fact, one study 
demonstrated that its concentration is especially high in patients with PDN as opposed to 
painless DN. Furthermore, in rodents, administration of methylglyoxal renders them 
hypersensitive to pain 342. Methylglyoxal’s neuron sensitising effect has been linked to post-
translational modifications of Nav.1.8, depolarizing its inactivation threshold. Thus, the 
availability of Nav1.8 at AP threshold is increased and with that, hyperexcitability of the neurons 
expressing it, usually nociceptors, increases, leading to hyperalgesia 342. Methylglyoxal’s 
potential to cause modifications stretches beyond VGSCs, as it has been shown to affect 
TRPA1 too. Like many of TRPA1’s agonists, methylglyoxal is an electrophilic metabolite and is 
able to interact and modify critical cysteine residues on TRPA1 causing a robust activation and 
hyperexcitability in nociceptive neurons 343. A strong link between methylglyoxal and the 
channels TRPA1 and Nav1.8 was demonstrated in experiments by Huang et al. (2016). They 
showed that subcutaneous administration of methylgyoxal in STZ rats produced nociception, 
which was reversed by using antagonists for TRPA1 (A967079) or Nav1.8 (A-803467). In their 
behavioural experiments, they confirmed the association of methylglyoxal in DN with 
mechanical allodynia and thermal hyperalgesia in the STZ rat 344. TRPA1 is further implicated 
in PDN pathogenesis due to its strong activation by ROS – highly abundant during diabetes 
and further enhancing TRPA1 potentiation by methylglyoxal 345.  
There is evidence describing altered expression levels of pronociceptive channels, including 
P2X3 346, TRPV1 58,156, certain VGKCs 347 and VGSCs 60,348–351, albeit, historically, the studies have 
not been consistent in their findings. For instance, in a comprehensive report by Craner et al. 
(2002), expression levels of VGSCs in a T1D rat model were investigated to reveal a significant 
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Nav1.1 and Nav1.7 348. These observations are in accordance with others who also report 
upregulated Nav1.3 expression 58,352 and downregulated Nav1.8 expression 58,353 in diabetic 
animals. However, they contrast with studies describing significant increase in both TTX-S and 
TTX-R currents and upregulated levels of both Nav1.7 and Nav1.8 in DRG cell bodies of 
diabetic rodents 58,349–351,354,355. Albeit their exact nature is still debated, dysregulated channel 
expression, particularly of VGSCs, has been agreed to have a key role in the development of 
neuropathic pain during DN. 
Painful manifestations vary vastly between DN patients - some develop painful symptoms as 
early as pre-diabetes while others never show a painful phenotype 356. Apart from the 
differences between the diabetes forms that may contribute to such variance, genetic 
variances in certain VGSCs have also emerged as possible modulators of an individual's risk 
of developing pain during DN. Nav1.7 has been of particularly great interest as a key 
determinant of neuronal excitability. Specifically, GoF mutations in this channel in a diabetes 
setting have been suggested to produce increased DRG sensitivity. Indeed, multiple variants 
have been discovered in the past years that were associated with PDN 75,357–359. Furthermore, 
a dozen of rare Nav.1.7 variants were recently identified in PDN patients, which correlated with 
earlier diagnosis of PDN, a more severe painful phenotype and greater mechanosensitivity 76. 
Finally, a newly emerging curious hypothesis implicates Nav1.7 along with Nav1.3 in a cause-
effect relationship between diabetes and painful neuropathy. The notion arises from the fact 
that these TTX-S channels are expressed in both DRG as well as pancreatic islet cells. It is 
therefore postulated as a possible model that diabetes as a metabolic disease and peripheral 
neuropathy arise as a result of dysregulation in Nav1.3 and Nav1.7 due to genetically inherited 
mutations. When both channels are dysfunctional, they render both sensory neurons and 
pancreatic cells more susceptible to damage, making diabetes and neuropathy go hand in 
hand. Albeit intriguing, this concept is still in its early stages 360–362. 
1.3.4. Current diabetic neuropathy treatments 
Diabetic neuropathy is the most debilitating complication of diabetes associated with the 
highest risk of mortality 363. Yet, despite the advancing understanding of the underlying 
pathophysiological mechanisms, to date, there are no approved disease-modifying or 
reversing pharmacological therapies for DN 226. This section will focus on the established DN-
modifying interventions and currently recommended pharmacological therapies targeted at 
alleviating the symptoms of PDN. Novel analgesic drugs for PDN that are under development 
will also be briefly discussed. The section will conclude with a short discussion of the possible 
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1.3.3.1. Diabetic neuropathy management  
The main approach evidenced to successfully prevent or delay DN progression is glycaemic 
control, usually via insulin supplementation. In T1DN patients, blood glucose management has 
been shown to improve NCVs and vibration thresholds and, when introduced early enough, to 
prevent the development of clinical neuropathy 235. In T1DN patients with severe neuropathy, 
even signs of neuropathy reversal were evident when blood glucose levels were normalised 
via more invasive interventions such as pancreatic and kidney transplantations.  
Albeit a successful approach in T1DN patients, improving glycaemic control in T2DN patients 
for delaying neuropathy progression is not as effective, even when extended to up to 5 years. 
In fact, in the Action to Control Cardiovascular risk in Diabetes (ACCORD) study, such 
prolonged intervention has been shown to be detrimental for T2D subjects as it increases 
hypoglycaemia and excess mortality amongst intensively treated individuals 364,365. Glycaemic 
control may be of minimal benefit for improving T2DN, however its limited efficacy provides 
the valuable insight that hyperglycaemia is certainly not the sole major process driving 
neuropathy progression in T2D and other therapy targets need to be explored. 
Apart from hyperglycaemia, T2D is characteristic with hyperlipidaemia and hyperinsulinemia, 
which have also been widely implicated in the progression of DN in T2D (see section 1.3.2.2. 
Metabolic pathways). Therapies targeted at lowering cholesterol (such as statins) or 
triglyceride levels (such as fibrates) have been suggested to slow DN progression in T2D 
patients, however no randomised clinical trials have evaluated their efficacy clinically 366,367.  
Hyperinsulinemia and insulin resistance (IR), on the other hand, are usually improved via 
weight management through diet and exercise regimes and in extreme cases, weight control 
surgical interventions (such as bariatric surgery). In fact, weight loss has been established as 
the safest and most efficient intervention to lead to remission of diabetes and reversal of 
neuropathy, with noted increase in IENFD, amelioration of small nerve fibre damage, alleviation 
of pain symptoms and improved microvascular function 368,369. The most widely prescribed 
pharmacological therapy targeting IR is metformin. It reduces the amount of glucose released 
in the blood by the liver, thus improving cellular sensitivity to insulin. However, high doses of 
metformin have been linked to vitamin B12 deficiency and a recent study demonstrated an 
inverse correlation between DN severity and vitamin B12 levels, suggesting that metformin 
might not be suitable for patients with severe DN phenotype 370. Other therapies employed that 
target DN progression include supplementation with alpha-lipoic acid (antioxidant) 371 and 
improving microvascular function via blood-pressure lowering drugs (lisinopril, trandolapril) 
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treatments targeting multiple pathophysiological mechanisms simultaneously 
(hyperglycaemia, hypertension, dyslipidaemia, insulin resistance). 
1.3.3.2. Management of painful diabetic neuropathy (PDN) 
Up to a third of diabetes patients develop symptomatic PDN, significantly affecting their quality 
of life. With the lack of pharmacological interventions modifying DN, symptomatic treatment 
remains the best-established way for managing pain 372. The rapid growth in our knowledge of 
pain-driving pathophysiological processes has yielded a plethora of promising therapeutic 
targets in these pathways.   
• Approved therapies for managing painful diabetic neuropathy 
A list of the most widely prescribed pharmacological therapies targeting pain during DN is 
outlined in table 1.5 and the treatment strategy outlined in Figure 1.8. The approved and most 
recommended therapies target the CNS and modify the processing of the pain signal in the 
brain. These include anticonvulsants, antidepressants, and opioids 230. The most widely 
prescribed anticonvulsant drugs are gabapentin and pregabalin, both acting as inhibitors of 
VGCCs thus reducing neuronal excitability. Recommended antidepressants are from one of 
two classes: serotonin and noradrenaline reuptake inhibitors (SNRIs, e.g. duloxetine, 
venlafaxine) or tricyclic antidepressants (TCAs, e.g. amitriptyline, nortriptyline). Both 
anticonvulsant 373–376 and antidepressant 377–380 therapies have been demonstrated to be 
effective at alleviating pain during diabetes and to be relatively well-tolerated. However, they 
are not without adverse effects, the most common of which include dizziness, confusion, 
fatigue and somnolence, which tend to be more severe in older patients 381. Nevertheless, 
generally the benefits of these drugs outweigh the side effects and anticonvulsants and 
antidepressants are thus currently recommended as 1st line treatments for PDN by several 
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Opioid prescription, on the other hand, remains controversial.  Albeit pain relief during PDN 
has been achieved with opioids in clinical trials, this drug class brings serious safety concerns. 
Due to their nature, opioids prescribed for treatment of chronic pain can lead to addiction, 
misuse and abuse and are associated with increased mortality due to overdose. Therefore, 
opioids such as tramadol are often only recommended as a 3rd line intervention for moderate-
to-severe pain and only after careful individual benefit-to-risk ratio assessment 382,383.  
Figure 1.8. Currently established treatment strategy for painful diabetic neuropathy. 
Anticonvulsants, serotonin and noradrenaline reuptake inhibitors (SNRIs) and tricyclic 
antidepressants (TCAs) make up first- and second line treatments for painful DN. Opioids are 
generally avoided and only prescribed as a third line treatment in extremely severe cases. In 
the case of first- and second line treatments generate tolerance or generally not well-tolerated, 
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Table 1.5. Current FDA-approved treatments for painful diabetic neuropathy with their therapeutic targets, most 
common side effects and serious adverse effects summarised. Adapted from Azmi et al. (2021) 
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The severity of PDN symptoms is often robust enough to justify the implementation of CNS-
modifying drugs as 1st line treatments. However, the chronic nature of DN demands long-term 
dependence on these therapies increasing the risk of developing drug tolerance, requiring 
higher doses and thus increasing adverse effects severity. Several non-CNS targeted 
therapies have been proposed that have shown success in relieving pain in DN. Topical 
treatments are a popular alternative for patients unable to tolerate the conventional systemic 
treatments. They also present with significantly lower risk of interactions with other 
medications making them a suitable option for patients with polypharmacy 384. The most 
popular topical treatments for DN pain are the capsaicin 8% patch and lidocaine 5% patch. 
Both have demonstrated significant pain reduction comparable to anticonvulsants and TCAs 
and have fewer and less serious side effects 385,386. Capsaicin 8% patches are now FDA-
approved for the treatment of neuropathic pain and both are proposed as 2nd or 3rd line 
treatments 376 (Figure 1.8). Nevertheless, they can cause side effects, e.g. skin irritation, rashes 
and, especially in the case of capsaicin, loss of IENF and altered thermal sensation, which can 
compromise patient compliance 387.  
• Novel pharmacotherapeutic agents in development 
Research into novel analgesic treatments for PDN is also focusing away from the CNS and 
onto the PNS. Table 1.6 presents an inexhaustible list of novel pharmacotherapeutic 
compounds in development for symptomatic pain relief during DN. Here, I will focus on 
discussing those targeted at modifying pain-associated ion channels expressed by 
nociceptors. 
Nociceptive ion channels have become an especially attractive target for novel analgesics due 
to their selective expression in peripheral nociceptive neurons 388. This facilitates the diversion 
of conventional therapies towards nociceptors thus limiting detrimental CNS side effects. At 
the same time, affecting pain signalling at the source by the selective inhibition of specific 
nociceptive channels could enhance drug efficacy. Furthermore, even in the case of limited 
individual drug efficacy, ion channel modulators present the opportunity for combination 
therapies with currently approved treatments (table 1.5), whereby lower doses of both can be 
implemented to limit side effects while benefiting from both drugs’ actions – a concept which 
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Table 1.6. A range of novel drugs in development for the treatment of painful diabetic neuropathy. Novel analgesic 
pharmacological interventions are targeted at different molecules and pathways. Some have been through clinical trials and 
side effects have been notices, whilst others are still in pre-clinical stages of development. Adapted from Rastogi & Jude (2021) 
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Of the DRG-expressed ion channels implicated in pain, Nav1.7 has perhaps been of highest 
interest as an analgesic target due to its high expression levels in DRG and strongly evidenced 
role in pathological pain conditions 33. A number of potential Nav1.7 blockers have been under 
development, showing promising results in preclinical studies of DN 393,394. However, none have 
yet been approved for clinical use due to their failure in clinical trials. For instance, a recent 
small trial of the Nav1.7 blocker PF-05089771 in PDN failed to show pain alleviation in patients 
395. Another VGSC inhibitor developed by Biogen, Vixotrigine was believed to be Nav1.7-
selective but has now been redefined as a non-selective VGSC blocker 396. Vixotrigine has 
shown limited efficacy but great tolerability in a phase II clinical trial for trigeminal neuralgia 
compared to placebo and is currently undergoing phase II trial for small fibre neuropathy in 
DN (ClinicalTrials.gov Identifier: NCT03339336). Interestingly, a recent study demonstrated 
that oxcarbazepine (a non-selective VGSC blocker) successfully attenuated pain responses in 
DN patients with irritable nociceptors compared to those with non-irritable nociceptors. This 
suggests that non-selective VGSCs might still find place in the clinical treatment of PDN 
provided that a more detailed patient phenotyping and hence stratification is performed 397.  
Blockers of Nav1.8 have also been of interest for the pharma industry: VX-150 has been 
advanced to phase IIb trials after demonstrating promising efficacy and safety in small fibre 
neuropathy clinical trials 398. Other Nav1.8 blockers such as A-803467 and PF-01247324 have 
shown promising selectivity and antinociceptive effects in preclinical studies 399–401. Similarly, 
several P2X3 blockers have been explored in animal studies (e.g. A-317491 and sinomenine) 
and have successfully relieved hyperalgesia by suppressing overexpression and 
overactivation of P2X3, however confirmation in human studies is lacking 195,402,403. Finally, TRP 
channels have been demonstrated to be particularly curious pain relief targets as both TRP-
channel agonists and antagonists have shown analgesic potential 404–408. Albeit several 
promising novel DN therapies are in ongoing clinical trials (table 1.6), numerous therapies 
targeting various pathogenic molecular mechanisms have shown great promise in preclinical 
studies only to fail to translate to the clinic 409. In fact, analgesics in general have only 2% 
success rate, which is 5 times less than other therapeutic areas. The low development success 
rate has led to gradually decreasing interest and investment in the area of pain therapeutics 
further exacerbating the issue of lack of adequate pain treatments 410. To date, no disease-
modifying pharmacotherapy has been developed for DN and the possible reasons behind this 
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1.3.3.3. Why are there no disease-modifying therapies for diabetic neuropathy? 
The problem with analgesics development for treating PDN extends to DN as a whole with 
currently no disease-modifying therapies available and largely disappointing clinical trial 
outcomes 230. The possible reasons behind this critical issue stretch across all steps in the drug 
development process from the clinical trials design all the way back to in vitro screening of the 
drug candidates. Clinical trials are recommended to introduce improvements in several 
aspects: 
➢ alternative endpoints, particularly focused on monitoring small nerve fibre physiology 
instead of currently recommended large-fibre-focused readouts 411;  
➢ detailed DN diagnosis with stress on underlying pathophysiological driver(s) 411–413 
➢ patient stratification according to key pathophysiological driver(s) of DN for enhanced, 
individualised therapies 414,415 
➢ following on the previous two points, focus on mechanism-based drug testing 
approach as opposed to “one size fits all” approach 
 
The complexity of DN poses great challenges in translating potential treatments from animal 
models to humans 416,417. Suggested improvements in this stage of the drug development 
include the implementation of multiple and improved preclinical screening methods with direct 
clinical equivalents as well as progression through several model systems 411. However, the 
most fundamental issue to consider is the choice of the preclinical model: how well does it 
reflect the DN aspects targeted and how comparable are they to the same aspects in humans? 
Finally, taking yet another step back in the development process, in vitro drug screening would 
also benefit from advanced techniques with improved readout sensitivity that are able to 
precisely separate drug action on target from its off-target effects. Such improvement will aid 
in the advancement of better-targeted and safer drugs towards preclinical and clinical 
development stages. For more details and an extensive analysis of current drug development 
practices and areas of improvement, see Jin et al. (2020) 411. 
Choosing the appropriate animal model of DN and technique to evaluate its phenotype are key 
steps in characterising functional changes and identifying potential treatment targets in the 
neurons. Further considerations for animal and in vitro models of DN will be discussed in more 
details next, followed by the introduction of a novel functional assay developed in our lab which 
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1.4. Modelling diabetic neuropathy  
So far, this chapter has delved into the details of DN and the known molecular mechanisms 
underlying its pathogenesis in order to highlight the enormity as well as depth of the clinical 
problem that this condition represents. Despite over 50 years of laboratory and clinical 
research, current treatments are far from achieving satisfactory effectiveness and safety 230.  
The development of high-quality therapies depends heavily on the adequate modelling of DN 
components in vitro or in animal models of pre-diabetes, T1D and T2D. To date, several in 
vitro technologies and over 20 rodent models of DN have been introduced offering the 
opportunity to choose the one most closely reflecting the specific DN aspects being 
investigated 418. Although, no model accurately mimics all aspects of DN as manifested in 
humans, in vivo and in vitro models arm researchers with the tools needed to keep advancing 
the understanding of the complex disease that DN is. In this section I will review some of the 
most common in vitro methods for reproducing DN conditions. Then, I will move on to 
discussing the most widely used T1DN and T2DN animal models. Finally, this part of the 
chapter will conclude with a comment on important considerations when selecting a model for 
DN research.  
1.4.1. Modelling diabetic neuropathy in vitro 
As the search for an effective drug to reverse or ameliorate DN progression continues, basic 
research focuses on unravelling the intricate molecular mechanisms propelling its 
development. To this end, tissue and cell culture techniques are especially instrumental 
because they allow for the isolated investigation of complex neuronal responses to different 
stimuli – a clear benefit over in vivo models, where a mixed-cell, global response is taking 
place. Other advantages of cell cultures to consider are, perhaps above all, that they allow for 
tight control over the extracellular environment. Thus, they are ideal for the detailed studying 
of a vast range of cellular processes, including cell death, neurodegeneration, hyper- and 
hypoexcitability and bioenergetics. With the added benefit of allowing for straightforward real-
time imaging and recording, they are also useful for tracking the time kinetics of intracellular 
molecular events, albeit in vivo imaging is now possible too. These advantages render cell 
cultures the perfect platform for high-throughput drug screens. Finally, in vitro techniques 
usually come with fewer ethical issues than using in vivo models of nerve diseases, particularly 
when investigating pain 419.  
The in vitro approach to DN research encompasses several different techniques, such as 
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recently, generation of neuronal cultures via the induced pluripotent stem cell (iPSC) 
technology.  
Primary neuronal cultures are the most widely used method for investigating DN pathogenesis 
in vitro 318,420–425.  Importantly, primary cultures of DRG neurons from an adult rat or mouse 
preserve the broad heterogeneity of the neuronal population within the ganglion. DRG neurons 
can be harvested from healthy, control animals and subjected to DN-inducing stimuli to 
investigate acute pathogenic responses. Alternatively, neurons can be harvested from a 
diabetic animal. This is an excellent example of marrying in vivo and in vitro techniques, 
benefiting from employing an animal model of diabetes as a DN-stimulus and an in vitro 
approach to assess the specific molecular and physiological events. 419. Generation of primary 
neuronal cultures involves the mechanical and/or enzymatic isolation of neurons into a cell 
monolayer which is then maintained in an optimal extracellular environment designed to mimic 
physiological conditions 426.  
DN entails a network of intersecting pathways driving its pathology and the choice of stimulus 
depends on the DN aspect under investigation. Most commonly, generating hyperglycaemic 
conditions is the first consideration, however, the question of the optimal glucose 
concentration used is still a much-debated issue in diabetes and DN studies. The physiological 
blood glucose concentration of healthy rodents is 4-8 mM 427, whereas in diabetic ones levels 
can exceed 20 mM 428–431. However, the vast majority of published in vitro studies using 
neurons in general (that did not investigate diabetes) maintain neuronal cultures in standard 
glucose concentrations of approx. 20-30 mM, depending on the culture medium used, which 
can be considered a hyperglycaemic environment in a diabetes-focused study. It is, therefore, 
advised that modelling of diabetes in vitro requires 7-20 mM additional external glucose in 
order to not deviate from established neuronal culture protocols and still recreate 
hyperglycaemic conditions as accurately as possible 419. Other stimuli that have been 
successfully used in in vitro DN research include pro-oxidants for the assessment of oxidative 
stress 422, methylglyoxal 432 and lipid oxidation products  for the evaluation of hyperglycaemic 
toxicity 433, oxidized low density lipoproteins for studying hyperlipidaemia 434 or serum from 
diabetic patients or animals 342,435.  
Primary cultures are not without limitations. As neurons are non-proliferative, the yield is low 
and each culture requires time-consuming collection of neurons. Notably, due to the nature of 
the process, neuron dissection involves nerve injury, triggering a switch in cultured neurons 
from a “housekeeping” to a “regenerative” phenotype 436 which should be considered when 




CHAPTER 1: INTRODUCTION 
requires caution when interpreting data and demands validation of findings in an in vivo setting 
419.  
An alternative to primary neuronal cultures is the use of immortalised cell lines, such as SH-
SY5Y 437,438, NTERA-2 439 and pheochromocytoma (PC12) 440,441 cells. Most are easy to obtain 
and maintain and provide an unlimited supply of a homogeneous population of cells. They 
have been extensively used in electrophysiological, molecular and biochemical 
neurophysiological research and represent a suitable platform for high-throughput drug 
screens necessitating vast numbers of cells. In addition, the use of cell lines eliminates the 
need to sacrifice animals for each culture, bringing a great ethical and time advantage. 
However, due to cell lines being even a further simplified culture of clonal cells, they do not 
reflect the heterogeneity of adult rodent neurons nor are they capable of developing processes 
such as dendrites and axons 442. 
A promising novel technology in the research of neuronal diseases are iPSCs. By harvesting 
fibroblasts from patients, one can genetically reprogram them into pluripotent cells 443 and then 
stimulate their differentiation into various neuronal cell types, including sensory 444, and SCs445. 
This method holds potential for circumventing a possible problem with interspecies differences 
that may underlie the poor translation of drugs efficacy from established in vitro and in vivo 
techniques to the clinic. 
The study of the intricate pathogenesis of DN has greatly benefited from in vitro models over 
the years. However, regardless of the in vitro model’s advantages and success, findings must 
always be confirmed in an in vivo model to validate the observations when other interfering 
factors are also present, as they would be in the patient.  
1.4.2. Experimental animal models of diabetic neuropathy 
In vivo models of diabetes and DN are instrumental for the understanding of behavioural, 
physiological and structural DN pathology and are key drivers of progress towards successful 
therapy strategies. Compared to in vitro methods, animal models offer the advantage of 
susceptibility to genetic manipulations and higher system complexity. The diseases they are 
tailored to represent are thus closer in pathological resemblance to humans allowing for a 
more holistic interpretation.  However, one big limitation remains the relatively short lifespan 
of rodents, which does not allow for the complete mimicking and investigation of the chronic 
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Over the years, a great diversity of rodent models of T1D and T2D have been developed and 
characterised (for a comprehensive review see 241,446,447). Although none has yet been 
perfected to reflect the human disease in its full complexity, virtually all stages of human 
diabetes and its neuropathic complication have been reproduced by an animal model 
designed for the purpose 241. 
There are three established parameters by which DN is confirmed in a diabetic rodent and the 
animal model is recognized as useful. These represent major aspects of human DN pathology, 
namely:  
1) behaviour – sensory abnormalities are evaluated by assessing thermal and 
mechanical sensitivity; 
2) nerve conduction velocity (NCV) – electrophysiological measures of nerve 
impairment assessing motor and sensory nerve conduction;  
3)  nerve structure – intraepidermal nerve fibre (IENF) density in the animal’s footpad 
is assessed to reveal anatomical evidence of fibre loss. 
Two out of three need to be significantly different from control animals for a neuropathic 
phenotype to be confirmed 448. 
There are three main approaches by which rodent models of diabetes are generated – they 
can be genetically induced, chemically-induced and diet-induced. 
1.4.2.1. Genetically induced models of diabetic neuropathy 
Transgenic rodent models have been developed for both diabetes types. The most widely 
used T1D genetically modified models are the non-obese diabetic (NOD) and B6Ins2Akita mice 
241.  NOD mice develop a T-cell-mediated autoimmune response against their β-cells caused 
by a polygenic immunodeficiency that they carry.  Thus, they spontaneously develop T1D, 
consistent with the pathogenesis in T1D patients. However, due to the polygenic nature of their 
genetic modification, diabetes and DN progression in NOD mice is variable and affected by 
diet, housing conditions and the sex of the animals and DN in this model is still 
undercharacterised 449. Nevertheless, studies using NOD mice have reported hyperalgesia by 
week 8 450 and hypoalgesia by week 12 312. B6Ins2Akita mice have a point mutation in the Ins2 
insulin gene impairing insulin production 451 resulting in T1D by 7 weeks of age (WoA) and the 
gradual development of sensorimotor neuropathy 452. NCV in this model has been reported to 
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impairments even at 24 WoA 453. Considering their current limitations, and the relatively 
controversial literature, DN phenotype in both NOD and B6Ins2Akita mice is still unclear and 
requires further characterisation.  
Research of T2DN has benefited from some excellent transgenic animal models. The most 
popular and best studied are monogenic mouse models carrying a mutation which impairs 
leptin signalling 447. Leptin is a hormone secreted after feeding to signal satiety and suppress 
appetite 454. Mutation in the leptin hormone or its receptor produce ob/ob and db/db mice, 
respectively. Both models develop chronic hyperglycaemia and hyperinsulinemia 428,455. Ob/ob 
mice are considered as an obesity and mild T2D model and DN in this model is understudied, 
however, they are reported to present with thermal hypoalgesia and reduced IENF density and 
sensory and motor NCV at 11 WoA 455.  
Db/db mice are the very first mouse model developed for the investigation of DN 428, shown to 
develop physiologically relevant T2D as early as 4 WoA. Compared to ob/ob mice, DN in the 
db/db mouse model has been better characterised with several studies reporting hyperalgesia 
and allodynia at 8-12 WoA and sensory loss at 12+ WoA accompanied by a significant 
decrease in motor and sensory NCV and IENF density 453,456–459. However, the relatively large 
number of studies using this mouse model has also generated considerable inconsistencies 
with regards to the DN phenotype with some reporting profound sensory anomalies while 
others see no significant differences from control animals 460. Neuropathy severity in the db/db 
mouse is also affected by the choice of mouse strain with hyperglycaemia more stable and DN 
more severe in the C57BKS db/db than C57BL/6 db/db mouse 453,461. Nevertheless, the 
progression of T2D and DN in the db/db mouse is considered to most closely mimic the natural 
history of these conditions in humans 453. Part of the experiments in this thesis involve the 
db/db mouse and this model will be discussed in depth in the relevant chapter (Chapter 5). 
1.4.2.2. Chemically induced models of diabetic neuropathy 
Rodents can also be rendered diabetic via a chemical induction process. The most common 
model of T1D, the streptozotocin (STZ) model, employs this approach. STZ is an alkylating 
compound known to selectively destroy β-cells 462. It is injected in the animal following one of 
two established protocols: either in a single high dose, producing a robust DN  but also bringing 
a high mortality rate due to severe nonspecific toxicity; or in multiple low doses – a less toxic 
approach producing gradual T1D but often with no or only moderate neuropathy phenotype 
463. Although an inexpensive, easy to optimise and adequate model for T1DN research and 
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damage – limitations that might impact measurements of pain responses and other parameters 
464. Furthermore, concerns have been raised over the direct neurotoxicity effects of STZ 465.  
More recently, STZ has been shown to directly activate neuronal TRPA1 resulting in acute 
allodynia 466. Despite its disadvantages, the diabetic STZ rat is by far the most extensively 
researched DN model, generating the vast majority of knowledge on the disease and its painful 
phenotype 242. 
1.4.2.3. Diet-induced models of diabetic neuropathy 
Drastic alterations in rodents’ standard nutrition have also been employed that establish T2DN 
and neuropathic pain by successfully mimicking human metabolic syndrome development. 
Several diet modification strategies have been tried but a high fat diet (HFD), has been 
repeatedly demonstrated to have undeniable success at inducing T2D and neuropathy in mice 
467. Usually, mice on a HFD develop obesity gradually, followed by metabolic imbalances, 
including hyperglycaemia and moderate hyperinsulinemia until T2D is fully established. DN is 
close to follow with decreased sensory NCV, IENF density and thermal hypoalgesia often 
reported in these mice 468. Although inappropriate diet is a leading cause for human T2D 
development too, compared to other approaches of DN induction, the diet approach can be 
time-consuming and its success varies due to influence from animal sex and age, diet duration, 
fat content and fat source. Nevertheless, diet-induced models of DN have proven useful in 
studies of prediabetes and obesity-associated neuropathies 467.  
1.4.2.4. Considerations when selecting a model 
DN progression is undeniably multifactorial and a complete model has not yet been developed 
for either of the diabetes types. Therefore, when selecting a model, it is critical to do so with 
the disease aspect being investigated in mind.  Further to that, model choice must also take 
into consideration factors such as duration and type of stimulus exposure, measurement tools, 
phenotype assessment techniques, and in the case of animals – their sex, age, diabetes type 
being induced, diet and diet duration, and degree of exposure to diabetes-inducing 
compounds and methods. For example, it has been well-documented, that male and female 
mice show significantly different DN phenotypes even when the same diabetes-induction 
approach is used 447. Female mice are more often used as genetically NOD models of diabetes, 
because they develop T1D symptoms much earlier 449, while male rodents are more suitable 
models for nutritionally-induced diabetes. Female rodents have also been reported to show a 
much more muted level of painful DN than males, presumed to be due to influence by specific 
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signalling 469,470. In addition, currently, an imbalance exists in the field of DN research. T1DN 
and its painful aspects are extensively researched (mainly in the STZ model) while clinical 
studies are mostly focused on T2DN cases due to their greater global prevalence. Although 
both diabetes forms lead to DN, it is vital that the model is of the diabetes type the findings will 
be translated to. Ensuring such synchronisation might contribute to closing the gap between 
animal and clinical studies. 
The elaborate study of in vitro and in vivo models of DN would not have been possible without 
the development of powerful techniques and tools. To investigate the neuronal excitability of 
DRG neurons from db/db mice, I employed a functional assay previously developed in our 
laboratory which combines Ca2+ imaging and the VGSC activator veratridine. In the final 
section of this chapter, I will briefly outline the characteristics of the different components of 
this assay and discuss its experimental applications to date. 
1.5. Veratridine-based calcium imaging assay for neuronal excitability  
assessment 
The major goal in neuroscience research is the understanding of the complex patterns of 
neuronal activity and the physiological and molecular events underlying different 
neurodegenerative conditions. To address this, one must be able to record the activity and 
analyse the changes in excitability of nerve cells. Electrophysiology and Ca2+ imaging are the 
two most popular approaches implemented to that purpose. Electrophysiological techniques 
such as voltage clamp, current clamp and patch-clamping are the ‘gold standard’ in 
neurophysiology research, providing direct report of a neuron’s electrical properties with high 
temporal precision 471. However, electrophysiological approaches are often invasive, usually 
requiring the insertion of electrodes in the cell, and limited to assessing only a small subset of 
neurons (most often – a single cell at a time), thus unable to monitor the neuronal dynamics in 
a heterogeneous population such as DRG neurons.  
For the simultaneous assessment of a great number of neurons in a diverse population, a 
medium-to-high throughput approach is more appropriate such as Ca2+ imaging. Furthermore, 
the research for new treatments against pain has been re-targeted from the CNS towards the 
nociceptors in the PNS and, more specifically, the ion channels they expressed  that regulate 
pain signalling. The development of novel, more efficient and safer analgesics creates a need 
to be able to single out and specifically target nociceptors with minimal or no impact on non-
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also able to discriminate nociceptors in a heterogeneous DRG neuronal population. Calcium 
imaging is a technique with the potential to answer these requirements. 
1.5.1. Calcium imaging technique 
In the neuron, Ca2+ ions play a central role in various processes across all parts of the nerve 
cell. A charge carrier and an important intracellular messenger, Ca2+ is involved in the 
regulation of neuronal development, apoptosis, neurotransmitter release and membrane 
excitation. At rest, the intracellular Ca2+ ion concentration in the neuron fluctuates between 50 
and 100 nM, however they can rise 100-fold during electrical activity. Therefore, the direct 
measurement of intracellular baseline Ca2+ levels as well as Ca2+ spikes is highly informative of 
a neuron’s activity and excitability 472. By harnessing this neuronal property, Ca2+ imaging can 
directly visualise the Ca2+ status of hundreds of individual neurons simultaneously. Compared 
to electrophysiological methods, it does so in a less invasive way and can be used to track the 
activity of neurons over time. Calcium imaging has been used widely by neuroscientists to 
record activity in neuronal populations 473. The imaging of Ca2+ ions depends highly on the use 
of appropriate Ca2+ sensor indicators. Calcium indicators allow for the real-time monitoring and 
recording of cellular Ca2+ signals in vitro as well as in vivo, discussed next. 
1.5.1.1. Calcium indicators 
To monitor neuronal activity based on intracellular Ca2+ levels, a Ca2+-binding indicator is 
required that would enable the optical measurement of neuronal Ca2+ concentrations. Such 
indicators have been in development since the 1960s 474,475, but it was Tsien et al. that 
revolutionised Ca2+ imaging by introducing a series of highly sensitive fluorescent Ca2+ sensors. 
These Ca2+ indicators alter their spectral properties upon binding free Ca2+ ions. Broadly 
speaking, they can be classified into two main categories: chemical Ca2+ sensors for in vitro 
imaging 476 and genetically encoded Ca2+ indicators (GECIs) for in vivo imaging 477. A summary 
of the structure and general properties of each class is presented in the diagrams of Figure 
1.9. 
 




CHAPTER 1: INTRODUCTION 
The most successful example of an in vitro chemical Ca2+ indicator is the widely used high-
affinity dye Fura-2. It is the result of the hybridisation of a highly Ca2+-selective chelator with a 
fluorescent chromophore (or fluorophore) 478 (Figure 1.9). Its ester form, Fura-2AM, is its 
membrane-permeable derivative that freely crosses the cell membrane. Once inside the cell, 
cellular esterases cleave the ester bond thus “locking” the dye inside 479. Fura-2 binds Ca2+ 
ions with high affinity (Kd ~ 145 nM), and has a relatively wide Ca2+ sensitivity, ranging between 
~100 nM and ~100 µM 480. The primary advantage of Fura-2 is that it is a ratiometric dye. The 
binding of free intracellular Ca2+ induces conformational changes in Fura-2, shifting its 
excitation wavelength from 380 nm (free Fura-2) to 340 nm (Ca2+-bound Fura-2). Its emission 
wavelength remains stable at ~ 500 nm at either excitation wavelength. The higher the 
intracellular Ca2+ concentration is, the stronger the excitation at 340 nm and the weaker the 
Figure 1.9. Structure and properties of chemical and genetically-encoded calcium indicators. Chemical 
calcium indicators, such as Fura-2, are made of a Ca2+-chelating site and a fluorophore. Binding of Ca2+ 
(red circle) changes the fluorescence emitted. In contrast, genetically-encoded calcium indicators (GECIs) 
are made of three main components: an enhanced green fluorescent protein as a fluorophore, 
calmodulin, which binds Ca2+ and M13, which binds Ca2+-bound calmodulin. The interaction between 
Ca2+-bound calmodulin and M13 leads to conformational intrmolecular changes resulting in an increased 
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excitation at 380 nm is. Thus, a quantitative measure of intracellular Ca2+ concentrations can 
be estimated, independently of the intracellular dye concentrations, by calculating the ratio of 
the emissions at the two excitation wavelengths (340/380). The ratiometric property of Fura-2 
makes it a highly popular choice due to eliminating issues with variables such as variable dye 
concentration, unequal cell thickness, dye leaking and photobleaching 481.  
• Genetically encoded calcium indicators 
After the establishment of chemical Ca2+ sensors, protein-based genetically encoded Ca2+ 
indicators (GECIs) were the next big breakthrough as they allowed for the imaging of neuronal 
activity in vivo 477. Their expression can be targeted to specific subpopulations of cells and 
maintained stable over months, allowing for the repeated observation of neurons. Thus, GECIs 
are invaluable in the research of nervous system development, maintenance, learning and 
memory. However, they remain slightly inferior to chemical Ca2+ indicators in terms of their 
signal-to-noise ratios. The most widely used form of GECIs is the single-fluorophore GCaMP 
family. It is composed of three main parts: a circularly permutated enhanced green fluorescent 
protein (eGFP) with the Ca2+-binding protein – calmodulin attached on one end and a 
calmodulin-binding protein M13 on the other. Upon binding free Ca2+, calmodulin interacts with 
M13, which induces a conformational change in eGFP. This results in the increase of emitted 
fluorescence by the fluorophore 477,482 (Figure 1.9).  Substantial progress has been made in 
recent years to develop improved GECIs classes with high-affinity sensors, improved dynamics 
range, kinetics and better signal-to-noise ratio for the reliable detection of neurons with low 
activity rates 483.  
1.5.2.  Activating neurons  
To record neuronal activity in vitro, apart from an appropriate Ca2+ indicator, Ca2+ imaging 
requires neuronal stimulation. This can be by a shift in extracellular conditions (e.g. 
temperature), electrical stimulation or pharmacological agents. Extracellular solutions with 
high K+ concentration are generally used to activate neurons by depolarising the membrane 
potential across the whole neuronal population thus opening multiple voltage-gated ion 
channels simultaneously in the process. Hence, the excitability information derived by such 
stimulation is limited to a ‘yes or no’ interpretation and is impossible to discriminate among 
neuronal subtypes 484.  
1.5.2.1. The constellation pharmacology approach 
Apart from activating all neurons in a population simultaneously, separate neuronal subsets 
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a mixed population of neurons was popularised by Olivera et al. under the term “constellation 
pharmacology” 485,486.  Specifically, they applied a variety of pharmacological agents (e.g. allyl 
isothiocyanate, capsaicin, histamine, ATP, menthol and acetylcholine), as well as agonists 
targeted at voltage-gated ion channels (e.g. TTX, tetraethylammonium – a VGKC blocker) to a 
heterogeneous DRG population of neurons and recorded individual responses by Ca2+ 
imaging. Based on the distinct sets of Ca2+ responses produced by each neuron they were 
able to identify and functionally characterize neuronal subtypes 485,487. The constellation 
pharmacology approach can therefore be applied not only for the functional characterisation 
of neuronal subtypes but also in drug screens to determine the specific selectivity of a drug, 
as well as the degree of any side effects. These can be established by comparing the Ca2+ 
responses induced by markers in control versus drug-treated cells 488; or by pre-establishing 
a Ca2+ response template to high K+ solution in cells and comparing the changes the drug 
would induce to changes induced by ion channel blockers with pre-determined specificity 
485,487,488. Albeit highly informative, this cellular neuropharmacological approach is not without 
limitations. Due to its nature, this method demands the testing of multiple markers in 
succession in order to characterise the constellation of neuronal ion channels and receptors. 
The more detailed the characterisation is, the greater number of agents need to be applied, 
creating lengthy protocols, which cannot be supported due to limitations by other factors, e.g. 
the eventual photobleaching of the Ca2+ indicator used. The need for elaborate, pre-
established Ca2+ response templates as well as the application of high K+ solution as a universal 
neuronal activator during drug screens are further examples of drawbacks of this experimental 
method.  
 1.5.2.2. Veratridine 
One pharmacological agent used in drug screens is veratridine (VTD) due to its ability to 
activate VGSCs. Veratridine is a lipid-soluble alkaloid toxin derived from the seeds of lilaceous 
plants. It was first purified in the 1950s and became commercially available as a 
pharmacological agent in the early 1970s. Initially used mainly as an insecticide, the interest 
in VTD’s neurotoxic properties gradually grew sparking research into its mechanism of action 
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Veratridine binds reversibly to the S6 VGSC segment – part of the pore domain of the channel. 
The toxin is selective for TTX-S VGSCs and preferably binds them in their open state. Notably, 
voltage-clamp experiments in neurons from rat DRG have shown that VTD can also bind TTX-
R channels although the dissociation rate is much faster than TTX-S channels, leading to 
transient responses 492.  Once bound, VTD locks the channel in its open conformation and 
prevents inactivation by shifting the activation threshold of the channel to a more negative 
potential 493. Thus, VTD leads to an increase in intracellular Na+ levels, depolarising the 
membrane and activating other voltage-gated ion channels resulting in increase in intracellular 
Ca2+ concentrations and increased overall neuronal excitability (Figure 1.10). Of note, for VTD 
to exercise its strong nerve depolarisation effect, the external medium needs to include Na+ 
ions in its composition, as demonstrated by early experiments on frog and single nerve 
fibres489. With its VGSC activator profile confirmed by further electrophysiology 
experiments491,494–496, VTD is now extensively used as a pharmacological tool in drug screening 
protocols to activate sodium channels and test the efficacy of VGSC blockers 497.  
Figure 1.10. Veratridine (VTD) action on voltage-gated sodium channels (VGSCs). VTD 
preferably binds TTX-S VGSCs such as Nav1.7. Upon binding, VTD “locks” the channel in 
its open conformation state, increasing the flux of sodium (Na+) ions into the cell. This 
causes membrane depolarisation and triggers the opening of other voltage-gated 
channels, including voltage-gated calcium channels (VGCCs). Their activation allows for 
the influx of calcium (Ca2+) ions into the cells, increasing the intracellular Ca2+ 
concentration (i[Ca2+]) which can be detected and measured using Ca2+ indicators and 
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1.5.3 Veratridine-induced calcium response profiles as functional 
indicators of DRG neuronal subpopulations 
In DRG, the TTX-S VGSCs available for VTD to bind to are Nav1.6 and Nav1.7. Of the two, 
Nav1.7 is the most predominantly expressed in all DRG, especially nociceptors, whereas 
Nav1.6, although expressed by all DRG neurons, is found mainly in large, non-nociceptive 
neurons 498. Although VTD preferentially binds to TTX-S VGSCs, it does not have specificity to 
a particular isoform. Applying VTD to a mixed population of DRG neurons, therefore, would be 
expected to produce mixed responses based on the constellation of VGSCs (and other 
voltage-gated ion channels) expressed by each neuronal type. 
This concept was elegantly demonstrated previously in our lab by Mohamed et al. 499, in Ca2+ 
imaging experiments with VTD on mouse DRG neurons. They showed that VTD elicited 
heterogeneous Ca2+ responses. Based on their decay rate and oscillation, the responses were 
classified into four distinct VTD-induced Ca2+ response profiles: rapid decay (RD), intermediate 
decay (ID), slow decay (SD) and oscillatory (OS) profile with the SD and OS profiles being the 
most frequently occurring (Figure 1.11 A, B). Additionally, three nociceptive agonists were also 
applied to the neurons after VTD:  
• α,β-methylene adenosine 5'-triphosphate (ATP) to mark non-peptidergic, IB4+ 
nociceptors, 
• allyl isothiocyanate (AITC) – marker of LTMRs and some peptidergic and non-
peptidergic nociceptors  
• capsaicin (CAP) to mark peptidergic nociceptors. 
 
The VTD-response profiles correlated with responses to the nociceptive markers (Figure 1.11 
C) revealing a strong association between the OS profile and nociceptors, whereas the SD 
profile correlated with non-nociceptors. These observations were further confirmed by size 
analysis of the imaged neurons, showing that virtually all OS, ID and RD neurons are small to 
medium diameter, while SD was the most prevalent profile in neurons of large diameter. An 
additional finding of this study was that 25-30% of the identified nociceptors did not respond 
to VTD and were therefore presumed to be the population of high-threshold “silent 
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Figure 1.11. Veratridine (VTD) applied to mouse DRG neurons produces four distinct VTD-response 
profiles that could be indicative of specific neuronal subpopulations. A) Example traces for each of the 
four distinct VTD-response profiles: Slow decay (SD, top left), rapid decay (RD, top right), intermediate decay 
(ID, bottom left) and oscillatory profile (OS, bottom right). B) Frequency of the occurrence of the VTD-
response profiles in VTD(+) DRG neurons. Most frequent is the OS profile (48 ± 4%), followed by SD (24.4 ± 
4%), RD (13.4 ± 4%) and ID (12.7 ± 2%). C) VTD-response profiles can be correlated to functional markers of 
nociceptors. DRG neurons were applied nociceptive agonists: α,β-methylene ATP, allyl isothiocyanate or 
capsaicin. Neurons responding to at least one of the three agonists applied are defined as nociceptors. 
nociceptors constitute 66% of all DRG neurons. Of them, 64% were of the OS, ID and RD VTD-response 
profiles. Non-nociceptors (neurons insensitive to any of the three nociceptive agonists) constituted 34% of 
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Thus, the study generated the first detailed characterisation of VTD responses in DRG neurons 
and their correlation with neuronal subtypes. What is more, it proposed the use of the VTD 
response profiles as broad functional markers of neuronal subpopulation that can discriminate 
nociceptors from non-nociceptors. Importantly, it presented the opportunity of developing the 
VTD-Ca2+ imaging assay into a platform suitable for drug screening as well as characterisation 
of neuropathology phenotypes 499. The promising findings by Mohamed et al. opened the door 
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1.6.  Aims 
The VTD-Ca2+ imaging assay has shown promise as a suitable technique for neuronal 
characterisation. However, before it can be applied, the link between the VTD-response 
profiles and neuronal subpopulations needs to be strengthened further. Therefore, the first 
aim and its objectives of this study are 
Aim 1: Validation of the VTD-Ca2+ imaging assay as a suitable drug screen platform 
(Chapter 3) 
• Confirm the link between VTD-induced Ca2+ response profiles and neuronal 
subpopulations by: 
o using DRG from mice with genetically ablated nociceptors 
o using specific and non-specific VGSC blockers and analyse the VTD response 
profiles patterns in DRG neurons 
 
Then, I endeavour to investigate the application of the assay as a method for characterising 
the neuropathological phenotype in a diabetic neuropathy model. The db/db mouse is one of 
the most popular models of type 2 diabetes, however, its diabetic neuropathy phenotype is 
still poorly characterised and the accumulated literature on the matter to date is highly 
controversial. Therefore, the second aim and objectives of the research presented here are: 
Aim 2: Application of the VTD-Ca2+ imaging assay and nociceptive agonists to 
characterise changes in excitability in neuronal subpopulations under diabetic 
neuropathy conditions (Chapters 4 and 5).   
• Characterise excitability changes in DRG neurons from healthy mice cultured in vitro 
under hyperglycaemic conditions using the VTD-Ca2+ imaging assay and nociceptive 
markers  
• Characterise morphological and excitability changes in DRG neurons isolated from 
diabetic db/db mice using VTD-Ca2+ imaging assay and nociceptive markers. 
Investigate the distinct excitability changes in the two diabetic neuropathy phases in 
the db/db mouse:  
o Early diabetic neuropathy phase 
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CHAPTER 2: MATERIALS & METHODS  
2.1 Materials 
2.1.1. Animals: 
C57/BL6 adult male mice (Charles River, Margate, UK), obtained at 5-7 weeks old were used in 
the experiments with healthy mice outlined in this thesis. For experiments investigating effects 
of diabetes on DRG neurons, a total of 12 male diabetic C57BKSdb/db mice (BKS.Cg-
+Leprdb/+Leprdb/OlaHsd) were used and 12 lean littermate mice were used as non-diabetic 
controls (BKS.Cg-+Leprdb/-Leprdb/OlaHsd) (Envigo, The Netherlands). Animals were kept in a 
12h light-dark cycle with free access to food and water. Mice were housed in groups of 3-4 and 
were allowed a week for acclimatisation upon arrival at the Biological Services Unit at the 
University of Sheffield in a temperature- (23 ± 2°C) and humidity- (40-70%) controlled holding 
room. During experimental periods, no animal was left alone in its unit for longer than 24h. All 
efforts were made to minimise animal suffering and reduce the number of mice used in the 
reported studies. All experiments with animals were conducted according to the UK Home Office 
Animals (Scientific Procedures) Act 1986. 
2.1.2 Cell culture reagents 
Name Supplier Catalogue No 
Albumin Bovine fraction V (BSA) Melford 
A1302 
Collagenase Type XI,100X (0.6 mg/mL) Sigma 
C9407 
Dispase, 100X (1 mg/mL) Sigma D4693 
Dulbecco’s Modified Eagle’s Medium/F12 with Glutamax 




Dulbecco’s phosphate buffered saline (DPBS), without Ca2+ 
and Mg2+, 0.0095 M (PO4) 
Lonza BE17-512Q 
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Penicillin/Streptomycin 100X Sigma 
P0781 
Poly-L-orinithine (20µg/mL) Sigma 
P3655 
2.1.3 Pharmacological compounds 
Name Supplier Catalogue No Stock concentration 
Solvent 
4,9-anhydrotetrodotoxin Tocris 6159 300 µM 
water 
A-803467 Abcam Ab120282 10 mM 
DMSO 
Allyl isothiocyanate (AITC) Sigma 377430 100 µM 
- 
Capsaicin Tocris 0462 10 mM 
ethanol 
Isoflurane (IsoFlo®) Abbott B506 100% 
- 
PF-04856264 Sigma 11916 10 mM 
DMSO 
PF-05089771 Sigma-Aldrich PZ0311 20 mM 
DMSO 
Veratridine Abcam Ab120279 5 mM 
ethanol 
α, β-methylene ATP Sigma M6517 10 mM 
water 
 
2.1.4. Reagents, chemicals and solvents 
Name Supplier 
Catalogie No 






Dimethylsulfoxide (DMSO) Sigma-Aldrich 276855 
Ethanol, absolute (HPLC grade) Fisher Scientific E/0665DF/17 








Magnesium chloride (Anhydrous) 
Melford 
M0535 










2.1.5. Tools, equipment and labware 
Name Supplier 
Catalogie No 
Calcium imaging perfusion chamber 
Warner instruments RC-25F 
Cellview™ cell culture dish, PS, 
35/10MM (Glass bottom, one 
compartment) 
Scientific Laboratory 
Supplies LTD - 





Disposable Scalpels (Surgical steel 
blades) 
Swann-Morton  0505  
Dumont #5 Forceps Fine Science Tools, FST 15018-10 
Luer-Lok syringes (50 mL) 
Becton Dickinson (BD) 300865 
Minisart® Syringe Filters (0.45 μm, 
Sartorius) 
Appleton woods 25926 
Portex Tubing ,30m non-sterile 
polythene tubing, [ 0.86 mm ID, 1.27 
mm OD] 
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2.1.6. Solution and medium recipes 
• DRG neurons digestion mix (stored at -20°) 
o Collagenase XI (0.6 mg/mll) 
o Dispase II (1 mg/ml) 
o DMEM/F-12 + Glutamax 
 
• Standard Extracellular Ringer Solution (stored at room temperature) 
o 140 mM Sodium Chloride, 
o 4 mM Potassium Chloride, 
o 2 mM Calcium Chloride, 
o 1 mM Magnesium Chloride, 
o 10 mM HEPES, 
o 5mM D-glucose (added on the day of experiment)* 
o pH = 7.4 at 25 °C, PH is adjusted with Sodium Hydroxide 
 
• High Potassium Ringer Solution (stored at room temperature) 
o 104 mM Sodium Chloride, 
o 40 mM Potassium Chloride, 
o 2 mM Calcium Chloride, 
o 1 mM Magnesium Chloride, 
o 10 mM HEPES, 
o 5 mM D-glucose (added on day of experiment)* 
o pH = 7.4 at 25 °C, PH is adjusted with Sodium Hydroxide 
*stored at 5°C once D-glucose is added 
2.2. Methods 
2.2.1. Preparation of mouse dorsal root ganglia neuronal culture   
2.2.1.1 Isolation of DRG 
The mouse was anaesthetized using isoflurane in an anaesthetic machine, then moved to a 
surgical table and culled by cervical dislocation in accordance with Schedule 1 procedures of 
UK Animals (Scientific Procedures) Act 1986. The animal’s spinal column was isolated by careful 
incisions along its length and unnecessary extra tissue (muscle and fat) surrounding it was gently 
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at a time, using a scalpel in order to be able to access the spinal cord. Halves of the spinal 
column were placed under a light microscope and spinal cord matter pushed away carefully 
using forceps in order to expose the sockets containing DRG underneath. Then DRGs were 
extracted one by one out of the spinal columns with forceps and placed into 35mm dish with 
PBS until end of isolation procedure. Once all DRGs were isolated, long extending axons were 
trimmed whilst still in PBS dish under the light microscope, using a scalpel. For experiments 
investigating mice with Nav1.8-expressing neurons ablated, DRG from Nav1.8Cre-DTA mice 99 
and littermate control mice were stored in ice-cold Hibernate-A medium (Gibco) containing 
penicillin/streptomycin whilst being transported from University College London (approximately 
5-hour journey), after which were dissociated as outlined.  
2.2.1.2 DRG digestion 
The PBS in the dish containing isolated and prepped DRG bodies was replaced with DRG 
digestion mix made up of 1 ml Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) with 
Glutamax medium containing Dispase (1mg/ml) and Collagenase Type XI (0.6 mg/ml). DRGs 
were then left in an incubator for 60 mins at 37°C and 5% CO2 for digestion.  
2.2.1.3 Dissociation of neurons and seeding 
At the end of digestion time, cells were triturated 10 times to ensure tissue separation from 
neurons. Resulting cell suspension was then carefully layered on the surface of 1.5 ml 15% 
Bovine Serum Albumin (BSA) in DMEM/F12. Mixture was centrifuged for 10 minutes at 21° at 
800 g (2000 rpm (rotor no. 4624/ Hettich Rotina 46R centrifuge)) set at minimum deceleration 
speed. The produced cell pellet was then gently washed with DMEM/F12 containing 10% Foetal 
Bovine Serum, 100 units/mL penicillin and 100 μg/mL streptomycin. Mixture was centrifuged 
once more at 200g (1000 rpm) for 3 minutes. Supernatant was removed and cells were 
resuspended in 60 – 100 µl of the above-described DRG culture medium and seeded on 
autoclaved and poly-L-ornithine- coated (20 μg/ml) 16mm glass coverslips with each seeding 
drop being 3-4 μl. Neurons were left in the incubator at 37°C / 5 % CO2 for 1 hour to allow 
adhesion to coverslip surface. Finally, plated cells were carefully flooded with DRG culture 
medium and incubated for a minimum of 24h at 37 °C / 5 % CO2 prior to experiments. 
2.2.1.4. Adjustments to glucose concentration in culture for in vitro hyperglycaemia 
experiments 
Mouse DRG neurons were cultured with standard DMEM/F12 (17.5 mM glucose) with 32.5 mM 
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were supplied with DMEM/F12 medium containing default amount of 17.5 mM glucose deemed 
optimal for neuronal survival 318 and were added 32.5 mM mannitol for osmotic control. Additional 
glucose administration to the culture was initiated after 1 day after culturing the neurons and 
maintained for up to 5 days with measurement taken on days 1, 2, 4 and 5 post - glucose addition. 
2.2.2. Calcium imaging of DRG neurons 
2.2.2.1. DRG cells loading with Fura-2AM 
All loading of neurons with a calcium dye took place in the dark. Working concentration of 2 µM 
of the calcium dye Fura-2AM was made up by mixing 1 µl Fura-2AM stock with 1ml standard 
extracellular Ringer solution (see section 2.1.6. Solution and medium recipes). Using a P1000 
pipette, solution was vigorously mixed for up to a minute to ensure complete solubilisation of the 
dye. Coverslips were carefully removed from culture plates with DRG medium and placed in a 
35mm dish, up to three at a time, taking care not to overlap. They were washed once with 
standard extracellular Ringer solution before loaded with Fura-2AM solution and left to incubate 
at 37 °C / 5 % CO2 for 30 minutes. After 30 minutes, Fura-2AM solution was removed and 
replaced with 1 ml standard extracellular Ringer solution and cells were left to incubate at 37 °C 
/ 5 % CO2 for another 15 minutes. Finally, cells were taken out and stored in an opaque container 
outside of incubator for another 15 minutes in order to allow for neurons to adjust to the room 
temperature at which calcium imaging experiments would take place. 
2.2.2.2. Experimental set up  
Recordings were performed at room temperature of 23 ± 2°C. Each Fura-2AM-loaded coverslip 
was mounted on a recording chamber (RC-25F, Warner instruments) and slowly and carefully 
added 1 ml standard extracellular Ringer solution to prevent dehydration of cells. Chamber was 
placed on the stage of an inverted Olympus, IMT-2 microscope fitted with a 40X oil-immersion 
objective (Olympus, 160/-, DPlanApo40UVPL). Due to technical issues this objective was 
replaced with a 40X dry objective. Coverslip surface was examined to locate a suitable field of 
view, comprising of optimal number of cells (20 – 45) and cell density. Simple PCI6 software was 
used for recording set up and image acquisition with background subtraction and ratiometric 
measurements (F350/380 nm). Regions of interest (ROI) were obtained for each cell of interest 
in the selected field, as well as an additional one for the background. Neurons were excited with 
alternating 350 nm and 380 nm light (Cairn Dual OptoLED system) at 1.6 s intervals. Image 
acquisition was carried out using a Hamamatsu C4742-95 camera. Solution perfusion was 
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2.2.2.3. Recording of calcium responses  
Upon launching of the perfusion system, a laminar stable flow across the coverslip was 
confirmed before recording commenced. Prior to addition of drug solutions during recording, 
neurons were initially perfused with standard extracellular Ringer solution for at least 5 minutes 
to ensure a stable initial calcium trace baseline is established. A wash of minimum of 5 minutes 
with standard extracellular Ringer solution was also included in between drug solution 
perfusions. Finally, high potassium extracellular Ringer solution (KCl, 40 mM) (see 2.1.6. Solution 
and medium recipes, page 66) was perfused at the end of each recording as a universal neuronal 
depolarising means to confirm viable neurons. Neurons irresponsive to high potassium 
extracellular Ringer solution were excluded from analysis. 
2.2.3. Data processing and statistical analysis of calcium imaging data  
2.2.3.1. Analysis of recorded calcium imaging responses 
Viable neurons identified by high potassium extracellular Ringer solution were selected for 
analysis. All recorded traces were analysed using GraphPad Prism 8 software, also used to 
generate all graphs in this thesis. Calcium signal baseline was established from 30 frames of 
signal prior to the addition of any drugs. A calcium response to a drug was identified as an 
increase in F350/380 ratio of 6 standard deviations or more above the mean of the baseline. 
Veratridine (VTD) responses were classified according to the four VTD-response profiles, or 
shapes, outlined previously by Mohammed et al. (2017) 499.   
 
The fractional difference (ΔF/F0) in fluorescence was established prior to amplitude, response 




 =  




Area under the curve was calculated using a built-in analysis function in GraphPad Prism 8 
implementing the ‘trapezoid’ principle for area under the curve measurement. The measured 
data included a 10-minute stretch of the recording, beginning at VTD application, due to the 
diversity in shapes and decay of VTD responses. Amplitude and response onsets were analysed 
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2.2.3.2. Neuronal cell size analysis 
Neuronal cell diameter analysis was carried out using the ImageJ software (version 1.53a for 
Windows). Cell circumference was obtained by manual tracing of each cell’s soma outline. Cell 
area was then calculated by the in-built software formula. The generated cell area was then used 
to calculate cell diameter following the formula:  
 




2.2.3.3. Statistical tests 
The unit used in statistical analysis was the mouse (N). The mean percentage of responsive 
neurons from each culture an N produced was calculated. Upon accumulation of sufficient 
independent samples (independent Ns) for each experiment, means of the Ns of each 
experimental group were compared to each other. To test the frequency distribution of cell sizes 
for normal Gaussian distribution, a normality test was performed (D'Agostino-Pearson and 
Kolmogorov-Smirnov normality tests), which yielded normal Gaussian distribution in all cases. 
To calculate the significant difference between two groups, a Student’s t-test was used. To test 
for significant difference in the mean values between three or more groups, one-way analysis of 
variance (ANOVA) with post Sidak’s multiple comparison test was used. The results are shown 
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CHAPTER 4:  ASSESSING EXCITABILITY CHANGES IN 
DRG NEURONS UNDER IN VITRO HYPERGLYCEMIC 
CONDITIONS 
4.1. INTRODUCTION 
The first step in answering this thesis’s research question: “What are the excitability changes 
in DRG neurons during DN?”, was to validate the use of the VTD-profiles as a functional marker 
for nociceptors and non-nociceptors in a heterogeneous neuronal population. In the previous 
chapter, VTD was shown to allow for the study of changes in VGSCs and place them in the 
context of specific neuronal subpopulations. Hence, the VTD-Ca2+ imaging assay was 
established as a suitable tool for the discrimination of neuronal subpopulations. As a result of 
its validation, several potential applications arose.  
For the experiments in this and the next chapter, I apply the VTD-Ca2+ imaging assay together 
with selected nociceptive agonists to characterise diabetes-induced excitability changes in 
DRG neurons exposed to hyperglycaemic conditions. Determining the distinct excitability 
changes occurring in nociceptors and non-nociceptors during DN would provide valuable 
insights into the pathophysiological mechanisms driving DN in sensory neurons. To this end, 
in the current chapter, I used the in vitro-induced hyperglycaemia model. 
In the literature, in vitro-induced hyperglycaemia has been mostly used to investigate the 
effects of acute exposure to high glucose on DRG neurons. Such studies have contributed 
vastly to DN research by demonstrating decreased cell viability 318,423,500,501, ROS rise 423,424,500, 
cell injury 423, increased Nav1.7 expression 351 and increased VGSC currents 424,502 in DRG 
when exposed to high glucose concentrations for up to 48h. However, to our knowledge, there 
are no studies exploring the effects of extended high glucose exposure time past the 48h mark 
on neuronal excitability neither are there studies sorting observed excitability changes to 
neuronal subtypes. Since VGSC currents and expression have been observed to increase in 
DRG neurons as early as 18h of acute high glucose exposure 351,424, we hypothesised that 
extending the exposure time will lead to further VGSC activity increase and neuronal 
excitability changes. Prolonged high glucose exposure of DRG neurons should more closely 
mimic the chronic hyperglycaemic conditions in humans and reflect physiological DN 
progression. Furthermore, apart from the immediate post-translational changes induced by 
hyperglycaemic conditions, transcriptional changes could also have the opportunity to take 
place. In time periods of 24h or less, such important transcriptional changes would be missed, 
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therefore, culturing DRG neurons in high glucose for an extended time period would allow for 
their detection.   
4.2. AIMS 
To assess the excitability changes in DRG neurons from C57BKS mice cultured in 
hyperglycaemic conditions for 1, 2, 4 and 5 days by analysing calcium responses induced by 
the VGSC agonist VTD and the nociceptive markers ATP, AITC and CAP. 
4.3. METHOD 
4.3.1. Glucose concentration and exposure time in in vitro-induced 
hyperglycaemia 
Mouse DRG neurons were cultured with standard DMEM/F-12 (17.5 mM glucose) with 32.5 
mM added glucose (total 50 mM) to induce hyperglycaemic, diabetic conditions. Control 
cultures were supplied with DMEM/F-12 medium containing its standard 17.5 mM glucose 
deemed optimal for neuronal survival 318  and added 32.5 mM mannitol as an osmolarity control 
to the high glucose medium. The hyperglycaemia-inducing glucose concentrations were 
selected on the basis of previous studies which have reported that in vitro glucose 
concentrations in the range from 30 to 45 mM lead to hyperglycaemic stress, oxidative stress, 
ROS elevation and cell injury in DRG neurons - all markers of DN (Table 4.1).  Furthermore, 
45 mM glucose treatment (1.8-fold above control) is similar to the ≥ 1.4-fold increase in blood 
glucose concentration in a person diagnosed as diabetic 503 and within the range of blood 
glucose concentration of diabetic mice 428–431,504 (e.g. db/db mice at 10 WoA have blood glucose 
concentration of ~ 32.7 ± 2.0 mM 504, which keeps increasing as diabetes progresses 
uncontrolled 428). Therefore, a total concentration of 50 mM glucose for the present 
experiments is consistent with other diabetic animal models and human diabetes and should 
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Table  4.1. Studies that used varying concentrations and exposure times of glucose in in vitro 












al. 1999 318 
Embryonic 
rat DRG 
30 – 330 mM 24h- 48h 
Observed concentration-dependent 
neuronal apoptosis and decrease in 
neurite outgrowth at glucose 
concentrations above 50 mM; optimal 
DRG survival and neurite growth require 
25–30 mM basal glucose (optimal 
concentration). 
Russell et 




45 mM 0- 24h 
In vitro as in vivo, variations in 
administered glucose as small as 10 mM 
from basal value (25 mM) induce neuronal 
injury. 









Short-term exposure of DRG neurons to 
high glucose concentrations enhance the 
VGSC activity and were attenuated via 
ROS-dependent mechanisms. 
Leinninger 






45 mM 3-6h 
High glucose promotes convergence of 
Drp1-mediated mitochondrial fission with 
pro-apoptotic proteins, resulting in 
mitochondrial injury and apoptosis. 
Vincent et 





45 mM 0-24h 
There were nearly identical levels of DRG 
neuron death at the endpoint with a 2h 
glucose exposure compared with 
prolonged hyperglycaemia for the whole 6 
or 24h time course of the experiment. 
Programmed cell death starts as soon as 
2h. 
 
After isolation and culturing, neurons were left to adjust for 24 hours before adding glucose or 
mannitol as opposed to introducing hyperglycaemia during the first cell flooding. This was to 
ensure that both groups had an equal opportunity to acclimatise to being in culture before the 
introduction of the potentially injurious effects of high glucose. After the addition of high 
glucose, culture was maintained for up to 5 days. Calcium imaging experiments took place at 
days 1, 2, 4 and 5 in high glucose. Therefore, total days in culture are equal to [days after 
adding glucose] + 1, e.g., day 1 of experiments is equal to 1 day in high glucose conditions 
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4.3.2. Calcium imaging 
DRG neurons were loaded with Fura-2 and responses recorded to nociceptive agonists: 
capsaicin (CAP, 200 nM), allyl isothiocyanate (AITC, 100 µM) and α,β-methylene ATP (ATP, 1 
µM) as well as VGSC potentiator veratridine (VTD, 30 µM). Standard calcium imaging protocol 
was followed as outlined in Chapter 2: Materials & Methods, section 2.2.2., page 68 .  
4.4. RESULTS 
4.4.1. The number of available neurons for imaging experiments declines 
with time in culture 
When selecting neurons for Ca2+ imaging experiments, firstly regions of interest (ROI) are 
specified around each neuron from which fluorescence intensity will be recorded. These are 
selected based on the neuron’s health (e.g., “shiny” membrane, absence of granulation, 
consistent round shape), quality and positioning relative to other neurons on the coverslip. 
After 48h in culture, neurite outgrowth and replication of non-neuronal cells begin 505. This 
creates overcrowded networks of overlapping neuronal processes and non-neuronal cells that 
obstruct the neurons in culture from being easily identified and selected for Ca2+ imaging in a 
ROI. We compared the cell yield per mouse per time point (day 1, 2, 4 and 5) in order to 
determine whether the number of available neurons for imaging experiments is affected with 
time. A neuron was defined as “available” if it was easily distinguishable, not overlapping with 
other culture components and hence the fluorescence it would emit would have been 
unobstructed. The total number of neurons for each day decreased as time in culture 
increased (table 4.2). Indeed, when comparing the number of available neurons per mouse for 
each time point, there was a significant decrease in the quantity of available cells for each 
Figure 4.1. A schematic of the experimental protocol used in the current experiments. After 24h of post-
dissociation (Day 1) acclimatisation, DRG neurons were added either glucose or mannitol (Day 2). Calcium 
imaging experiments took place In days 3, 4, 6 and 7 in culture which correspond to days 1, 2, 4 and 5 in high 
glucose conditions, respectively. 
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consecutive day compared to day 1, for both the control and high glucose groups (figure 4.2). 
The number of cells imaged for each condition was 1,871 for CTRL and 1,888 for the 50 mM 
group. By day 5, there was a reduction of 4.2- and 4.7-fold for CTRL and 50 mM group, 
respectively, compared to day 1 (CTRL: from 191.6 ± 20 in d1 to 46 ± 3.8 neurons in d5; 
50mM: from 194 ± 17.9 in d1 to 40.7 ± 11 neurons in d5, p < 0.001). There was no significant 
difference in the number of neurons available between the two conditions for each day. These 
results demonstrated a consistent decrease in the number of neurons available for Ca2+ 
imaging experiments the longer the culture was maintained. 
4.4.2. Time in culture, but not in vitro-induced hyperglycaemia, affects 
responses to nociceptive agonists  
Diabetes has been shown to sensitise nociceptors in DRG neuronal populations from animal 
models of DN as well as in in vitro-induced high glucose conditions 506–509. Therefore, three 
well-established nociceptive agonists were applied: α,β-methylene ATP (ATP), allyl 
isothiocyanate (AITC) and capsaicin (CAP), to see whether in vitro hyperglycaemic conditions 
would lead to the sensitisation of corresponding nociceptive receptor channels and the 
nociceptive subpopulations they mark. Agonists were applied consecutively as opposed to 
Table  4.2. The total number of neurons decreases the longer the culture is maintained. The total 
number of neurons was recorded for each day of culture (1, 2, 4 and 5) and compared between control 
(CTRL) and high glucose-treated (50 mM) neurons. The number of mice (n) is shown in columns next to 
the cell count. 
Figure 4.2. The availability of neurons for Ca2+ imaging declines the longer the culture is maintained. 
Each bar represents the average number of neurons available per mouse for the respective timepoint, 
derived by dividing total cells of each time point by the number of mice (n) they were derived from in 
Table 4.2.  D1, CTRL = 191.6 ± 20.1; 50mM = 194 ± 17.8; D2, CTRL = 128 ± 8.1, 50mM = 132.4 ± 13.1; D4, 
CTRL = 67.5 ± 28, 50mM = 67 ± 28; D5, CTRL = 46 ± 3.8, 50mM = 40.1 ± 11.1; * = significance compared 
to D1 CTRL, *p<0.05, **p<0.01, ***p<0.001; & = significance compared to D1 50mM, &p<0.05, 
&&p<0.01, &&&p<0.001. One-way ANOVA with multiple comparisons 
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added together. In the control group of neurons, responses to AITC in days 4 and 5 were 
significantly lower than day 1 by 2.5- and 2-fold, respectively (decrease from D1 65 ± 3% to 
D4 25.6 ± 7.7% and D5 32.3 ± 1.9%). The percentage of AITC(+) neurons between conditions 
within each day were not significantly different. Thus, the percentage of AITC(+) control 
neurons decreased significantly with time in culture (Figure 4.3 B). In the high glucose group, 
all days of measurements (2, 4 and 5) showed significantly lower response rates to AITC than 
day 1 by 1.4-, 2.2- and 2.7-fold, respectively (decrease from D1 64.8 ± 1.9% to D2 48.1 ± 4.1%, 
D4 30.2 ± 0.7% and D5 24 ± 5.2%) (Figure 4.3 B). The percentage of ATP(+) (Figure 4.3 A) 
and CAP(+) (Figure 4.3 C) neurons was comparable between conditions as well as overtime 
within each condition. Collectively, these results indicate steadily decreasing response rates 
to AITC in cultured DRG neurons with time, irrespective of extracellular glucose levels. 
Figure 4.3. Responses of DRG neurons under control and hyperglycaemic conditions to nociceptive 
agonists.  
A) no significant difference in the responses to ATP between conditions as well as overtime within each 
condition. CTRL: D1=24.1±2.9%, D =22.4±4.8%, D4 = 11.1±1.7%, D5 = 15.65±9.7%; 50mM, D1 = 20±2.7%, 
D2 = 16.5±2%, D4=13.8±1%, D5=17.4±5%; B) The percentage of AITC(+) neurons was significantly 
decreasing with each day spend in culture compared to day 1 (D1) in both the control and hyperglycaemic 
cultures. CTRL: D1 = 65 ±  3%, D2 = 55.1 ± 3.2%, D4 = 25.6 ± 7.7%, D5 = 32.2 ± 1.9%; 50mM, D1 = 64.8 ± 
1.9%, D2 = 48.1 ± 4.1%, D4 = 30.2 ± 0.7%, D5 = 24 ± 5.2%; C) no significant difference in the responses to 
ATP between conditions as well as overtime within each condition. CTRL: D1 = 23.9 ±  4.4%, D2 = 34.1 ± 
5.1%, D4 = 38.8 ± 7.5%, D5 = 37.9 ± 3.1%; 50mM, D1 = 23 ± 3.2%, D2 = 31.1 ± 4.3%, D4 = 43 ± 13.5%, D5 = 
32 ± 2%. * = significance compared to D1 CTRL, *p<0.05, **p<0.01, ***p<0.001; & = significance compared 
to D1 50mM, &p<0.05, &&p<0.01, &&&p<0.001. Where significance is not denoted, the difference is not 
significant. One-way ANOVA with multiple comparisons. Mean±SEM. CTRL=control (open bars); 50mM = 
hyperglycaemic culture (blue bars); D# = day#. ATP=α,β-methylene ATP, AITC=allyl isothiocyanate, 
CAP=capsaicin. On the right handside of each, intracellular calcium signal trace following stimulation with 
the respective agonist, averaged from all responsive neurons (24) from one experiment. Black – average 
trace from one experiment; grey – showing the SEM for each second of the recorded trace; black arrows 
indicate the time point of respective drug application. 
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4.4.3. Time in culture leads to subtle changes in VGSC activity, affected 
by in vitro induced hyperglycaemia 
High glucose concentrations have been reported to cause excitability changes in DRG neurons 
contributing to (P)DN 349. We hypothesised that these changes are likely to involve 
modifications in VGSC activity and thus, will be detected using the VTD-based Ca2+ imaging 
assay. First, we looked at the percentage of VTD-irresponsive neurons – the percentage of 
VTD(-) neurons remained similar from day 1 to day 5 in culture in both the control and 
hyperglycaemic cultures (Figure 4.4 A). The percentage of VTD(-) neurons was also 
comparable between the CTRL and hyperglycaemic groups for each day, with non-significant 
differences. This suggests that neither hyperglycaemic conditions in this model nor time spent 
in culture influence overall VGSC-induced neuronal excitability.  
Next, we classified the VTD(+) neurons into the four VTD-response profiles, in order to detect 
excitability changes within neuronal subpopulations. VTD-response profile rates overtime 
showed no significant differences between days within the CTRL and 50mM groups as well as 
between the CTRL and 50mM groups for each day (Figure 4.4 B,C,D,E).  
 
 
Figure 4.4. Responses to VTD by DRG neurons cultured for 1 to 5 days in high glucose or standard 
conditions. Neither time spent in culture not high glucose levels influenced the responses to VTD in 
cultured DRG neurons.  
A) Percentage of VTD(-) neurons, CTRL: D1 = 27.5 ±  1.4%, D2 = 28 ± 2.1%, D4 = 26.9 ± 4%, D5 = 26.1 
± 6%; 50mM, D1 = 32.1 ± 1.9%, D2 = 22.7 ± 3.6%, D4 = 35.8 ± 10.5%, D5 = 30.1 ± 4.7%; B) Percentage 
of VTD(+) neurons of the SD profile, CTRL: D1 = 20.1 ± 2.8%, D2 = 24.2 ± 3.5%, D4 = 28.5 ± 2.9%, D5 = 
29.7 ± 6.6%; 50mM, D1 = 18.2 ± 2.7%, D2 = 24.8 ± 2.2%, D4 = 22.2 ± 9.4%, D5 = 29 ± 4.2%; C) 
Percentage of VTD(+) neurons of the OS profile, CTRL: D1 = 38.6 ± 2.4%, D2 = 34.2 ± 2.8%, D4 = 40.1 
± 1.6%, D5 = 30.9 ± 5.3%; 50mM, D1 = 35.4 ± 2.3%, D2 = 39.9 ± 3.6%, D4 = 30.1 ± 2.8%, D5 = 29.9 ± 
4.1%; D) Percentage of VTD(+) neurons of the ID profile, CTRL: D1 = 7.4 ± 1.2%, D2 = 6.8 ± 1.4%, D4 = 
4.7 ± 0.5%, D5 = 8.2 ± 3.2%; 50mM, D1 = 7.8 ± 1.1%, D2 = 5.8 ± 1%, D4 = 8.3 ± 2%, D5 = 9 ± 3.3%; E) 
Percentage of VTD(+) neurons of the RD profile, CTRL: D1 = 3.7 ± 0.4%, D2 = 5.6 ± 1.4%, D4 = 0 ± 0%, 
D5 = 4.8 ± 1.1%; 50mM, D1 = 5 ± 1.1%, D2 = 5.6 ± 0.6%, D4 = 2.9 ± 0.3%, D5 = 1.2 ± 1.2%; Where 
significance is not denoted, the difference is not significant. One-way ANOVA with multiple 
comparisons. Mean ± SEM. CTRL = control (open bars); 50mM = hyperglycaemic culture (filled bars);F) 
Intracellular calcium signal trace following stimulation with VTD shaping the responses SD (left) and 
OS (right), averaged from all SD- or OS-profiled neurons (12 and 19, respectively) from one 
experiment.; Black – average trace from one experiment; grey – showing the SEM for each second of 
the recorded trace; black arrows indicate the time point of respective drug application. 
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Further analysis was performed of the average amplitude, time to peak and area under the curve 
(AUC) of the VTD responses for each of the four profiles (Figure 4.5). Significantly smaller 
amplitudes by 1.7-fold were observed in the OS profile in day 5 compared to day 1 of the control 
(decrease from d1 0.47 ± 0.06 to d5 0.27 ± 0.06, p < 0.05) but not the high glucose population 
(Figure 4.5. D). Significant amplitude reduction by 2-fold was also evident in the RD profile between 
control day 1 and control day 5 neurons (decrease from d1 0.39 ± 0.03 to d5 0.2 ± 0.02, p < 0.05) 
(Figure 4.5. J). Similar amplitude trends were evident in the SD and ID profiles, albeit non-
significant (Figure 4.5. A,G). These shifts indicate a possible time-in-culture-dependent effect on 
the Ca2+ signal amplitude in untreated cells. A significantly shorter onset to peak in the OS profile 
was also observed in day 4 high glucose neurons compared to same day control cells (d4 CTRL = 
113.3 ± 29.3 s; d4 50mM = 42.2 ± 9.7 s, p < 0.05), although the sample size (n=2) is too small for 
concrete conclusions (Figure 4.5. E). These observations could point towards an effect increasing 
time in culture exercises on VGSC activation-induced Ca2+ signal strength in nociceptors that is 
attenuated by the presence of high glucose levels.  
Taken together, these results indicate no effect of high glucose conditions on the response rates 
of cultured DRG neurons to nociceptive agonists and the VGSC agonist VTD. However, VTD-
response amplitude changes with time in culture were noticed only in the untreated population of 
neurons, suggesting an effect high glucose conditions on signal amplitudes of nociceptors. 
Furthermore, time in culture might influence the response rates to some nociceptive agonists 
(AITC).  
Figure 4.5. Analysis of the effect time in culture and hyperglycaemic conditions have on VTD-response 
parameters. The amplitudes of neurons responding to VTD with the OS and RD profile were significantly smaller 
on the 5th day in culture in control neurons compared to day 1. A) SD amplitude. CTRL: D1 = 0.39 ± 0.05%, D2 =  
0.37 ± 0.03%, D4 =  0.29 ± 0.18%, D5 = 0.29 ± 0.05%; 50 mM: D1 = 0.44 ± 0.05%, D2 = 0.4 ± 0.04%, D4 = 0.34 ± 
0.08%, D5 = 0.27 ± 0.04%; B) SD onset time to peak. CTRL: D1 = 100.5 ± 9.12%, D2 = 72 ± 13.42%, D4 = 84.8 ± 1%, 
D5 = 93.28 ± 20.36%; 50 mM: D1 = 94.54 ± 18.42%, D2 = 88.08 ± 18.78%, D4 = 74.5 ± 13.1%, D5 = 67 ± 17.23%; 
C) SD AUC. CTRL: D1 = 152.8 ± 35.29%, D2 = 147.4 ± 17.93%, D4 = 86 ± 65.4%, D5 = 108.8 ± 14.73%; 50 mM, D1 = 
152.1 ± 19.79%, D2 = 149.2 ± 13.42%, D4 = 112.5 ± 23.55%, D5 = 92.38 ± 20.71%; D) OS amplitude. CTRL: D1 = 
0.47 ±  0.05, D2 = 0.43 ± 0.02, D4 = 0.34 ± 0.07, D5 = 0.28 ± 0.06; 50mM, D1 = 0.42 ± 0.05, D2 = 0.41 ± 0.01, D4 = 
0.35 ± 0.04%, D5 = 0.33 ± 0.04%; E) OS onset time to peak. CTRL: D1 = 74.78 ± 7.16%, D2 = 74.44 ± 6.28%, D4 = 
113.3 ± 29.25%, D5 = 76.58 ± 8.07%; 50 mM: D1 = 74.96 ± 10.92%. D2 = 79.4 ± 11.8%, D4 = 42.15 ± 9.65%, D5 = 
88.33 ± 5.42%; F) OS AUC. CTRL: D1 = 92 ± 15.94%, D2 = 98.64 ± 12.71%, D4 = 66.35 ± 33.85%, D5 = 63.88 ± 
17.07%; 50 mM: D1 = 81.88 ± 16.03%, D2 = 155 ± 48.06%, D4 = 79.85 ± 15.45%, D5 = 81.53 ± 19.05%; G) ID 
amplitude. CTRL: D1 = 0.44 ± 0.04%, D2 = 0.49 ± 0.07%, D4 = 0.28 ± 0.04%, D5 = 0.36 ± 0.04%; 50 mM, CTRL: D1 
= 0.45 ± 0.08%, D2 = 0.3 ± 0.03%, D4 = 0.34 ± 0.13%, D5 = 0.31 ± 0.03%; H) ID onset time to peak. CTRL: D1 = 
110.7 ± 14.01%, D2 = 98.62 ± 15.14%, D4 = 141.2 ± 55.85%, D5 = 92.4 ± 12.81%; 50 mM: D1 = 112.7 ± 10.32%, D2 
= 114.7 ± 24.73%, D4 = 116.1 ± 9.7%, D5 = 97.3 ± 14.24%; I) ID AUC. CTRL: D1 = 66.16 ± 11.99%, D2 = 81.58 ± 
16.68%, D4 = 13.45 ± 0.95%, D5 = 45.65 ± 10.64%; 50 mM: D1 = 73.46 ± 11.53%, D2 = 61.76 ± 5.87%, D4 = 38.65 
± 10.65%, D5 = 48.1 ± 4.92%; J) RD amplitude. CTRL: D1 = 0.39 ±  0.03, D2 = 0.32 ± 0.05, D4 = no RD neurons 
recorded, D5 = 0.2 ± 0.02; 50mM, D1 = 0.47 ± 0.08, D2 = 0.32 ± 0.02, D4 = 0.19 ± 0.15, D5 = 0.19. K) RD onset time 
to peak. CTRL: D1 = 148.7 ± 8.49%, D2 = 157 ± 27.32%, D4 = no RD neurons recorded, D5 =  158.7 ± 38.49%; 50 
mM: D1 = 147.4 ± 18.58%, D2 = 166.3 ± 13.52%, D4 = 180.8 ± 82.25%, D5 = 123.3 ± 0%; L) RD AUC. CTRL: D1 =  
47.72 ± 8.51%, D2 = 45.98 ± 12.31%, D4 = no RD neurons recorded, D5 = 20.83 ± 4.73%; 50 mM: D1 = 46.3 ± 
7.79%, D2 = 49.74 ± 8.64%, D4 = 22.55 ± 17.85%, D5 = 36.1 ± 0%.* = significance compared to D1 CTRL, *p<0.05. 
Where significance is not denoted, the difference is not significant. One-way ANOVA with multiple comparisons. 
Mean ± SEM. CTRL = control (open bars); 50mM = hyperglycaemic culture (filled bars); D# = day #. 
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4.5. DISCUSSION 
In this chapter, I outlined physiological experiments with DRG neurons under in vitro 
hyperglycaemic conditions. Cells cultured in a high glucose environment over 1, 2, 4 or 5 days 
showed no significant changes in their excitability, nociceptor sensitivity or VTD-induced Ca2+ 
response parameters compared to control. However,  a decrease in the response rate to AITC 
was noted in both treated and untreated neurons as time in culture increased. Furthermore, 
we observed decreasing amplitude of the Ca2+ signal in response to VTD with time in culture 
in control but not in hyperglycaemic neurons, indicating possible extended effect of high 
glucose conditions on VGSC excitability. 
In vitro hyperglycaemia has been routinely used to investigate changes in excitability of DRG, 
however predominantly only for short-term exposure. Previous research employing short-term 
in vitro hyperglycaemia has found that high glucose levels cause an increase in TRPV1 
expression and currents in DRG neurons 506,510  as well as changes in VGSCs, including 
increased TTX-R current density 424,502 and increased Nav1.7 expression 351. Based on them, 
we expected that by inducing hyperglycaemia in vitro for short (1-2 days) and long-term (4-5 
days) we will be able to detect changes in the VGSC and nociceptors excitability by Ca2+ 
imaging responses to different agonists. Here, in vitro induced hyperglycaemia did not 
produce the expected effects on DRG neurons excitability. However, there were differences 
in several values which were all associated with the time neurons had spent in culture. These 
findings can be summarised in the following: 
• Decrease in the response rate to AITC in both high glucose-treated and control 
populations (Figure 4.3) 
• Decrease in the VTD-induced Ca2+ response amplitudes of the OS and RD profiles in 
the control population, but not the high-glucose population of cells (Figure 4.5 D, J) 
 
These observations are informative of possible changes in neuronal electrophysiology after 
maintaining neurons in culture for up to 6 days, with or without altered extracellular glucose 
conditions. On the other hand, these findings might be a product of the specifics of the 
particular protocol for culture conditions used (discussed in more detail in Chapter 6). 
Neuronal dissociation and axotomy during the culturing process is injurious to neurons and 
has been well-documented to cause hyperexcitability in small DRG neurons via reducing AP 
threshold and increasing the AP duration and firing frequency 511–513. Furthermore, the 
electrophysiological properties of acutely dissociated neurons are different from neurons 
cultured for 1+ days, with VGSC (such as Nav1.8) and VGCC expression and current density 
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decreasing with time 102,511,514. The gradual decrease in neuronal excitability with time spent in 
culture could indicate neurons ‘settling’ and ‘healing’ after their excitability was increased 
immediately after dissociation due to its injurious nature 515. Here, the decreases in VTD-
response amplitude in nociceptors (OS) (Figure 4.5 D) were focused in the control population, 
whereas the high glucose group of neurons was not affected. The lack of significant decrease 
in nociceptive excitability in the hyperglycaemic population suggests that the high glucose 
environment could be preventing DRG neurons from bringing excitability down to normal 
physiological levels and thus “healing”. Therefore, hyperglycaemia might render restoring 
normal neuronal physiology post-injury slower and more difficult. In an in vivo setting, wound 
healing has been well-documented to be delayed in diabetic rodents 516–518 and in diabetes 
patients 519 and so it is a possibility that a similar delay may occur also to neurons healing from 
damage during diabetes. The slower decrease of neuronal hyperexcitability post-dissociation 
might translate into prolonged pain sensation post-injury caused by diabetes. Currently, no 
clinical studies have explored this idea specifically, however DN patients are known to present 
with exaggerated pain responses to harmless or mild painful stimuli (allodynia and 
hyperalgesia, respectively) 234,356,520, which could support the concept of persistent and/or 
exaggerated wound-induced pain in diabetes patients. In any event, these results can serve 
as a caution for the interpretation of Ca2+ imaging data using ion channel agonists when 
recording responses from primary DRG neuron cultures over time. 
Increased activity of nociceptive ion channels, such as TRPV1, TRPA1 and P2X3 has also been 
reported in DRG neurons during diabetes 58,343,521–523. Here, short- and long-term exposure to 
high glucose conditions did not induce any significant changes in the response rates to the 
nociceptive agonists to these three receptors. Our results directly contradict two studies from 
2018 reporting increased responses to CAP in DRG neurons cultured under high glucose 
conditions 506,510. Lam et al. 506 report a significantly increased response rate to CAP in adult 
mouse DRG neurons cultured in high glucose conditions (25mM) glucose for 7 days. A 
possible reason for this discrepancy might be their choice of control and hyperglycaemic 
glucose concentrations of 5mM and 25mM, respectively. These are not comparable to the 
concentrations used in the experiments from this chapter, or the ones used in the majority of 
in vitro hyperglycaemia studies on DRG neurons 318,423,500. An extracellular glucose 
concentration of 25mM can be considered within the optimal range for neuronal survival in 
culture, whereas a concentration of 5mM has been demonstrated to lead to neuronal apoptosis 
and cellular damage 423. Therefore, the higher rates of CAP responses observed by Lam et al. 
are likely to represent the normal neuronal function, whereas the lower values seen in the 
control population are likely to be indicative of a hypoglycemic effect on CAP responses. Yet, 
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in direct contrast to the observations by Lam et al., others, employing the same experimental 
glucose conditions and exposure time as them, have observed a decrease in CAP-induced 
Ca2+ influx in mature DRG neurons 524. The second study reporting increased CAP-evoked Ca2+ 
responses is by Bestall et al. (2018) who cultured DRG from naïve adult male rats in 50 mM 
glucose for 24 hours. Their study is the closest to ours in experimental design, yet we report 
conflicting results. A possible reason for the inconsistency could be due to a species difference 
(rat vs mouse) and/or the fact that relatively specific DRG were isolated (T1-L5), whereas, here, 
all DRG were isolated for experiments indiscriminately.  Finally, another in vitro study using 
50B11 immortalised rat DRG neuronal cell line reported an increase in responses to AITC 
when neurons were cultured in 66 mM glucose 525. Albeit overlapping with observations in vivo 
343,344, these in vitro results directly contradict ours, perhaps because of the different in vitro 
culture models utilised. An immortalised DRG neuronal cell line would not possess the 
complete arsenal of ion channel, receptors, exchangers and proteins contributing to shaping 
the net response to an agonist and therefore might not necessarily generate a complete 
picture of the final response. Therefore, the cell line may not be representative of the same 
populations of neurons with decreasing sensitivity to AITC.  It is, thus, yet to be confirmed 
whether prolonged exposure to hyperglycaemic conditions in vitro is a suitable method for 
determining functional changes in nociceptive ion channels. 
Neither short- nor long-term exposure to a hyperglycaemic extracellular environment affected 
the VGSC excitability of DRG neurons in my experiments. A literature search found very little 
on the question of prolonged exposure of DRG neurons to high levels of glucose in vitro (40-
60 mM)) and the effect on VGSCs. A number of prior studies have noted an increase in the 
VGSC activity through increased levels of Nav1.7 expression 351 or increased density of TTX-
R currents 349,502 of DRG neurons cultured in up to 60mM glucose for 18-24h. This corresponds 
to day 1 in my experiments, where no significant increase in VTD(+) cells and thus, in contrast 
to previous studies, no increase in overall VGSC activity was observed. There are a couple of 
possible explanations why these data differ. First, the studies reporting increase in VGSC 
activity derived their neurons from rats as opposed to the mouse neurons used here, which 
might account for potential interspecies differences in VGSC excitability during 
hyperglycaemia. However, to the best of our knowledge, there are currently no studies in 
literature comparing VGSC expression levels and activity between mice and rats and the VTD-
Ca2+ imaging assay has yet to be validated in another rodent species. Second, only one study 
used DRG neurons from a mature rodent 502 like ours, however, only small (20-25 µm) L4-L5 
DRG were selected for experiments. This, combined with the species difference (rat vs mouse 
here) and the very low control glucose conditions (5.5 mM) could contribute to the differences 
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in results reported by them and here. All other studies used embryonic DRG neuron cultures 
as opposed to the adult DRG neurons used here. Embryonic DRG neurons require 
supplementation with NGF to support neuronal survival in culture. NGF is known to alter 
electrophysiological properties of cultured DRG neurons 526–530. It has also been widely 
implicated as a key driver of hyperalgesia during DN, with its expression levels significantly 
increased in DRG 456,531. NGF is also demonstrated to sensitise TRPV1 and increase DRG 
responses to capsaicin 532,533. Although the mechanisms of elevated NGF expression during 
diabetes are still unclear, it has been postulated that a hyperglycaemic environment is a trigger 
for increased NGF expression as a protective mechanism of tissues 456. Therefore, the 
combination of supplemented NGF and high glucose to embryonic neurons in culture might 
produce a stronger hyperexcitability phenotype represented by increased VGSC activity 
compared to mature DRG neurons cultured in high glucose in the absence of NGF. Due to its 
role in DN hyperalgesia, addition of NGF to a hyperglycaemic culture could in fact be a sensible 
approach to recreating a physiological DN environment in a DRG culture. This and additional 
culture modifications to replicate DN more closely are discussed in more detail in Chapter 6 
along with further limitations of the current experiment and future directions. 
Taken together, the results from the in vitro-induced hyperglycaemia experiments are 
somewhat informative of events in the DRG culture when maintained for a prolonged time. 
Furthermore, our observation point to subtle changes hyperglycaemia might cause in VGSC 
excitability over extended exposure by maintaining neuronal excitability elevated after 
dissociation. Nevertheless, these experiments did not produce the expected, clear-cut overall 
increase in neuronal excitability after short- and long-term exposure to high glucose, seen in 
similar studies. The most likely reason for this outcome is the limited DN environment that we 
can be recreated in a dish which might not suffice to produce a phenotype strong enough to 
be detected by Ca2+ imaging with VTD and nociceptive agonists in our protocol. The 
multifactorial complexity of DN, especially T2DN, would require an individual extensive study 
of its own to extrapolate its components and optimise an in vitro T2DN model. Due to project 
time restrictions, it was decided to circumvent this lengthy process and opt for proceeding 
with investigating changes in excitability of DRG neurons derived from an in vivo model of 
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CHAPTER 5: ASSESSING THE EXCITABILITY CHANGES 
IN DRG NEURONS FROM DIABETIC DB/DB MICE  
5.1. INTRODUCTION 
The last chapter described experiments with DRG neurons under in vitro-induced high glucose 
conditions. Using an in vitro hyperglycaemia model to detect DRG excitability changes serves 
as a more ethical alternative to deriving neurons from diabetic animals. In addition, it reduces 
potential variability between controls and treated cells as both are isolated from the same 
animal as opposed to deriving diabetic cells from a diabetic animal and control cells from a 
healthy one. It also allows for the precise control of external glucose concentration, which 
varies in mouse models of diabetes and DN 419,534. However, inducing hyperglycaemia in vitro 
represents only one, albeit main key drivers of DN pathogenesis– the high glucose levels. 
Furthermore, it is closer to reflecting T1DN rather than T2DN, as T2DN is driven by additional 
mechanisms such as aspects of the metabolic syndrome (insulin resistance, dyslipidaemia), 
together with hyperglycaemia. The many subcomponents and high complexity of T2DN 
pathogenesis renders it extremely difficult to model in vitro with high accuracy 419. Therefore, 
to ensure all components of T2DN were in place, the second hyperglycaemia model I used 
was the T2D C57BL/Ksdb/db mouse model. 
The C57BL/Ksdb/db (just db/db hereon) mouse is an excellent T2D model and, based on the 
established DN model requirements 448, is recognised as one of the most robust existing 
models of DN 453. Its diabetic phenotype was first discovered in 1966 by Hummel et al. 535. It 
wasn’t until 1995, however, that its genetic mutation was identified 536,537. The db/db mouse is 
a homozygous mutant knockout for the leptin receptor. Leptin is a hormone secreted by 
adipose cells and enterocytes in the small intestine after food intake. It controls appetite by 
binding to its receptor in the hypothalamus and inhibiting hunger and feeding behaviour 
(hence often referred to as the ‘satiety hormone’)446,536. The db/db mouse carries a deletion 
mutation in the gene encoding the leptin receptor, resulting in leptin signalling deficiency 536,538. 
Eliminating leptin signalling leads to the mice exhibiting uncontrolled overeating behaviour 
(hyperphagia) simultaneous with decreased activity and thus energy expenditure. Blood 
insulin levels begin elevating at 10-14 days of age (DoA) followed by elevation in fasting blood 
glucose levels and dyslipidaemia (Figure 5.1). At 3-4 weeks of age (WoA), obesity and insulin 
resistance have developed and the phenotype culminates into T2D for the rest of the mouse’s 
lifespan (Figure 5.2) 539.  The severity of the genetically induced disease causes continuous 
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secreting pancreatic β-cells 540. This, in combination with the secondary derangements 
brought about by obesity, it leads to death by 10 months of age 541.  
Around 8 WoA, db/db mice develop DN 431. Robertson & Sima were the first to describe the 
electrophysiological and morphometric changes in the nerves of db/db mice and were the first 
to provide a detailed characterisation of the DN phenotype in this model 428,542. Their research 
revealed the key observation that DN progression in the db/db mouse mimics closely the 
phases in human patients. 
The early phase of DN in db/db mice develops at 8–12 WoA and is called ‘metabolic’ (MET). It 
was characterised by severe motor (MNCV) and milder sensory (SNCV) nerve conduction 
velocity impairments as well as mild axonal atrophy in both myelinated and unmyelinated fibres 
(Sima and Robertson, 1978; Norido et al., 1984). The MET phase was later further defined 
behaviourally with the presence of mechanical allodynia, hyperalgesia 456,461,507,543–546 and heat 
hypersensitivity 547,548, albeit the literature is highly controversial (see figure 5.1, Metabolic 
phase). In addition, a MET phase characteristic is that functional and structural deficiencies 
are generally reversible with metabolic interventions (usually, through glycaemic control with 
insulin administration) 429.  
Figure 5.1. An excerpt from a paper by Guest and Rahmoune (2018) characterising the diabetic phenotype of 
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Figure 5.2. A comprehensive summary of the  available molecular, physiological, behavioural and 
transciptomic research on the db/db mouse model with observations categorised according to diabetic 
neuropathy phases observed by Sima and Robertson (1978). MA, mechanical allodynia; IENF, intraepidermal 
nerve fiber; NCV, nerve conduction velocity; MNCV, motor nerve conduction velocity; SNCV, sensory nerve 




↓NCV (incl. MNCV and SNCV) 459,549,640 
Mild axonal atrophy 549 
↓IENF density 459 
Damaged myelin sheath and reduced myelin 
thickness 459 
MA  (↑ overall sensitivity to mechanical stimuli) 
60,461,507,544–546,583 
↓mechanical sensitivity459,460 
≠ thermal sensitivity 460,546 
↑thermal sensitivity 547,569 
↓thermal sensitivity 459 
↑NGF, ↑CGRP, ↑SP  expression 583 
↑ expression of pro-inflammatory 
molecules 544,552,559 
↑ expression of Nav1.6 in large-diameter 
neurons 60 
↑ levels of mTRPA1 507 
 
NEU Phenotype 
↓NCV (incl. MNCV and SNCV) 430,453,551,553,555,665 
Severe axonal atrophy and dystrophy/  
loss of large fibres 550,553,640,666 
Severe ↓IENF density 453,551,553 
Damaged myelin sheath and reduced myelin 
thickness 667 
MA  (↑ overall sensitivity to mechanical 
stimuli) 60,556 
↓mechanical sensitivity 553,555,583 
↑thermal sensitivity 556 
↓thermal sensitivity 430,453,551,553,554 
↑ expression of pro-inflammatory molecules 
430,551,558,559  
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The late, ‘neuronal’ phase (NEU) in db/db mice develops from ~20 WoA and continues until 
the end of the mouse’s life. It is characterised in the db/db mouse with an exacerbated MET 
phase phenotype of axonopathy and impaired MNCV and SNCV alongside with marked 
decrease of IENF density as well as loss of myelin sheathing 428,429,453,549–553. Most studies agree 
on the presence of structural nerve damage but still report contradicting behavioural findings 
(see figure 5.1, Neuronal phase). For example, 20+ week old db/db mice have been reported 
to present with increased mechanical and thermal sensory thresholds and hypoalgesia by 
some 337,430,453,458,552–555, however others have observed increased sensitivity to mechanical 
stimuli and mechanical allodynia 544,556.  
Additionally, several microarray and RNA-Seq analyses have shown an upregulation of 
immune and inflammatory molecules and pathways 430,552,557–559 in the peripheral nerves of 
db/db mice to begin as early as 8 WoA and continue throughout the rest of the DN progression 
contributing towards peripheral nerve fibre degeneration, as well as pain behaviour in the early 
stages of DN 456. Finally, studies investigating the function, molecular mechanisms and 
expression levels of ion channels during DN in this mouse model are scarce. One study 
reported sustained increased expression levels of the large diameter neurons-associated 
VGSC Nav1.6 in DRG of db/db mice from 8 WoA up until 20 WoA (end of experimental period) 
which was correlated to mechanical allodynia in these mice 60. More recently, Wang et al. 
(2018) reported no increase in total protein expression of either TRPA1 or TRPV1. However, 
membrane-associated TRPA1, but not TRPV1, expression was increased and activity 
upregulated in db/db mice (6-7 WoA), further linked to impaired AMPK signalling and 
mechanical allodynia 507. 
The abundance of behavioural, morphometric, and transcriptomic studies as well as the limited 
molecular research, has highlighted some key phenomena likely to underlie observed T2DN-
associated behaviours in the db/db mouse, however there is no conclusive evidence on the 
pathophysiology of the pain during the progression of DN in T2D. Furthermore, the T1D STZ 
rodent is by far the most widely studied DN model, generating an imbalance in research 
between animal studies and clinical trials, which are largely targeting the T2D population of 
patients 241,418.  This demands more intensive research into the mechanisms driving T2DN. 
Finally, to the best of our knowledge, there are no physiological studies investigating the 
functional changes in db/db mouse DRG neurons during the MET and NEU phases of DN. 
Based on the above rationale, and on the established robustness of its DN phenotype, the T2D 
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5.2. AIMS 
To assess the excitability changes and changes in size distribution in specific subpopulations 
of DRG neurons from C57BKSdb/db (db/db) mice, isolated at two different time points: 1) early 
(metabolic, MET) and 2) late (neuronal, NEU) stages of diabetic neuropathy by analysing the 
Ca2+ signals generated in response to the VGSC agonist VTD and nociceptive agonists ATP, 
AITC and CAP. 
To compare excitability changes between the MET and NEU phases of DN in this mouse model 
in order to track the progression of diabetic neuropathy and its effect on DRG physiology. 
5.3. METHODS 
5.3.1. DRG neuron culture from db/db mice 
DRG neurons were collected from db/db (BKS.Cg-+Leprdb/+Leprdb/OlaHsd) mice at 8 -12 
weeks of age (WoA) (metabolic phase) and 22 - 28 WoA (neuronal phase) as well as from lean, 
DN phase-matched control mice (BKS.Cg-+Leprdb/-Leprdb/OlaHsd). Neurons were cultured 
in standard DMEM medium and left to incubate for at least 24 hours before experiments. 
5.3.2. Calcium imaging 
DRG neurons were loaded with Fura-2 and responses recorded to nociceptive agonists: 
capsaicin (CAP, 200 nM), allyl isothiocyanate (AITC, 100 µM) and α,β-methylene ATP (ATP, 1 
µM) as well as VGSC potentiator veratridine (VTD, 30 µM). Standard calcium imaging protocol 
was followed as outlined in Chapter 2: Materials & Methods section 2.2.2., page 68.  
5.4. RESULTS 
5.4.1. The number of DRG neurons derived from db/db mice for each 
phase and condition 
For the following experiments, 24 mice in total were sacrificed (6 MET CTRL, 6 NEU CTRL, 6 
MET db/db and 6 NEU db/db). The total number of neurons imaged for each group is 
presented in table 5.1. The number of neurons used for these experiments from N5 and N6 in 
each phase and condition is generally smaller due to a diversion of some of the cells from 
these cultures to another set of experiments (not described in this thesis). Overall, the total 
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5.4.2. The overall cell size distribution is shifted towards smaller cells in 
DRG from db/db mice 
The soma diameters of the DRG neurons from db/db and phase-matched lean control mice 
used for the experiments presented here were measured. Neurons from each condition group 
(db/db or lean) and phase (MET or NEU) were pooled for soma diameter analysis. Frequency 
distribution analysis of DRG sizes for each DN phase was performed and plotted as a histogram 
(Figure 5.3). In the MET phase, the median cell diameter was slightly smaller in db/db than in 
lean mice (lean = 21 µm, 2473 cells; db/db = 20.6 µm, 2716 cells) (Figure 5.3A). In the NEU 
phase, the mean cell diameter of DRG from db/db mice was still smaller than lean (lean = 21.4 
µm, 2562 cells; db/db = 19.8 µm, 2562 cells), however here, the distribution of the diabetic 
DRG is shifted to the left (Figure 5.3B).  
Table 5.1 Number of neurons for each mouse (N) of each phase (MET or NEU) for each condition (CTRL 
or db/db). Each cell with cell count represents one mouse’s total cell yield. Twenty-four mice were used in 
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Neurons were classified according to their soma diameter into three categories: small- (<20 
um), medium- (20-30 um) and large (>30 um), consistent with diameter range groupings 
commonly used in other studies 560,561 (Figure 5.4). During the MET phase, the percentage of 
large cells in db/db mice was significantly lower than that of lean cells by ~35%  (lean = 13.1 
± 1.5%, db/db = 8.5 ± 0.7%; p<0.05, n = 6 each) (Figure 5.4 A,B). The vast majority of neurons 
in both lean and db/db mice were small and medium-sized, however, there was no significant 
difference in the percentage of small and medium-sized cells between lean and diabetic mice 
in the MET phase. In the NEU phase,  52% of db/db DRG neurons fell in the small-sized group, 
compared to 37.5% of lean neurons (n = 6 mice from each group, p < 0.05) (Figure 5.4 C,D). 
The increased number of small-diameter cells in diabetic mice was matched by the 
significantly fewer medium-sized cells compared to lean (38% vs 49%, respectively, n = 6 
each, p < 0.05). There was no significant difference observed in the large-sized DRG group. 
Collectively, the results from both DN phases point to a shift in the size distribution of diabetic 
cells towards smaller-diameter and away from medium and large-diameter neurons that starts 
during early and progresses through late DN stages.  
Figure 5.3. Frequency distribution of neuronal diameter sizes from control (lean) and diabetic (db/db) mice 
for each phase of diabetic neuropathy: early, metabolic and late, neuronal. A) Metabolic, lean = 21 µm, 2473 
cells; db/db = 20.6 µm, 2716 cells; B) Neuronal, lean = 21.4 µm, 2562 cells; db/db = 19.8 µm, 2562 cells.  Dotted 
vertical lines represent median for their respective population. Plotted as number of cells observed in each 2 
µm bin of diameter. Lean = grey bars, db/db = light blue bars; darker blue bars represent lean and db/db overlap.  
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Figure 5.4. Distribution of neuronal soma diameter in three size groups: small (< 20 µm), medium (20 - 
30 µm) and large (> 30 µm).  A) Percentage of small, medium and large neurons from lean and db/db 
mice derived during the metabolic phase. Lean: small = 41.2 ± 2.9%, medium = 45.7 ± 1.8%, large = 13.1 
± 1.5%; Db/db: small = 43.6 ± 2.8, medium = 48 ± 2.8%, large = 8.5 ± 0.7%; B) Pie chart representation of 
the mean percentage of small, medium and large neurons  from lean and db/db mice of the metabolic 
phase; C) Percentage of small, medium and large neurons from lean and db/db mice derived during the 
neuronal phase. Lean: small = 37.5 ± 3.7%, medium = 48.9 ± 2.5%, large = 13.6 ± 1.4%; Db/db: small = 52 
± 4.8, medium = 38.1 ± 3.3%, large = 9.9 ± 1.6%; D) Pie chart representation of the mean percentage of 
small, medium and large neurons  from lean and db/db mice of the neuronal phase. *p<0.05; Two-tailed 
paired Student’s t-test, shown mean ± SEM. 
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5.4.3. Persistent increase in the sensitivity to capsaicin in small DRG 
neurons from db/db mice 
We wanted to assess DRG neurons from db/db mice for excitability changes in the context of 
nociception. To this end, we applied ATP, AITC and CAP. Each cell can respond to only one 
of the agonists, to a combination of any two (ATP/CAP+, ATP/AITC+ or AITC/CAP+), to all 
three together (all(+)) or none of them (agonist (-), or non-nociceptors). To identify if any of 
these specific populations is affected, we dissected the responses to the three nociceptive 
agonists into all 8 possible response combinations. Diabetes caused an increase of 1.8-fold in 
the number of neurons responding to all three agonists simultaneously (all(+)) (from 3.3 ± 0.7% 
to 6.1 ± 0.9%, p < 0.05) in the MET phase (Figure 5.5A). The increase in this subpopulation, 
together with the non-significant increases in the rest of the CAP(+) subpopulations (Figure 
5.5A), lead to a 1.2-fold increase in the percentage of total CAP(+) DRG neurons in db/db mice 
(Figure 5.5C) (from 28.4 ± 1.8% to 34.2 ± 1.7%, p < 0.05). The total percentages of agonist(-), 
ATP(+) and AITC(+) db/db cells remained comparable to control levels (Figure 5.5C). The 
results from this phase indicate an early on increase in the sensitivity of DRG neurons to 
capsaicin, mainly occurring in one subpopulation of neurons (all(+)). 
Likewise, in the NEU phase, the percentage of all(+) cells remained significantly higher than 
lean controls (1.9-fold, from 1.4 ± 0.2% to 2.7 ± 0.5%, p < 0.05) (Figure 5.5B). Here, the 
percentage of neurons responding to CAP-only as well as ATP and CAP together (ATP/CAP) 
was significantly higher in db/db mice by 1.5-fold (from 10.2 ± 0.9%  to 15.3 ± 1.1%, p < 0.005) 
and 4-fold (from 0.4 ± 0.1% to 1.6% ± 0.4%, p < 0.05), respectively (Figure 5.5B). These rises 
were at the expense of cells responsive to AITC-only, the percentage of which decreased by 
1.3-fold (from 35.7 ± 1.1% to 24.8 ± 1.5% p < 0.01). The changes in response rates within each 
of these individual nociceptive subpopulations brought about a significant 1.3-fold increase in 
the total response rates to CAP (from 31.3 ± 1.2% to 40.7 ± 2.5% p < 0.001) and 1.1-fold 
decrease in total percentage of AITC(+) DRG neurons (from 57.1 ± 0.6%% to 51.3 ± 2.1%, p 
< 0.05) (Figure 5.5D). These findings point to an ever persisting and increasing sensitivity of 
DRG neurons to CAP in the NEU phase, which seems to have spread to affect more 
subpopulations of neurons, coupled with a decreased sensitivity to AITC.  
To further characterise the additional CAP(+) neurons in each phase, the size distribution of 
CAP(+) DRG neurons from db/db and lean mice was analysed. In the MET phase, the medians 
of lean and db/db neuron sizes were 18.8 µm (n = 661 cells) and 19.6 µm (n = 928 cells), 
respectively (Figure 5.6 A). The additional CAP(+) neurons in the db/db mice fell in the 14-26 
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Figure 5.5. The percentage of lean and db/db-derived neurons responsive to nociceptive agonists in each phase of diabetic 
neuropathy. A, B) Percentage of neurons responsive to each nociceptive agonist individually (ATP, AITC, CAP), in combination 
with another (ATP/AITC, ATP/CAP, AITC/CAP), all together (all(+)) or none (agonist(-)) during the metabolic and neuronal 
phases. A) Metabolic, lean: ATP = 1.5 ± 0.4%, AITC = 36.1 ± 1.4%, CAP = 7.9 ± 1%, ATP/AITC = 5.3 ± 1.3%, ATP/CAP = 1.7 ± 1%, 
AITC/CAP = 14.5 ± 1.6%, all(+) = 3.3 ± 0.7%, agonist(-) = 29.8 ± 1.9%; Metabolic, db/db: ATP =1.2 ± 0.4%, AITC =  30.3 ± 2.9%, CAP 
= 10.5 ± 0.8%, ATP/AITC = 5.4 ± 0.6%, ATP/CAP = 1.3 ± 0.3%, AITC/CAP = 16.4 ± 0.9%, all(+) = 6.1 ± 0.9%, agonist(-) = 29 ± 2%. B) 
Neuronal, lean: ATP = 0.9 ± 0.2%, AITC = 35.7 ± 1.1%, CAP = 10.2 ± 0.9%, ATP/AITC = 3 ± 0.5%, ATP/CAP = 0.4 ± 0.1%, AITC/CAP = 
18.9 ± 1.3%, all(+) = 1.4 ± 0.2%, agonist(-) = 29.5 ± 1.3%; Neuronal, db/db: ATP = 1.1 ± 0.2%, AITC =  24.8 ± 1.5%, CAP = 15.3 ± 
1.1%, ATP/AITC = 2.8 ± 0.6 %, ATP/CAP = 1.6 ± 0.3%, AITC/CAP = 21 ± 2.3%, all(+) = 2.7 ± 0.5%, agonist(-) = 30.8 ± 1.8%. Two-tailed 
paired Student’s t-test. C,  D) Total percentage of neurons which responded to each of the three agonists irrespective of the 
response’s nature (e.g., CAP here is the total responses when CAP, ATP/CAP, AITC/CAP and all(+) from Figure 5.5A or C are 
added together). A) Metabolic, lean: Agonist(-) = 30.7 ± 2.1%, ATP = 13.6 ± 3.7%, AITC = 57.3 ± 2.7%, CAP = 28.4 ± 1.7%; Metabolic, 
db/db: Agonist(-) = 30.1 ± 1.5, ATP = 15.4 ± 1.3%, AITC = 56 ± 2.4%, CAP = 34.2 ± 1.7%; D) Neuronal, lean: Agonist(-) = 30.8 ± 1.2%, 
ATP = 6 ± 0.8%, AITC = 57.1 ± 0.6%, CAP = 31.3 ± 1.2%; Neuronal, db/db: Agonist(-) = 31.2 ± 1.8%, ATP = 8.4 ± 1%, AITC = 51.3 ± 
2.1%, CAP = 40.7 ± 2.5%. Multiple comparisons following a One-way ANOVA. *p<0.05, **p<0.005, ***p<0.001. Shown mean ± 
SEM; E) Intracellular calcium signal trace following stimulation with the respective agonist, averaged from all responsive neurons 
(20) of one experiment. Black – average trace from one experiment; grey – showing the SEM for each second of the recorded trace; 
black arrows indicate the approximate time point of respective drug application. 
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Sizes were also grouped into small medium and large. In the MET phase, there was a 
significant increase in the number of CAP(+) db/db neurons of medium-diameter (1.4-fold 
increase, control med 9.8 ± 1.2%; db/db med 13.9 ± 1%, p < 0.05) (Figure 5.6. C). There was 
no significant difference between db/db and control neurons of small- and large-diameter in 
this phase. This suggests that the increased sensitivity to CAP in db/db mice during the MET 
phase is contributed to by medium-diameter neurons but not the small or large cells. Of note, 
the increase in all(+) neurons in the db/db mice during the MET phase (Figure 5.5 A) was also 
contributed for by a population of medium-diameter neurons, where a significant 3.5-fold 
increase in the percentage of medium-sized all(+) neurons was noted (from 0.9 ± 0.3% to 3.1 
Figure 5.6. Size distribution of CAP(+) neurons from control (lean) and diabetic (db/db) mice for each 
phase of diabetic neuropathy: early, metabolic and late, neuronal. A) Metabolic: lean = 18.8µm, 661 cells; 
db/db = 19.6 µm, 2716 cells; B) Neuronal:  lean = 19.9 µm, 789 cells; db/db = 18.8 µm, 1053  cells.  Dotted 
vertical lines represent median for their respective population. Plotted as number of cells observed in each 
2 µm bin of diameter. Lean = grey bars, db/db = light blue bars; darker blue bars represent lean and db/db 
overlap. C) Percentage of small, medium and large CAP(+) neurons from lean and db/db mice derived during 
the metabolic phase. Lean: small =  15.7 ± 1.2%, medium = 9.8 ± 1.2%, large = 0.6 ± 0.1%; Db/db: small = 
17.3 ± 1.5%, medium = 13.9 ± 1%, large = 0.5 ± 0.1%; D) Percentage of small, medium and large CAP(+) 
neurons from lean and db/db mice derived during the neuronal phase. Lean: small =  14.3 ± 1.1%, medium 
= 14.2 ± 2.6%, large = 0.8 ± 1.2%; Db/db: small = 22.9 ± 2.6%, medium = 13.9 ± 1.2%, large = 0.8 ± 0.2%; 
*p<0.05. ***p<0.001; Two-tailed paired Student’s t-test, shown mean ± SEM. 
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±  0.4%, p < 0.001) (Figure 5.7 A), further confirming the all(+) population of neurons as the 
main contributor to the total increase in CAP sensitivity in MET phase db/db mice .   
In the NEU phase, the medians of lean and db/db neuron sizes were 19.9 um (n = 1053 cells)  
and 18.8 µm (n = 789 cells), respectively, with the additional CAP(+) cells from db/db mice 
falling in the 8-20 µm diameter range (Figure 5.6 B). This translated to a significant 1.6-fold 
increase in the number of CAP(+) small-sized db/db neurons in the NEU phase (from 14.3 ± 
1.1% to 22.9 ± 2.6%, p < 0.001) (Figure 5.6 D).  
The drop in AITC(+) neurons in the NEU phase (Figure 5.5 B,D) could be correlated to a 
significant 1.8-fold decrease in the percentage of medium-diameter AITC(+) db/db neurons in 
the NEU phase (from 20.1 ± 1.9% to 11.5 ± 2.2%, p < 0.001), suggesting that the neurons 
losing their AITC sensitivity are of medium-diameter (Figure 5.7 B). 
Together, the changes in the size distribution of CAP(+) neurons during DN progression are 
indicating that the increasing sensitivity to CAP in db/db mice is dynamic, migrating from 
medium to smaller-diameter DRG neurons as neuropathy advances. The common medium-
diameter size between the additional all(+) and CAP(+) db/db neurons of the MET phase 
strengthen the role of the all(+) subpopulation of neurons in the overall increased CAP 
sensitivity.  
Figure 5.7. Distribution of neurons responsive to specific all nociceptive agonists in the MET phase 
or AITC-only in the NEU phase in three size groups: small (< 20 µm), medium (20 - 30 µm) and large 
(> 30 µm).  A) Percentage of small, medium and large neurons responsive to ATP, AITC and CAP 
simultaneously (all(+)) from lean and db/db mice derived during the metabolic phase. Lean: small = 
2.1 ± 1.4%, medium = 0.9 ± 0.3%, large = 0%; Db/db: small = 2.6 ± 0.5%, medium = 3.1 ± 0.4%, large 
= 0.03 ± 0.03%; B) Percentage of small, medium and large neurons responsive only to AITC (AITC(+)) 
from lean and db/db mice derived during the neuronal phase. Lean: small = 11.5 ± 1.3%, medium = 
20.9 ± 1.9%, large = 1.3 ± 0.5%; Db/db: small = 10.6 ± 1.4%, medium = 11.5 ± 2.2%, large = 0.9 ± 0.3%;. 
***p<0.001; Two-tailed paired Student’s t-test, shown mean ± SEM. 
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5.4.4. VGSC activity in small DRG nociceptors from db/db mice is 
increased during the course of diabetic neuropathy 
Diabetic conditions have been shown to lead to an upregulation of VGSCs expression and 
activity, especially during early phases of neuropathy 58.  We hypothesised that the VGSC 
excitability will have also changed in the db/db mice DRG neurons. We used the VTD-Ca2+ 
imaging assay to assess the VGSC excitability in nociceptors (OS VTD-response profile) and 
non-nociceptors (SD VTD-response profile). In the MET phase, responses to VTD showed an 
increase in excitability (Figure 5.8 A): the number VTD-irresponsive (VTD(-)) neurons 
decreased by 1.14-fold (from 36.6 ± 0.7% to 31.5 ± 2.1%, p < 0.005). This decrease was 
matched by the increase in the percentage of VTD(+) cells of the OS profile by 1.16-fold (from 
34.2 ± 1.1% to 39.6 ± 1.1%, p < 0.005). The response rates of the SD, ID and RD VTD-response 
profiles were not significantly different from lean mice (Figure 5.8 A). 
 
 
Figure 5.8. Responses to VTD by DRG neurons derived from lean or db/db mice during the metabolic or neuronal phase 
of diabetic neuropathy. A) Metabolic phase, lean: VTD(-) = 36.6 ± 0.7%, SD = 21 ± 1.1%, OS = 34.2 ± 1.1%, ID = 4.6 ± 0.3%, 
RD = 3.6 ± 0.4%; db/db, VTD(-) = 31.5 ± 2.1%, SD = 20.5 ± 1.4%, OS = 39.6 ± 1.1%, ID = 4.4 ± 0.5%, RD = 3.9 ± 0.2%; B) 
Neuronal phase, lean: VTD(-) =  39.9 ± 2.2%, SD = 22.4 ± 1.7%, OS = 30.8 ± 1.9%, ID = 4.1 ± 0.4%, RD = 2.6 ± 0.6%; db/db, 
VTD(-) = 36 ± 1.3%, SD = 21 ± 1.2%, OS = 34.3 ± 0.7%, ID = 5 ± 0.5%, RD = 3.4 ± 0.4%. One-way ANOVA with multiple 
comparisons. **p<0.005. Mean ± SEM. Open bars = lean (control); filled bars = db/db. C) Intracellular calcium signal trace 
following stimulation with VTD shaping the responses SD (left) and OS (right), averaged from all SD- or OS-profiled neurons 
(12 and 19, respectively) from one experiment.; Black – average trace from one experiment; grey – showing the SEM for 
each second of the recorded trace; black arrows indicate the approximate time point of respective drug application. 
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In contrast, in the NEU phase, there was no significant difference in the total response rate to 
VTD nor within any of the VTD-response profiles, however, albeit non-significant, a trend of 
increased OS responses in db/db neurons persisted (Figure 5.8 B). Of note, there were no 
significant differences in the amplitude, time to peak or AUC of calcium responses between 
db/db mice and controls (data not shown). 
Analysis of the cell size distribution within the MET phase OS population (Figure 5.9 A,C) 
showed that there was no change in size distribution between lean and db/db neurons, but 
there were more OS db/db neurons in the 14-28 µm (small to medium-diameter) size range. 
This suggests that the additional OS neurons of the MET phase in db/db mice (Figure 5.8 A) 
are not focused in one neuronal size specifically but are likely to be mostly medium in diameter. 
Figure 5.9. Size distribution of neurons with the OS VTD-response profile from control (lean) and 
diabetic (db/db) mice for each phase of diabetic neuropathy: early, metabolic (MET) and late, 
neuronal (NEU). A) Metabolic: lean = 20µm, 825 cells; db/db = 20.1 µm, 1048 cells; B) Neuronal:  lean 
= 20.1 µm, 793 cells; db/db = 19.3 µm, 894  cells.  Dotted vertical lines represent median for their 
respective population. Plotted as number of cells observed in each 2 µm bin of diameter. Lean = grey 
bars, db/db = light red bars; darker red bars represent lean and db/db overlap. C) Percentage of small, 
medium and large OS neurons from lean and db/db mice derived during the metabolic phase. Lean: 
small =  15.8 ± 1.8%, medium = 13.9 ± 0.8%, large = 2.1 ± 0.3%; Db/db: small = 16.9 ± 2%, medium = 
18.1 ± 1.3%, large = 1 ± 0.3%; D) Percentage of small, medium and large OS neurons from lean and 
db/db mice derived during the neuronal phase. Lean: small =  13.5 ± 1.7%, medium = 13.6 ± 1.2%, large 
= 1.7 ± 0.3%; Db/db: small = 18.3 ± 1.7%, medium = 12.5 ± 1.6%, large = 1.2 ± 0.3%; *p<0.05; Two-
tailed paired Student’s t-test, shown mean ± SEM. 
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In the NEU phase, we saw an increase in the percentage of OS cells, however It was not 
significant (Figure 5.8 B). Therefore, we looked into the changes in the distribution and 
percentage of OS cells within the different sizes of db/db neurons to see whether the OS 
increase was focused within a particular neuronal subpopulation (Figure 5.9 B,D). There was 
a leftward shift in the distribution of db/db OS neurons, with more OS profiles in the 8-20 µm 
(small-diameter) diameter range (Figure 5.9 B). The additional OS neurons of the NEU phase 
in db/db mice were of small diameter – the percentage of small neurons in db/db mice was 
significantly higher than that of lean mice by 1.4-fold (lean = 13.5 ± 1.5%, db/db = 18.3 ± 1.7%, 
p < 0.05), while there was no significant difference between lean and db/db neurons in the 
small and large diameter groups (Figure 5.9 D). These insights suggest that the increase in 
OS neurons begins in the MET phase in small and, mostly, medium-diameter neurons and 
persists during the NEU phase, focusing into small-diameter neurons of db/db mice.  
We wanted to find out whether the additional OS cells were also CAP(+). To do this, we 
performed isolated analysis of the OS population for the response rates to the ATP, AITC and 
CAP in the 8 possible combinations (Figure 5.10). In the MET phase, there was a significant 
increase of 2.2-fold in the percentage of all(+) OS neurons in db/db compared to lean mice 
(from 6.2 ± 1.3% to 13.4 ± 2.3%, p < 0.05) (Figure 5.10 A). This showed that the additional OS 
cells of the db/db mice in the MET phase were of the ‘all(+)’ population, identified to be also 
Figure 5.10. The percentage of OS neurons from lean and db/db responsive to nociceptive agonists – 
alone or in combinations, in each phase of diabetic neuropathy. A) Responses of OS neurons to agonists 
during the metabolic phase, Lean: ATP = 2.4 ± 0.8%, AITC = 40.2 ± 3.2%, CAP = 4.7 ± 0.7%, ATP/AITC = 12.2 
± 2.9%, ATP/CAP = 3 ± 1%, AITC/CAP = 11.9 ± 1.3%, all(+) = 6.2 ± 1.3%, agonist(-) = 19.4 ± 2.4%; db/db: ATP 
= 2.2 ± 0.7%, AITC = 32.3 ± 2.9%, CAP = 5.7 ± 0.5%, ATP/AITC = 12.1 ± 1.8%, ATP/CAP = 2.5 ± 0.7, AITC/CAP 
=  11.6 ± 1.3%, all(+) = 13.4 ± 2.3%, agonist(-) = 20.3 ± 2%; B) Responses of OS neurons to agonists during 
the neuronal phase, Lean: ATP = 1.7 ± 0.6%, AITC = 48.4 ± 2.1%, CAP = 4.4 ± 2.5%, ATP/AITC = 7.7 ± 1.4, 
ATP/CAP = 0.5 ± 0.2%, AITC/CAP = 13.8 ± 1.2%, all(+) = 3.3 ± 0.5%, agonist(-) = 20.3 ± 2.7%; db/db: ATP = 
2 ± 0.5%, AITC = 32.6 ± 2.7%, CAP = 11.2 ± 1.9%, ATP/CAP = 3 ± 0.7%, ATP/AITC = 7.2 ± 1.5%,  AITC/CAP = 
20.6 ± 1.8%, all(+) = 6 ± 1.5%, agonist(-) = 17.4 ± 2%. Two-tailed paired Student’s t-test. *p<0.05, 
**p<0.005, ***p<0.001. Shown mean ± SEM 
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the main contributor to the overall increase in CAP sensitivity in that phase (Figure 5.5 A,C). 
The same analysis performed on the OS population of neurons in the NEU phase revealed that 
there was an increase in the percentage of OS neurons by responding to CAP alone by 2.5-
fold (from 4.4 ± 2.5% to 11.2 ± 1.9%, p = 0.0559) or with another agonist (ATP/CAP, 5.9-fold, 
from 0.5 ± 0.2% to 3 ± 0.7%, p < 0.005; AITC/CAP, 1.5-fold, from 13.8 ± 1.2% to 20.6 ± 1.8%, 
p < 0.05) (Figure 5.10 B), identified to be amongst the main contributing populations to the 
overall CAP increase noted in the NEU phase in db/db neurons (Figure 5.5 B,D). These 
analyses suggest it is likely that the OS subpopulations of neurons affected by increased VGSC 
excitability could be the same subpopulations affected by increased sensitivity to CAP in each 
phase of DN. 
Taken together, these results suggest that DN leads to an early-phase overall increase in 
VGSC excitability mainly in medium-diameter DRG neurons responsive to multiple nociceptive 
agonists. The concentration of this increase in the OS population confirms that these changes 
are occurring in nociceptors. As DN progresses into the NEU phase, the increased excitability 
of OS neurons shifts to affect small-diameter nociceptors. The subpopulations affected by 
increased VGSC activity overlap with those affected by increased CAP activity, suggesting 
that the same subpopulation of neurons could be affected during the course of DN.    
5.5. DISCUSSION 
The experiments described in this chapter aimed to examine the excitability changes occurring 
during the course of DN in DRG neurons isolated from the well-established T2DN db/db mouse 
model. A significant loss of large neurons was observed in the early, MET phase of DN, 
whereas there was a leftward shift in the size distribution in the late, NEU phase of DN. There 
were functional changes taking place in the DRG neurons of db/db mice during the MET and 
NEU stages of DN. DRG neurons from db/db mice showed increased sensitivity to CAP as well 
as increased VGSC excitability in nociceptors in both DN phases. The neurons with increased 
CAP sensitivity in the MET phase were mainly of medium diameter, expressing the receptors 
for ATP, AITC and CAP simultaneously (P2X3, TRPA1 and TRPV1, respectively), whereas those 
in the NEU phase were small in diameter, expressing TRPV1 alone or with another receptor. 
Parallel to the that, in the NEU phase there was also a significant decrease in the sensitivity to 
AITC, contributed by medium-diameter neurons. Collectively, these results point to distinct 
populations of neurons being affected by changes in excitability in each of the two DN phases: 
mostly medium-diameter nociceptors, expressing P2X3, TRPA1 and TRPV1 in the MET phase; 
and small-diameter TRPV1-expressing nociceptors as well as medium-diameter TRPA1-
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physiological functional and size characterisation affected DRG subpopulations during DN in 
the db/db mouse . 
5.5.1. Cell size distribution in db/db mice DRG through the course of 
diabetic neuropathy 
In the current study, we show that during the MET phase, there was a significant decrease in 
the number of large-diameter cells, where their percentage in db/db mice was 1.4-fold lower 
than lean. In comparison, during the NEU phase of DN, diabetic mice had a significantly 
increased percentage of small DRG neurons (<20 µm) by nearly 1.4-fold (Figure 5.3 B). At the 
same time, the percentage of medium-diameter (20–30 µm) DRG neurons was reduced as 
well as that of large-diameter neurons (>30 µm), albeit not significantly. These observations 
indicate a potential loss of medium-to-large-diameter neurons during late stages of DN, that 
could possibly have its beginnings in the MET phase.  
Our observations are consistent with those made in the NEU phase by Shi et al. (2013) who 
found 33% neuronal loss in sections of lumbar 5 (L5) DRG of 32/33-week-old db/db mice but 
no change in 5/6-week-old mice. The lost neurons were of medium-to-large diameter (20–40 
µm, according to their size groups). This loss is correlated with hypoalgesia and hyposensitivity 
demonstrated by behavioural experiments 555. Here, we observe a total of 16% decrease in 
neurons from db/db mice of the same size range (~11% medium + ~5% large). The 
discrepancy in the percentages noted by us and Shi et al. could be attributed to the difference 
between the DRGs selected for analysis by them (L5 only) and us (all DRGs along the spinal 
column length). To our knowledge, theirs is the only study that investigated the changes in the 
distribution of DRG neuron sizes in the db/db mouse and in a T2DN model in general. As 
summarised in Figure 5.2, most studies on the db/db mouse model have focused on 
investigating the distal (axonal) as opposed to the more central (DRG) changes induced by 
DN. Therefore, as far as the same mouse model of DN is concerned, the size distribution 
results observed here agree to some extent with those observed in vivo. 
The little information available on diabetes-induced morphological abnormalities at the level of 
DRG from other animal models of DN is controversial. In STZ rat models, a significant reduction 
in the perikaryal volume (size of the neuronal cell body) is noted in the DRG of STZ rats but 
only at 1 month of induced diabetes 562. However, later, Zochodne et al. (2001) report no 
change in size distribution at 2 months but a significant reduction in the perikaryal volume after 
12 months of induced diabetes 563, leading to a shift of the size distribution to the left, 
reminiscent of the one observed in the NEU phase here. In addition, apoptosis is confirmed to 
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particularly vulnerable 564. On the other hand, several studies confirm that loss of DRG or 
reduced perikaryal volume is evident only in 12-13-month-old rats with chronic DN and not in 
the early stages 563,565–567. Finally, in 10-month-old BB/Wor diabetic rats, a severe loss of small- 
but not large-diameter DRG has been noted 318, contradicting all previous and our own 
research results. Nevertheless, the vast majority of reports from the T1DN rat models outlined 
above are in overall agreement with the study in db/db mice and our results. It appears that 
most agree on some form of DRG neuronal loss to occur in late DN stages and predominantly 
in large-diameter neurons, similar to our observations. The general coherence amongst 
observations from T1DN and T2DN models suggests that the mechanism underlying DRG loss, 
at least in the late stages, is common and therefore likely to be driven by a shared mechanism 
underlying T1D and T2D such as hyperglycaemia. However, it remains unclear whether DRG 
loss preferably affects specific subpopulations and whether it is due to cell soma 
shrinkage563,565,566, dying-back process 567 or apoptosis 318,564, as each has been reported to 
occur.  
5.5.2. Diabetic neuropathy leads to increasing sensitivity to capsaicin in 
db/db mouse DRG neurons 
Capsaicin is an agonist for the noxious heat-gated TRPV1 channel, a non-selective cation 
channel and a marker of peptidergic nociceptive neurons 132. Physiologically, TRPV1 plays a 
key role in the generation of thermal hyperalgesia under inflammatory or tissue injury 
conditions 148,149,568. During the MET phase of DN, our results showed an increase in the total 
responses to CAP (Figure 5.5 C) in medium-diameter (20-30 µm) neurons of db/db mice 
(Figure 5.6 A, B) and therefore, a likely sensitisation or increase in expression levels of its 
receptor TRPV1. We showed that this increase was focused within a specific neuronal 
subpopulation expressing P2X3 (ATP receptor), TRPA1 (AITC receptor) and TRPV1 
simultaneously (the ‘all(+)’ subpopulation) (Figure 5.5 A).  
In their comprehensive 2016 study, Li et al. combined transcriptomic, electrophysiological and 
morphological data from mouse DRG neurons and classified them into 16 molecularly distinct 
subtypes, each with particular set of proteins expressed 15. Referencing the known expression 
ion channels of the identified all(+) subpopulation from our results with their categories 
revealed that it is likely the ‘all(+)’ subpopulation is of the C1 cluster – small (<30 µm according 
to their own size classification), mechano-heat-nociceptors, responding to noxious mechanical 
and thermal stimuli. Another cluster expressing P2X3, TRPA1 and TRPV1 together is the C10 
cluster representing the large-diameter (36-42 um) mechanoreceptors 15. However, this 
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experiments did not exceed 29 µm. Behavioural studies in db/db mice confirm the presence 
of mechanical allodynia during the MET phase of DN (week 6-8) 456,507,547,569. Some report 
mechanical allodynia to occur together with thermal hyperalgesia (TH) 547,548, consistent with 
the suggestion of an early stage sensitisation of mechano-heat-nociceptors. Pain of burning 
quality has also been reported to occur in DN patients, often in parallel to mechanical allodynia, 
prickling, itching, tingling and ‘electric’ pain sensation, mainly in the feet and hands 356,570–573. 
These clinical observations agree with the early-phase behavioural data from db/db mice and 
the suggested increased overall TRPV1 activity we report in db/db DRG neurons. 
Alternatively, referencing the all (+) subpopulation with the DRG subtypes defined by Zeisel et 
al. by using their online search tool for gene combinations 
(http://mousebrain.org/genesearch.html ) revealed that the all(+) neurons are most likely a 
subpopulation of non-peptidergic neurons (particularly, the “PSNP6” group). In turn,  Zeisel et 
al. reference their own classification with that of Usoskin’s and the “PSNP6” group 
corresponds to their NP3 group of neurons. Usoskin et al. describe the NP3 cluster as non-
peptidergic, unmyelinated neurons of small-to-medium diameter (~20 µm). Interestingly, they 
strongly suggest that the NP3 DRG neurons are most likely involved in inflammatory itch and 
pruritus (general itching), thus suggestive of an alternative or additional function of the all(+) 
population in our results. Chronic pruritus has been well-documented as a symptom in DN 
patients, reported by 3 – 49% of diabetics 574,575. Albeit not investigated as a behaviour in the 
db/db mouse model of DN, increased scratching behaviour has been reported in STZ rats and 
linked to DN 576,577. Itch-specific neurons have been identified to be unmyelinated C-fibre 
nociceptors expressing the Mas1-related G-protein-coupled receptor A3 (MrgprA3) 578 as well 
as P2X3, TRPA1 and TRPV1 together 14. Albeit not the only itch-contributing neurons, they were 
defined as essential and sufficient for pruriception 578.  The mechanism underlying the pruritus 
phenotype in DN is still not clear, however, mounting evidence shows that pruriception is 
dependent on the recruitment of TRP channels 579. Specifically, pruriception was shown to be 
alleviated and scratching behaviour reduced in mice after pharmacological blockade of TRPA1 
and TRPV1 580. Furthermore, inflammatory mediators, known to be upregulated during DN, 
such as interleukin (IL-) 2, IL-4, IL- 13, IL-31 and NGF 256,552,557, have also been shown to 
sensitise TRPV1 and TRPA1 and contribute to itching and scratching 577,581. This suggests that 
the increased activity of the all(+) subpopulation of db/db neurons in our results could be 
driven by their exposure to diabetes-driven inflammatory mediators in vivo and could translate 
to increase an increase in itch and scratching behaviour related to DN.  
From the metabolic abnormalities in the early, MET phase arises progressive structural 
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the well-established damage and reduction of IENF density as well as loss of myelin sheathing 
and slowing of NCV in animal models and patients 258. In contrast to the positive symptoms 
(pain, prickling etc.) characteristic for the MET phase, the accompanying symptoms of the 
NEU phase are generally negative, i.e. decreased sensory function, numbness, impaired touch 
and vibration perception and in some patients, mechanical and thermal hypoalgesia 372,520. It is 
now well-documented that pain is not just a defining feature of  the MET phase and can develop 
at any stage of DN. In fact, the more severe the sensory deficits become, the higher the risk of 
developing neuropathic pain episodes is 237. Moreover, one of the outcomes of IENF damage 
is bursts of spontaneous activity expressed as pain attacks 237,582. Although the sensory deficit 
symptoms of DN have been well-established to originate from structural nerve damage, the 
mechanisms underlying the paradoxical pain during sensory deficits are still poorly 
understood. 
Here, we report a further increase in total CAP responses, as DN progresses into the NEU 
phase in db/db mice (Figure 5.5 D). Compared to the MET phase, in the NEU phase, this total 
increase is contributed to mostly by small-diameter cells  responding to CAP (Figure 5.6 C,D) 
and thus expressing TRPV1 (Figure 5.5 B). This points to the sensitisation to CAP spreading 
to envelop other subpopulations of DRG neurons, likely focusing on small, C-fibre nociceptors. 
Since the affected population in this phase is of small neurons expressing TRPV1, an increased 
activity in these cells could translate to increased thermal pain sensitivity in vivo. 
Virtually all behavioural studies of db/db mice show increased mechanical and/or thermal pain 
thresholds in the NEU phase 430,453,553–557,583, thus contradicting the increase in TRPV1 activity 
observed here. However, it is worth noting that behavioural thermal sensitivity tests in animals 
are performed using assays such as the ‘hot plate’, ‘Von Frey’ and ‘tail-flick’ methods. These 
tests rely on the cutaneous perception of stimuli and the results are, therefore, affected by the 
integrity of the intraepidermal innervation. Thus, an increase in thermal and mechanical 
thresholds is perhaps more indicative of subcutaneous IENF damage rather than any central 
channel alterations. The conflict between db/db behavioural results of decreased thermal 
sensitivity and the increased TRPV1 activity we report could suggest that there is an ongoing 
central sensitisation, upstream of the subepidermal innervation, by stimuli affecting the DRG 
and not the terminal ends, causing pain of different types, degrees and frequency that might 
not be detected via conventional animal behavioural tests.  
In humans with DN, thermal hyperalgesia has been reported in some patients with mild DN 
early in the disease’s course 584, whereas the advanced phases of the disease are more 
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Nevertheless, heat hyperalgesia is still experienced by some DN patients in the advanced DN 
stages 356. Our results could provide a possible explanation for this by suggesting that 
increased TRPV1 sensitisation and/or expression in DRG is responsible for the increased 
responsiveness to CAP observed and thus might contribute to spontaneous heat pain. 
Consistent with our predictions, the most common combination reported in patients is 
numbness coupled with burning pain and prickling 238,356,586, shown by Baron et al. to occur 
together in 26% of tested DN patients, with the next most common sensory profile being 
episodic pain attacks (16%) 356. The increased TRPV1 activity in  DRG we report and the 
decreased sensitivity to mechanical and thermal stimuli reported by behavioural studies in 
db/db mice in the NEU phase confirm that functional changes can keep exacerbating in the 
soma of DRG neurons despite disconnection from the skin and impaired external inputs 
detection. Therefore, a continuous central sensitisation of TRPV1 in small C-fibre nociceptors 
could be a key player in the development of pain, specifically of burning quality, simultaneously  
with IENF damage and functional sensory deficits in DN patients. 
What could lead to the ongoing central sensitisation of TRPV1 in DRG during DN? As 
mentioned, increased levels of inflammatory mediators have been reported in DRG neurons 
during early and late stages of DN and shown to sensitise TRPV1 by activating kinases such 
as PKC 142–144,256,552,557. Protein kinase C activation by the overproduction of glucose metabolites 
(such as DAG) is also one of the main mechanisms underlying DN development (see Chapter 
1, section 1.3.2.2., page 34). Thus, PKC overactivation by different pathways can lead to the 
hypersensitisation of TRPV1 in DRG 143,144. The levels of one inflammatory mediator in particular 
– NGF, have been reported to be increased in the DRG of db/db mice during the MET phase, 
implied to contribute to the early phase painful phenotype, which could be as a result of NGF 
increasing TRPV1 sensitisation and expression levels 340. Furthermore, insulin, which is 
abundant in the early phase of T2DN, has also been implied in increased TRPV1 activity by 
enhancing its translocation to the membrane and lowering its activation threshold, thus 
facilitating its activation by non-painful stimuli 291–293. Therefore, ongoing central sensitisation 
of TRPV1 could be a potential source of the thermal hyperalgesia and/or pruritus during the 
early, MET phase and of the paradoxical  spontaneous pain during sensory deficits in the late, 
NEU phase. 
5.5.3. Diabetic neuropathy leads to a decrease in the sensitivity to AITC in 
the db/db mouse DRG neurons 
Parallel to the increased sensitivity to CAP, in the NEU phase, we also observed a decrease in 
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significant drop in the percentage of medium-diameter DRG neurons (Figure 5.7 B) responding 
to AITC only (Figure 5.5 B), (expressing TRPA1). The TRPA1 channel is activated by a variety 
of chemicals, cold temperatures and ROS 163,166,169. Its role in painful DN pathogenesis has also 
been well-documented 184,185,587,588. TRPA1 is activated and sensitised during DN by diabetes-
generated endogenous compound, such as methylglyoxal 343,407,589 and conditions, such as 
oxidative stress 345. This sensitisation of TRPA1 is linked to the DN phenotype of mechanical 
allodynia and hypersensitivity. In db/db mice, one group recently demonstrated that AMPK 
activity is impaired in DRG neurons causing an increase in membrane-associated TRPA1 and 
agonist-evoked TRPA1 currents and mechanical allodynia 507. These findings contradict our 
observations of decrease in AITC response rate and hence possible TRPA1 desensitisation 
and/or decreased expression. However, their report on TRPA1 covers the MET phase of DN 
in the db/db mouse and not the NEU phase, where our observations take place. It is, thus, still 
inconclusive what changes occur in the activity of TRPA1 in the advanced DN stages in this 
mouse model. 
The rest of the limited literature covering changes in TRPA1 activity during DN is largely 
focused on the STZ model of T1D and involves considerable controversy. For example, using  
mice with STZ-induced diabetes, Hiyama et al. demonstrated the involvement of TRPA1 in 
cold, but not mechanical, hypersensitivity in the early DN stage (2 weeks after diabetes 
induction). However, in the late stages (8 weeks after diabetes induction), mechanical 
hyposensitivity and loss of IENFs was shown to occur independently of TRPA1, as TRPA1-KO 
STZ mice developed a neuropathic phenotype comparable to WT STZ mice 590. The 
involvement of TRPA1 in early-phase symptoms of mechanical hypersensitivity in STZ rats was 
further confirmed by others in the literature 588,591. In contrast, increased expression levels and 
activity of TRPA1 in the STZ mice was reported at late stages (5 weeks after diabetes 
induction) and correlated to itch and hypoalgesia, as revealed by the attenuated neuropathic 
symptoms in TRPA1-KO mice and after pharmacological blockade of TRPA1 592. Further to 
that, all TRPA1-related findings derived from the STZ-induced diabetes rodents have to be 
interpreted with caution as Andersson et al. demonstrated a direct activation of TRPA1 by STZ 
in vitro and in vivo, where topical administration evoked TRPA1-dependent polymodal 
hyperalgesia and systemic administration produced acute sensory loss 466. Thus, at this time 
the degree and exact mechanisms underlying the involvement of TRPA1 in DN pain and 
sensory deficits at the different disease phases is still largely uncertain. 
With the literature on the subject being scarce, we can only speculate the possible events 
driving the decrease in AITC responses and therefore TRPA1 activity we see here. It is unlikely 
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reduction in AITC responses is noted in medium-diameter cells (Figure 5.7 B), whereas the 
increase in CAP is contributed for by small-diameter cells (Figure 5.6 D). Had there been a 
functional transformation of TRPA1(+) to acquire TRPV1 activity, we would have seen an 
increase in medium-diameter CAP(+) cells in the NEU phase as well as small. Therefore, the 
decrease in AITC responses we report in the NEU phase could be attributed to decreased 
TRPA1 activity due to desensitisation, downregulation of TRPA1 expression or an inhibitory 
mechanism triggered by DN, or, alternatively, due to loss of medium-diameter TRPA1(+) 
neurons. Further experiments in the db/db mouse model tracing TRPA1 expression and 
activity throughout the course of DN are required to confirm or refute these theories. 
5.5.4. DRG neurons form db/db mice have increased VGSC activity in 
cells with the OS VTD-response profile 
DN has been well documented to alter VGSC activity and expression in sensory 
neurons350,424,593,594. Here, we report an increase in VGSC excitability in db/db mice during DN 
(Figure 5.8). The increase in excitability was focused within the neuronal population of the OS 
VTD-response profile, previously confirmed to represent nociceptors 499,595. The increase in 
OS neurons was evident during both phases of DN, however, in the MET phase it occurred in 
small and medium nociceptors (Figure 5.9 A,C), whereas in the NEU phase it was focused only 
within small-diameter nociceptors (Figure 5.9 B,D).  
Is it possible to identify the VGSC contributing to the OS increase? DRG neurons express 
several different VGSCs: Nav1.3, Nav1.6 and Nav1.7 (TTX-S), and Nav1.8 and Nav1.9 (TTX-
R). All have been demonstrated to be altered and to contribute to pain during nerve injury and 
neuropathies 31,360,593,596, including DN 351,352,424,597–600. Veratridine preferably binds TTX-S 
channels in their open-state and prevents them from inactivating 492. Due to the broad selective 
nature of VTD for TTX-S VGSC over TTX-R and not for any VGSC isoform in particular, it is 
difficult to correlate the increase in OS-response neurons seen to increased activity in any 
specific VGSC without further supporting experiments. As each neuron expresses a 
‘constellation’ of ion channels, changed expression levels and/or activity of any of them can 
shape the net VTD response and lead to an increase in a particular VTD-response profile.  
Only one paper investigated the expression levels and activity of a VGSC in the db/db mouse 
DRG during DN. In 2012, Ren et al. assessed the expression levels and activity of Nav1.6 in 
the db/db mouse during the progression of DN. Nav1.6 is a TTX-S VGSC, highly expressed in 
large-diameter DRG neurons, predominantly involved in transmitting tactile information 601 but 
also reported to contribute to painful DN in rodent models 58,593. The research group reported 




CHAPTER 5: ASSESSING THE EXCITABILITY CHANGES IN DRG NEURONS FROM DIABETIC DB/DB MICE 
of db/db mice. This upregulation was speculated to have been driven by the increased 
expression of neurotrophins and inflammatory mediators in the DRG during DN. It was also 
correlated with the demonstrated sustained mechanical allodynia in these mice, further 
implicating Nav1.6 involvement in painful DN 60. These conclusions confirmed the increased 
Nav1.6 expression during DN noted by Craner et al. in the STZ rat 593. We have shown that a 
low dose of a Nav1.6 blocker 4.9-TTX leads to a decrease in the percentage of OS DRG 
neurons in WT mice 595 see Chapter 3). It is then a possibility that the VGSC activity increase 
in OS neurons seen in the DRG of db/db mice here is as a result from increased expression 
levels of Nav1.6 in the DRG. However, it remains rather unlikely, given that Nav1.6 is 
predominantly expressed in large-diameter neurons and we only noted an increase in VGSC 
activity in small and medium neurons. Furthermore, the 4.9-TTX blocker led to a decrease in 
the percentage of SD neurons as well, therefore had there been an upregulation of Nav1.6 in 
the DRG of our diabetic mice, we would have expected it to be reflected by an increase in the 
SD profile as well as the OS. It can therefore be assumed that an upregulation of Nav1.6 is 
unlikely to have contributed to increase in the OS-response profile seen. 
The rest of the TTX-S channels in DRG, Nav1.3 and Nav1.7 upon which VTD acts directly, 
have both been implicated in DN and pain 360. Nav1.3 is another TTX-S channel shown to have 
upregulated expression in DRG neurons, triggered by inflammation and nerve damage 
44,45,602,603. It has also been implicated to have a role in nerve injury-related pain 47,105,604,605, 
however experiments with a Nav1.3 null mutant demonstrated that Nav1.3 is neither necessary 
nor sufficient for the development of such pain 606. In STZ-rat models of painful DN with 
confirmed mechanical allodynia, Nav1.3 is reported to have lasting increased expression 
levels, usually accompanied by alteration in other VGSCs as well 352,593,607. Given the conditional 
upregulation of Nav1.3, it is likely that the inflammatory environment in the db/db mouse has 
increased Nav1.3 expression levels in DRG neurons, which translated in an increased VGSC 
activity, as detected by the increase in the OS population. 
In rats with painful DN, Nav1.7 has been shown to have robustly upregulated expression in 
small DRG neurons 58,350,594,608. We have also previously suggested that increases in the OS 
VTD-response profile rates could be indicative of increase in the activity of Nav1.7 channel in 
DRG (595, see Chapter 3). However, it is unlikely that the increase in OS VTD-profile seen in 
the DRG of db/db mice here is indicative of an increase in Nav1.7 activity or expression levels, 
as Nav1.7 is expressed in all DRG neurons (i.e. nociceptors and non-nociceptors). Had there 
been a significant increase in its expression or activity we would have expected to see this 
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The literature on the role of Nav1.8 in painful DN is controversial. Nav1.8 cooperates with 
Nav1.7 in DRG neurons, where Nav1.8 is reliant on Nav1.7’s hyperpolarised activation to 
depolarise the membrane sufficiently for Nav1.8’s activation 92,93. Experiments with global 
Nav1.8KO mice show a compensatory increase in Nav1.7 expression 87. Indeed, in diabetic 
animals downregulation of Nav1.8 is accompanied by an increase in Nav1.7 expression 593.  As 
well as downregulated 353, Nav1.8 is reported to be upregulated in diabetic rat DRGs too 594. In 
addition, one study demonstrated that Nav1.8 expression is unchanged in diabetic STZ mice 
but methylglyoxal, a metabolite formed by excessive glucose, causes post-translational gating 
modifications of Nav1.8 which, together with causing slow inactivation of Nav1.7, contribute to 
the painful phenotype of the diabetic mice 342. It could be the case that Nav1.8 activity or 
expression is upregulated in DRG of db/db mice and contributes to increase in OS, 
Alternatively, if Nav1.8 expression is downregulated during DN, Nav1.7 is expected to take 
over and sustain neuronal excitability and OS levels. 
Nav1.9, a TTX-R VGSC, has also been demonstrated to be upregulated in diabetic DRG 
neurons from STZ rats with allodynia, where the increase of Nav1.9 mRNA and protein was 
observed in neurons of all sizes. The increase is greater in large-diameter neurons, whereas 
its expression in control DRG was primarily by small and medium-diameter neurons 593. It is 
therefore unlikely that Nav1.9 solely contributed to an increase in the OS-VTD profile in small 
DRG neurons of db/db.  
From all the information above, it is most likely that more than one VGSCs could have 
contributed to the increased OS responses we saw in db/db mice. Moreover, other classes of 
ion channels, such as VGKC and VGCC, shape the net Ca2+ signal response to VTD and so, 
any expression or functional changes in them can alter the VTD-profiles produced and 
contribute to the increase seen in OS profile. For example, gabapentin, a widely-prescribed 
VGCC blocker  is effective at alleviating painful symptoms in DN patients 374,609. Thus, functional 
and expression levels in VGCC and other channels should be investigated by further functional 
and biochemical assays.  
5.5.5. Diabetic neuropathy leads to excitability changes in specific 
neuronal subpopulations  
A summary of the known properties of the neuronal subpopulations affected and the changes 
observed is presented in Table 5.2 and Figure 5.11. In the MET phase of db/db mice, the net 
effect was an increase in CAP-responsive cells (Figure 5.5 C) and increase in VGSC excitability 
(Figure 5.8). The additional CAP(+) neurons were mostly medium diameter nociceptors 
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(Figure 5.5 A). In the same phase, the increased VGSC activity was due to increase in the 
percentage of OS neurons which were also small- to medium diameter nociceptors (Figure 
5.9 A,C) of the all(+) subpopulation (Figure 5.10 A). Thus, there is a considerable overlap 
between the properties of the subpopulations affected by increased CAP and VGSC sensitivity 
in the MET phase in db/db mice.  
In the NEU phase, the net effect was an increased number of CAP-responsive cells (Figure 
5.5D). Here, the additional CAP(+) cells were focused within a subpopulation of small-diameter 
nociceptors (Figure 5.6 B,D) expressing TRPV1 (Figure 5.5 B). Also, the increased VGSC 
activity was attributed to additional OS-profile cells also of small-diameter (Figure 5.9 B,D) and 
also expressing TRPV1 (Figure 5.10 B). Therefore, the subpopulations affected during the NEU 
phase in db/db mice also overlap in their properties. 
The features of the increased VGSC excitability subpopulations largely match those of the cell 
subpopulations identified with hypersensitisation to CAP in each phase. This could indicate a 
possible correlation between the increased TRPV1 sensitivity and VGSC excitability. I.e., the 
same neuronal subpopulations are affected by these two phenomena in DN in the db/db mice: 
predominantly medium-diameter nociceptors expressing P2X3, TRPA1 and TRPV1 together in 
the MET phase; and small-diameter nociceptors expressing TRPV1 in the NEU phase. In 
addition, the drop in AITC-responsive neurons in db/db mice during the NEU phase was 
attributed to a subpopulation of medium-diameter neurons of the OS profile expressing 
TRPA1. Since their parameters differ from those of the neuronal subpopulation affected by 
CAP(+) increase, it is likely that this is a separate effect on a different neuronal subpopulation. 
 
 
Table 5.2. Summary table of the identified properties of the DRG neuronal subpopulations affected in db/db 
mice in the metabolic (MET) and neuronal (NEU) phases of diabetic neuropathy. Net effect for each phase 
shown in the bottom row.  Green background denotes increase, whereas red background denotes a decrease 









Further experiments including tracing ion channel expression levels throughout the course of 
DN in the db/db mouse are needed in parallel to VTD-Ca2+ imaging to further characterise the 
identity of the specific subpopulations raising DRG neuronal excitability and potentially shaping 
a painful phenotype. The next and final chapter discusses further limitations and 






Figure 5.11. Graphic summary of the affected subpopulations  of DRG neurons and their known properties in 
db/db mice in the metabolic (MET) and neuronal (NEU) phases of diabetic neuropathy. Dotted outline of 
receptor channels mean that the neuron might express both, one or none of them together with TRPV1. Green 
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CHAPTER 6: LIMITATIONS & FUTURE DIRECTIONS  
Diabetic neuropathy is a debilitating condition significantly affecting the quality of patients’ life, 
especially if accompanied by painful symptoms. Despite decades of animal and clinical 
research, the multifactorial mechanisms driving the positive and negative sensations caused 
by DN are still poorly understood. There are no disease-modifying or reversing drugs approved 
and DN continues to represent a therapeutic challenge 230. The only successful strategy 
remains diabetes prevention via glycaemic control through diet and lifestyle management. To 
date, several treatments have been approved for the symptomatic relief of painful DN, however 
first- and second-line drugs target pain pathways in the CNS and produce modest analgesia 
at the cost of serious, potentially fatal side effects 376.  
In recent years, research into novel analgesic agents for the treatment of pain has turned to 
targeting the PNS to avoid serious CNS adverse effects whilst improving drug efficacy. Several 
promising targets have been identified, the most popular being PNS-expressed ion channels 
implicated in pain for example VGSCs Nav1.7, Nav1.8 and Nav1.9 33,610. Novel ion channel 
blockers or activators drugs are in development and ongoing pre-clinical and clinical studies 
393,394,399–401 (also see Table 1.5). However, a common issue is the poor translation of drug 
efficacy from the animal model to the DN patient with most novel pharmacotherapies failing 
clinical trials. For example the failed translation of aldose reductase- and PKC-inhibitors 
efficacy from the STZ rat model of DN to DN patients 247,249. To design better targeted drugs 
with minimal off-target effects, a better understanding of the mechanisms driving DN pathology 
and its modelling is required as well as a simple, efficient, medium-to-high throughput assay 
able to distinguish nociceptors from non-nociceptors. 
Therefore, the aim of the current study was to aid this process by assessing the neuronal 
excitability changes occurring during DN in DRG neurons in vitro and from a diabetic mouse 
model. We expected that neuronal excitability shifts will be present at different degrees in the 
different subpopulations of neurons within a mixed DRG population. Therefore, first, the VTD-
Ca2+ imaging assay was validated for its ability to discriminate nociceptors from a 
heterogeneous neuronal population and for its use as a potential drug screening tool, as 
outlined in Chapter 3. The next two chapters described following experiments exploring the 
application of the VTD-Ca2+ imaging assay in combination with other nociceptive agonists to 
characterise excitability changes during DN in DRG neurons from healthy mice cultured under 
in vitro hyperglycaemic conditions (Chapter 4) or DRG neurons derived from the diabetic 
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In this chapter, discussion will encompass advantages and future perspectives for the VTD-
Ca2+ imaging assay regarding its optimisation and application. I will discuss the main limitations 
of our study with focus on the in vitro DN experiments and how realistic it is to replicate DN in 
a dish as well as using DN mouse models for assessing DRG excitability changes. Finally, the 
key findings and implications of the experiments will be briefly discussed with 
recommendations for future research. 
6.1. Veratridine and Ca2+ imaging as a tool with multiple applications  
This study began with the aim of validating the previously generated results by our lab for the 
use of VTD-induced Ca2+ responses as broad markers for DRG neuronal subpopulations. A 
detailed characterisation of the VTD-responses was carried out previously by our lab 499. Here, 
using DTA mice with genetically ablated nociceptors, I demonstrated a strong link between 
the OS VTD-response profile and nociceptors, whilst non-nociceptors were associated with 
the SD profile (Chapter 3, Figure 2). Thus, the use of the VTD with Ca2+ imaging as a tool for 
assessing neuronal excitability in specific neuronal subpopulations was confirmed and the 
“VTD- Ca2+ imaging assay” was established.  
6.1.2. Advantages 
The VTD-Ca2+ imaging assay’s main advantage is that it allows for the efficient screening of a 
heterogeneous population of neurons. Thus, the VTD response profile pattern generated 
integrates all responses present in the population, which would give a more realistic idea of 
what a drug’s effect would be in a physiological environment. This contrasts with patch-
clamping-based in vitro assays, where the investigated effect might not be detected as a result 
of the low-throughput screening efficiency. The ability to cover a heterogeneous population of 
neurons with a single assay screen is also advantageous over cell-line-based screening 
methods. Often the first choice in novel drug characterisations, heterologous expression 
systems are used to express the target protein against which drugs are screened. However, 
the absence of the full set of ion channels, exchangers and receptors can hide off-target effects 
of the compound investigated. The VTD-Ca2+ imaging assay is able to detect specific 
excitability changes in distinct neuronal subpopulations in each screen. Therefore, the 
development of the assay as a medium-to-high throughput screening tool in primary sensory 
neurons will aid in the complete characterisation of a drug’s efficacy and safety profile, as it 
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Apart from its functionality, another advantage of our system is the wealth of data generated 
with minimal resources and in a relatively short amount of time. For example, in our 
experiments with db/db mice,  over 6 weeks of imaging experiments, a total of 10 313 neurons 
were imaged from 24 mice, giving an imaging efficiency of approx. 430 neurons per mouse. 
Such recording capacity ensured each animal made a maximum contribution to the study with 
minimal waste of cells. Moreover, the large numbers of neurons for each mouse contributed 
to the validity of the observed phenotype.  
Our screening productivity is comparable to standard Ca2+-imaging of DRG neurons. However, 
here, we employ VTD as a main neuronal exciting agent instead of a high-potassium solution 
(KCl), most commonly used to excite cells in Ca2+ imaging protocols. High-potassium solutions 
directly depolarise the membranes of all neurons in a DRG population, thus activating them 
simultaneously 484. Here, due to VTD’s action on VGSCs, the responses generated are shaped 
by the constellation of ion channels, receptors and exchangers expressed by each neuron. 
Therefore, neuronal responses are more nuanced and thus more informative compared to the 
binary “yes” or “no” information provided by responses to KCl. 
Imaging Ca2+ responses to VTD and agonists in neurons provided us with basic information of 
the response rates to the drugs administered. Moreover, each recording also yielded a vast 
amount of data available for analysis, including measuring the amplitude of Ca2+ responses, 
time to peak and AUC. Each recording also provided an image of the neuronal population 
allowing for the  estimation of neuronal diameter and subsequent analysis of cell size 
distribution.  Such wealth of data allows for the in-depth multifactorial characterisation of the 
responses from each neuronal population imaged and hence the building of a more complete 
picture of the neuronal phenotype under investigation.  
6.1.3. Limitations & Recommendations 
Nevertheless, a major limitation of the VTD-Ca2+ imaging assay is the data analysis component. 
The diversity and abundance of information generated demands comprehensive analysis 
across several softwares. At present, this analysis is manual, with each neuronal trace of 
responses analysed individually. The process is laborious and time-consuming and manual 
data handling can be subject to conscious or unconscious bias.  
Finally, AUC measurements are performed automatically by a software according to a method 
outlined in Chapter 2: Materials & Methods, section 2.2.3.1, page 70. Although facilitating the 
analysis, the application of the same estimation formula on each trace does not produce a 




CHAPTER 6: LIMITATIONS & FUTURE DIRECTIONS 
drug based on a pre-specified baseline, which is the average value of the signal during the 30 
seconds prior to adding the drug. Assuming a perfectly steady and horizontal baseline, areas 
under the curve calculated will be near 100% accurate for all traces. However, occasionally, 
even the slightest fluorescent dye bleaching during an experiment can cause a small deviation 
of the resting calcium baseline and transiently or steadily shift it. If this shift is within the 30 
seconds specified for baseline, they are incorporated into the baseline calculations and lead 
to gain or loss of estimated AUC depending on whether the trace has been shifted upwards 
or downwards, respectively. Albeit infrequent, such cases occur and can “pollute” the 
estimated overall AUC value averaged for the whole neuronal population.  
Therefore,  perhaps the optimisation that this assay would benefit from the most, is automation 
of the data analysis process. Automating the calculation and tabulation of parameters will 
significantly reduce human error and the time taken. Furthermore, it would allow for the 
integration of a more complex formula for the AUC estimation which would account for 
potential deviations in the baseline of the Ca2+ signal.   
To develop a full picture of the usefulness of VTD-response profiles, the assay needs to be 
further developed. For example, at present, the assay has only ever been applied to mouse 
DRG neurons. Further characterisation using rat and human DRG (hDRG) would elucidate 
differences in DRG excitability between species. Transcriptomic analysis of rodent and hDRG 
have demonstrated different levels of expression of some pain-related ion channels. Chang et 
al. showed that Nav1.7 had higher expression levels in hDRG than mouse DRG, whereas 
mouse DRG had higher expression of Nav1.8 611. Therefore, the VTD-response patterns 
produced by hDRG might be significantly different from that of rodent DRG, highlighting 
potential interspecies functional discrepancies. This could provide insights into why certain 
analgesics have shown efficacy in rodents but not in humans. Adapting the VTD-Ca2+ imaging 
assay to examine responses in hDRG would, therefore, benefit drug screening programmes. 
The VTD-Ca2+ imaging assay can also be advanced by conducting more experiments with 
genetically modified animals (e.g., KO models of certain VGSCs, or knock-in for GCAMP Ca2+ 
sensors to allow in vivo imaging) as well as ion channel-blocking or activating drugs of various 
specificities. This would allow for the in-depth interrogation of each VTD-response profile and 
the contributing ion-channel(s) that shape it. This is of particular importance for clarifying the 
identity of the ID and RD profiles, which, although underrepresented, have a very distinct VTD-
response shape of a single, transient peak.   
Finally, experiments using DRG exposed to an inflammatory or injury-like in vitro environment 
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“silent nociceptors”, believed to be “unsilenced” under such conditions 3,4.  It is hypothesised 
these neurons express predominantly TTX-R channels 499, but it is yet to be determined what 
VTD-profile they will produce once activated. 
6.1.4. Applications  
The confirmation of the VTD-Ca2+ imaging assay as a tool able to discriminate excitability 
changes between nociceptors and non-nociceptors has opened many doors for its potential 
uses. Its application as a drug screening assay was tapped into during the experiments with 
pharmacological channel blockers presented in Chapter 3. They demonstrated that the VTD 
responses produced by a certain drug can be informative of its specificity to nociceptors and 
degree of side effects on non-nociceptors. Moreover, we demonstrated that the assay can be 
used for investigating the effect of combining lower doses of 2 (or more) drugs to improve 
efficacy and minimise off-target effects. Combination therapies have been undergoing clinical 
trials and, in many cases, have proven more successful than individual ones and placebo 613–
618, however the majority are still targeting the CNS. It would be interesting to see whether 
such approach can be applied to novel molecules targeting PNS-expressed ion channels. This 
can facilitate the analgesic drug development process, whereby failed ion channel-modulating 
agents can be resurrected into combination therapies instead of developing novel ones. This 
makes the VTD-Ca2+ imaging assay a suitable platform for pre-clinical drug tests on primary 
cultures of heterogeneous neurons. Furthermore, by using a primary culture of human DRG 
(hDRG) neurons, this could help bridge the translational gap between pre-clinical and clinical 
research. Thus, VTD-Ca2+ imaging can be used to assess the efficacy and safety of channel 
blockers and activators downstream of the VGSC activation step in the process of AP 
generation and propagation. However, a limitation to bear in mind is that, as a drug screening 
tool, the VTD-Ca2+ imaging assay would not be able to provide information on the efficacy of 
drugs inhibiting initial transducing events, e.g., blockers of TRP channels. This is because 
signal transduction is a step prior to VGSC activation, where VTD exercises its action. 
The VTD-Ca2+ imaging assay can also be applied for the characterisations of DRG excitability 
phenotype in the context of different neuropathological conditions. In Chapter 5, I described 
and discussed experiments with DRG from the db/db mouse model of DN. In a DN setting, the 
assay was able to detect excitability changes in nociceptors expressed as increase in the 
percentage of neurons with the OS profile (Figures 5.8, 5.9, 5.10). The assay can be applied 
in other DRG-sensitisation models, such as paclitaxel-induced peripheral neuropathy 619 or 
inflammatory conditions 612. It would also be interesting to compare VTD-response profiles 
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by the db/db mouse. A comparison of this nature can elucidate DN-driving mechanisms in the 
different induced diabetes animal models and provide insights into the discrepancies seen in 
neuropathic complications between the two diabetes types. 
Finally, the VTD-Ca2+ imaging assay can contribute for the validation of stem cell differentiation 
protocols 620. Research efforts have been focused into the development of functional DRG 
cultures derived from iPSC for the study of peripheral neuropathies 621. How well such novel 
cultures compare to natural human DRG could be determined by comparing the VTD-
response profiles both will produce. Thus, one can estimate whether the expression of the 
constellation of ion channels in the membrane of stem cell-derived neurons is comparable to 
the physiological, natural DRG neuron. 
6.2. Modelling diabetic neuropathy in a dish – a realistic goal or an 
unfeasible challenge? 
It is common practice when investigating the pathology of a disease to replicate its aspects on 
cultured cells in vitro in order to study the mechanisms in a controlled and isolated 
environment. In vitro high glucose conditions have been used as a way of modelling DN 
extensively and have largely contributed to our knowledge of the mechanisms underlying 
diabetic neuropathy and pain 318,420–425. In the experiments outlined in the present study, in vitro-
induced hyperglycaemia did not produce the expected increase in neuronal excitability as 
increased VGSC activity 351,424,502 or increase in responses to nociceptive agonists implied 
elsewhere 506,510,525, as the response rates remained comparable to control (Figures 4.3, 4.4). 
It is difficult to explain this outcome, but it might be related to differences between the age and 
type of the DRG used, differences in glucose concentration and exposure time used by me 
and others, as well as other variables in the culture conditions. 
Our in vitro results contradict virtually all previous studies using in vitro high glucose 
conditions, which report increase in CAP-evoked currents or VGSC activity or 
expression351,424,456,502,506,510,531,622. As discussed in detail in chapter 4, the possible reasons for 
these discrepancies are the extensive use of embryonic or neonatal DRGs by others 351,424,502,506 
as opposed to adult DRG used here; the use of rat DRG 349,351,502,510 or immortalised rat DRG 
cell line 622 rather than mouse DRG used here; and the selection of specific DRG for culturing 
and experiments, e.g. lumbar DRGs 502,506,510 or only those of 20-25 µm 502 as contrasted with 
the isolation of DRG from the full spinal column length here, which might account for a potential 




CHAPTER 6: LIMITATIONS & FUTURE DIRECTIONS 
With our in vitro experimental design differing substantially in one or more aspects form others, 
we can only speculate how the conditions we introduced could be amended to achieve a high 
glucose-driven increase in DRG excitability. One thing to consider can be the degree and 
duration of hyperglycaemia exposure itself. Albeit well-supported by studies investigating its 
acute effects, the extracellular glucose concentration of 50mM used here might not have been 
potent enough to produce an effect on neuronal excitability represented by changes in VGSC 
activity detected in the VTD-response profile patterns generated. Also, in the present 
experiments, glucose concentration was increased to hyperglycaemic levels acutely after 24h 
and glucose in the medium was not replenished daily to maintain high concentration. DRG 
neurons have higher energy requirements and metabolic rates compared to other cells and 
tissues 318,623. Their energy demands are likely to be even higher than normal for the first 24h 
following dissociation for culture as the neuron’s metabolic rate is altered to support axonal 
regeneration 624. Hence, cultured neurons might metabolise the available sugar abundance 
and re-adapt to control glucose levels in the 24 hours before experiments begin. Although, to 
our knowledge, this does not seem to be a practice in similar studies, daily replenishing of 
glucose in the medium might be an avenue worth exploring for Ca2+ imaging experiments with 
neurons cultured for more than 24h.  
Another possible explanation for the absence of a hyperexcitability phenotype in our 
experiments is the lack of the full spectrum of DN aspects driving neurodegeneration. 
Historically, DN’s pathology was largely believed to be “glucocentric”. This is true to a large 
extent, as high blood glucose levels are toxic for the vasa nervorum, the neurons themselves 
and the Schwann cells supporting them. However, it is now known that glucose-independent 
mechanisms work in synergy with hyperglycaemia-driven processes to produce DN and pain. 
The major pathways were introduced in detail in Chapter 1: Introduction, section 1.3.3. One of 
the main glucose-independent triggers of neuronal damage in a DN setting is dysregulated 
insulin signalling. Insulin is an important neurotrophic factor for neuronal growth and is often 
added to neuronal culture media for trophic support 623. Poor insulin availability, as in T1D and 
late stages of T2D, as well as insulin overabundance, like in early T2D, both contribute to 
neuronal health damage, independently of hyperglycaemic conditions 286,296–298,303. For the 
experiments outlined in Chapter 4, the DRG cultures were not supplied with any insulin. Thus, 
the in vitro DN conditions we designed were closer to replicating those in T1DN and late T2DN, 
where neurons are in an environment with excess glucose and little insulin. Supplementation 
of the DRG culture with excess insulin together with high glucose levels might have brought 
culture conditions closer to those in early T2DN and might have produced detectable neuronal 
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introduce its trophic support effects to the cells, which may play down or negate 
hyperglycaemia-induced neuronal damage. In fact, it is possible that the large quantity of 
available insulin, at least in the initial stages of T2D, is responsible for maintaining neuronal 
health and, to an extent counteract the neurodegenerative effects of hyperglycaemia during 
T2D. This might explain the less aggressive symptomatic expression of T2DN compared to 
T1DN in the early stages of diabetes 233,252,253. Insulin’s production cessation due to β-cell 
destruction in T2DN advanced stages might then be responsible for the rapid progression of 
DN symptoms in the later stages of T2DN. This idea is reinforced in studies by Huang et al. 
who cultured mature sensory neurons with high insulin and normal glucose levels and reported 
increased hexokinase activity and ATP synthesis amongst other events. Hexokinase drives the 
first committed step of glycolysis, hence its upregulated activity indicates augmented glucose 
metabolism and energy generation 625. In an in vitro hyperglycaemic setting, this could 
ameliorate the effects of high glucose on the neuronal health and thus mask a neuropathic 
phenotype. In another study, the group demonstrated that maintaining STZ-rat-derived DRG 
neurons in high glucose and supplementing them with insulin led to improved mitochondrial 
function. Furthermore, administering low dose insulin injection to STZ rats improved their 
sensory phenotype but without affecting hyperglycaemia in the rodent 626. Their results call for 
caution when considering supplying in vitro cultures with insulin. Despite the growing evidence 
of its role in the DN pathogenesis, due to the hormone’s nature it would be challenging to tease 
out its beneficial from neurodegenerative effects in vitro. Nevertheless, neuronal IR is a well-
evidenced feature of T2DN 627 and future research into modelling DN in vitro should explore 
its adequate implementation in a culture model. 
NGF is another trophic factor, considered an essential component of neonatal DRG culture 
protocols 628–630. NGF expression is also upregulated in animal models of injury 631,632 and 
inflammation 340, including DN 456,531,567,633. In animal models of both T1DN 531,633,634 and T2DN 
(db/db mice 456), increased levels of NGF are detected and correlated to increased pain 
sensitivity. Although the mechanisms behind its increased expression are unclear, it is 
speculated that NGF levels increase during DN as a neuroprotective response to the metabolic 
stressors accompanying the disease 456. From all of the above, neurotrophic factors such as 
NGF and insulin might be key drivers in the pathogenesis of DN and hence valuable 
components to include in an in vitro model, however should undergo careful consideration 
before being implemented and resulting outcomes should be interpreted with their trophic 
effects in mind. 
Other components of DN pathology that have been directly introduced in in vitro DN models 
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direct glucose toxicity modelling 432 and oxidised LDLs to directly model hyperlipidaemia 434. 
Although elucidative of the mechanism via which each might contribute to DN in isolation,  no 
studies have yet modelled an in vitro DN environment incorporating several components 
together. Such an approach might pose difficulties, since an environment with a number of 
variables is less susceptible to tight control and manipulation. Nevertheless, identifying the 
optimal number and types of components able to be successfully and sustainably introduced 
in an in vitro neuronal environment might allow for a modelling of DN in a dish closer to that in 
humans. 
Finally, a limitation of extending culture time to 6 days is the reduced number of neurons 
available for imaging with time. Twenty-four hours after plating, neurons start extending 
neurites and by day 3 in culture a dense axonal network is present 505. In addition, proliferation 
of non-neuronal cells such as fibroblasts, satellite glia and SCs begins. This can obstruct 
neurons from being easily identified and selected for imaging experiments. The reduced 
availability of neurons as time in culture progresses inevitably leads to fewer cells imaged per 
day due to the limited number of coverslips and animals (Table 4.2, Figure 4.2). The reduced 
number of available neurons and hence ROIs of sufficiently good clarity for recording can be 
an important source of  data variability. Unfortunately, to our knowledge, controlling neurite 
outgrowth without aggressive treatments that might introduce a phenotype is unfeasible.  
Future experiments might benefit from exploring compounds preventing minimising the 
amount of non-neuronal cells proliferation in culture,  such antimitotic agents, e.g. 5-fluoro-2'-
deoxyuridine 635,636 although caution should be taken when interpreting data from cultures 
containing additional elements. Alternatively, the restricted number of available neurons after 
2 or more days in vitro can be compensated for by increasing the total sample size for the time 
point to ensure statistically valid quantity of data. 
6.3. Studying excitability of DRG neurons derived from diabetic 
animals 
The second big aim of the present study was to assess for excitability changes present in DRG 
neurons derived from diabetic db/db mice. This was also an opportunity to explore the 
application of the VTD-Ca2+ imaging assay as a tool for characterising the excitability 
phenotype of DN in sensory neurons. The VTD-Ca2+ imaging assay detected changes in VGSC 
excitability expressed as an increase in the OS profile in both phases of DN in db/db mice 
(Figures 5.8, 5.9, 5.10). Nociceptive agonists revealed an increase in the sensitivity to CAP 
which persisted and increased into the late, NEU phase of DN (Figures 5.5, 5.6, 5.7). We 
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to-medium nociceptors and later affect small, TRPV1-expressing nociceptors as DN 
progresses (Table 5.2, Figure 5.11). These results implicate specific neuronal subpopulations 
affected at early and late stages of DN and could serve as a foundation for further research 
into them and the molecular mechanisms driving excitability changes. Their further 
characterisation will, in turn, aid the identification of specific targets for the development of 
pain-alleviating or DN-modifying therapies. In addition, this is the first study to investigate 
physiological excitability changes in the db/db mouse in both phases of DN.  
The db/db mouse is perhaps the most widely used model of T2D due to the collection of 
advantages they bring over other diabetic models (Table 6.1). The robust development of 
diabetes and subsequent complications follow closely the natural progression in human 
patients, making them also one of the most preferred models of DN 453. Perhaps the main 
advantage of this model is that DRG neurons are chronically exposed to neurodegenerative 
DN conditions that go beyond hyperglycaemia, including oxidative stress, hyperinsulinemia 
and IR, inflammation and dyslipidaemia. We and others 431,637 have demonstrated that isolating 
and culturing DRG from db/db mice in standard medium and conditions produces a DN 
phenotype, hence allowing for their studying without supplementing the culture with additional 








Table  6.2. List of some disadvantages of the T2D db/db mouse model of diabetic neuropathy. 
Disadvantages References 
Short lifespan (30 – 40 WoA) 
668 
Leptin signalling impairments are much less severe in human patients 
669 
Leptin-based mouse models are often infertile, and generating significant 
numbers is time consuming. 447 
Impairment of leptin signalling might have indirect consequences on other 
biochemical pathways 
669,670 
DN phenotype depends on strain used (C57BKS vs C57BL/6) 
453,459,671 
 
Table  6.1. List of some advantages of the T2D db/db mouse model of diabetic neuropathy. 
Advantages References 
Parallels human T2D and pathogenesis to a very high degree: 
• Persistent hyperglycaemia 
• Obesity 
• Dyslipidaemia: persistent high blood cholesterol and 
triglyceride levels 
• Insulin resistance 
• Inflammation 
456,458,541,549,666,671 
Mimics human DN progression qualitatively and temporally: 
• Hyperalgesia and allodynia 8-12 weeks 
• Thermal and mechanical hypoalgesia after 12 weeks* 
• Decreased NCV 
• Loss of large myelinated fibres 
• Axonal atrophy and dystrophy 
• Loss, shrinkage and breakdown of myelin 
T2D phenotype validated with anti-diabetic drugs 
672–674 
Shown to exhibit a pre-diabetic state 
675 
Develop severe hyperglycaemia and display advanced stages of the 
disease without the need of any external diet or pharmacological 
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The db/db mouse does not come without some disadvantages, outlined in table 6.2. Perhaps 
the main disadvantage, and a limitation of these experiments, is that the db/db mouse strain, 
like every genetically modified disease model, presents with lower genetic differences thus 
producing lower variability in DN onset and/or progression. This is in contrast to humans, 
where different DN patients present with different degrees and timings of functional and 
structural changes 638. Despite that, however, a similar trend is observed in both the db/db 
animal model and DN patients, whereby the early phase of DN is regulated by complex 
metabolic drivers producing contradicting behavioural reports in the db/db mouse (see table 
4.2) and varying degrees of sensitivity changes in patients 639. On the other hand, the sensitivity 
loss and structural changes during the late DN phase is well documented in both, animal 
models 252,453,640 and humans 230,234,639. This perhaps implicates the db/db mouse as a more 
suitable model for investigating the late, structural effects on sensory neurons during DN. 
However, studies reporting positive functional and behavioural changes in the animal model 
during early phase DN could still benefit a subpopulation of patients experiencing similar 
events. 
DN is characteristic with its stocking-and-glove distribution, affecting the toes and feet first, 
followed closely by the fingers and hands 641. Each dorsal horn afferent nerve is dedicated to 
innervating a specific area of skin or organ, i.e., its dermatome. The nerves innervating the 
areas affected first by DN are lumbar spinal nerves 4 and 5 (L4 and L5) for the toes and feet, 
and cervical spinal nerves 6, 7 and 8 as well as sacral spinal nerve 1 (C6, C7, C8 and S1, 
respectively) for the fingers and hands. Often, studies exploring functional and structural 
changes in the nerves during DN would isolate only DRG from L4/L5, noting functional and 
structural alterations 254,337,544–546,637,642,643. In the present study, DRG from the whole length of 
the spinal column were isolated for studying DN. Assuming that the DN phenotype is 
concentrated largely in the lumbar DRG, then dissection of all DRG indiscriminately could lead 
to “dilution” of the neuropathic phenotype and milder excitability changes being observed as 
opposed to isolating specific DRGs. Future studies can explore this concept by preparing DRG 
cultures from specific spinal column segments of nerves evidenced to be highly affected in 
DN, such as the lumbar nerves. This would provide a focused investigation of DN effects on 
specific organs and body areas and should be interpreted as part of the bigger picture of the 
DN pathogenesis. It would be interesting to see a meta-analysis of studies using all DRGs as 
opposed to specific ones from diabetic animals and whether the results obtained via these two 
different approached differ substantially. 
One potential source of weakness in this study, which could have affected the neuronal 
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standard environment. That is, isolated DRG were not maintained in high glucose conditions, 
neither was insulin, NGF or other DN-characteristic elements added to the medium. Upon 
being faced with this choice when designing the experiments, we addressed relevant literature 
and established that virtually all studies using DRG from animal models of DN did not alter the 
culture medium to reflect DN conditions. Hence, the decision was made to undertake the same 
approach with the present experiments and observe the phenotype produced. Had it been the 
case that no significant differences were noticed between control and diabetic animal neurons, 
then experimental design would have been modified to introduce a modified DRG medium 
reflecting DN conditions. Since excitability changes were observed early in the course of the 
experimental period, it was agreed to proceed with the current method. However, it would be 
interesting to see whether maintaining neurons in a high glucose/NGF/insulin medium prior to 
experiments would produce a starker phenotype to the one observed here. 
The scope of this study was limited to Ca2+ imaging experiments and some analysis of cell size 
and distribution. These were isolated experiments, unsupported by our own behavioural, 
structural, or other data. Further experiments are needed to fully understand the mechanisms 
underlying the DN-induced changes in neuronal excitability observed here. Is the increase in 
excitability in nociceptors due to altered expression and/or activity levels of a particular VGSC? 
Is the increase in sensitivity to CAP due to increased TRPV1 expression or simply enhanced 
activation? Immunohistochemistry experiments tracing changes in expression levels of ion 
channels during the MET and NEU phases of DN implicated would contribute to answering 
these questions. Are neurons from diabetic mice shrinking or apoptotic? Quantitative analysis 
of neurons’ apoptotic tendencies throughout DN progression (e.g., using nuclei-labelling 
techniques) can provide insights. Further experiments would add to the physiological data 
provided by this research and contribute to a complete study on the DN phenotype 
progression in the db/db mouse sensory neurons.  
6.4. CONCLUSION 
The journey of this project started with the establishment of the VTD-Ca2+ imaging assay as 
able to discriminate between nociceptors and non-nociceptors via the VTD-response profiles 
generated by DRG neurons. It was then taken forward towards different applications including 
as a screening platform for ion channel blockers, individually or in combination, assessing their 
efficiency and safety. The application of the VTD-Ca2+ imaging assay as a tool for 
characterising neuropathological conditions was explored in the context of diabetic 
neuropathy in vitro as well as in vivo. By employing VTD-Ca2+ imaging as well as nociceptive 
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subpopulation of DRG neurons from T2D db/db mice in the early, MET and late, NEU phase of 
the disease’s course. This is the first detailed physiological characterisation of the diabetic 
neuropathy-driven excitability changes at the different phases in the T2D db/db mouse model. 
Identifying distinct neuronal subpopulations affected during DN could aid in their better 
targeting by novel pharmacological interventions developed. Finally, the VTD-Ca2+ imaging 
assay can have multiple applications, including as a screening platform and disease and iPSCs 
characterisation tool. In the future, this work can take several directions, for example focusing 
on the improvement of the VTD-Ca2+ imaging assay and its analysis process; and/or further 
characterisation of the db/db mouse model of DN and the identity of the neurons most affected 
during the different stages. Overall, this research hopes to eventually contribute to elucidating 
the complex mechanisms underlying diabetic neuropathy and aid in bridging the gap between 
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